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5Abstract:
HSCR has been felt to be a polygeneic disease on the basis of an incompletely penetrant sex
modified transmission, which may be either autosomal dominant or recessive in different kindred.
During the 1990’s several of the genes involved in this transmission have come to light. Other genes
remain to be discovered.
This thesis contributes to the understanding of the phenotype and genotype of polygeneic
HSCR.
• A unique distribution of aganglionosis and sex distribution is shown for Ondine’s Curse,
Hirschsprung disease (Haddad syndrome). Certain other features of this condition are defined.
• The distribution of associated abnormalities in Down Syndrome is shown to be affected by the
presence of HSCR.
• A locus on chromosome 2 was defined which has since been shown to be the site of the
SMADIP1 gene, mutated in some syndromic cases of HSCR.
• GDNF mutations are shown to be rare contributors to HSCR. One particular polymorphism
(“R93W”) is demonstrated which probably contributes to the phenotype in association with
RET mutations.
• The T366A polymorphism in GFRα1 shows a tendency to be under-represented in HSCR.
• The RET haplotype comprising polymorphisms in exons 11 and 15 is shown to be rarer in
HSCR than in control populations.
• Consistent with the presence of mutations in genes widely expressed in the developing nervous
system, more widespread subtle abnormalities are demonstrated in the autonomic system of
HSCR patients than simply colonic aganglionosis.
• The outcome of DS/HSCR is shown to be dependent on not only length of aganglionosis, and
the presence of other associated malformations, but also the child’s developmental capacity.
The above findings support the polygeneic nature of HSCR, and expand the range of genetic loci in the
disease, as well as expanding the range of phenotype in the condition.
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Abbreviations.
ACE Antegrade Continence Enema
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ASD Atrial Septal Defect
BAER Brain Stem Auditory Evoked Response
BAPS British Association of Paediatric Surgeons
BSAER Brain Stem Auditory Evoked Response
BW Birth Weight
CA Colonic Atresia
CCHS Congenital Central Hypoventilation Syndrome. (Also Ondine’s Curse.)
CHD Congenital Heart Disease
CNS: Central nervous system
CSC Chronic Severe Constipation
CXR Chest X ray
DA Duodenal Atresia
DC Descending Colon
DGGE Denaturing Gradient Gel Electrophoresis.
DS: Down syndrome
ECE-1 Endothelin converting enzyme 1.
EDNRB: endothelin B receptor.
EGG ElectroGastroGram
ENS: Enteric nervous system
ET3: endothelin 3
FISH Fluorescence In Situ Hybridisation.
FMTC Familial Medullary Thyroid Carcinoma
GA General Anaesthetic
GDNF: Glial Derived Neurotrophic Factor.
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16
UDT Undescended Testis
UTI Urinary Tract Infection.
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Chapter 1. Aim of the thesis.
To better understand the underlying mechanisms of HSCR by better understanding its clinical
characteristics
1.1 Definition.
1.2 Hypothesis
1.2.1 Specific predictions
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1.1 Definition:
Hirschsprung's disease is a condition characterised by absence of ganglion cells for a variable
length in the distal bowel, but which may extend to involve the whole bowel. This absence of ganglion
cells results in failure of relaxation of the affected bowel, with a resulting functional obstruction of
variable severity, present but not always obvious, from the first day of life. “Ultrashort” HSCR,
(synonym: “Internal sphincter achalasia”) will be considered as a type of HSCR for the purposes of
this thesis. Other dysganglionoses, although related, are not considered to be HSCR.
1.2 Hypothesis:
The observed low frequency of RET and other mutations supports the notion that HSCR is a
polygenic disease. I propose that it is not only a polygenic disease, but a poly-system disease. It affects
not only the ENS, but also may effect the autonomic nervous system, CNS, and peripheral nervous
system in various ways depending on genetic and other factors that are only partly understood.
This thesis seeks to support the multifactorial threshold model for HSCR by:
1.) Defining particular subgroups of HSCR associated with particular chromosomal loci.
2.) Defining the incidence of mutations in a particular gene (GDNF), and investigating polymorphisms
in some associated genes.
3.) Defining new features associated with HSCR that may help in understanding the genetic
contribution, or even point to new loci.
1.2.1 Specific predictions are that:
1.) DS predisposes to HSCR both by the presence of rare alleles on chromosome 21, and by interaction
of those alleles with susceptibility alleles elsewhere. DS/HSCR will therefore have features that are
distinct from both DS and HSCR.
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1.5) That we can use this clinical information to predict outcome in these children.
2.) That children with OC/HSCR will also have specific features, distinct from other HSCR and OC.
3.) That OC/HSCR is one end of a spectrum of autonomic defects in HSCR.
4.) That children with a Goldberg-Shprintzen like syndrome will have a contiguous gene deletion
syndrome, and that we can pick up the deletion using molecular and cytogenetic techniques.
5.)  That screening GDNF ought to reveal mutations, or that there ought to be an excess of rare
polymorphisms in GDNF in HSCR.
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Chap 2. Literature review.
2.1 Background.
2.2 Genetics.
2.3 RET
2.4 Other genes.
2.4.1 GDNF
2.4.2 Importance of GFRa1
2.4.3 NTN and other TGFβ related proteins
2.4.4 RET downstream signalling.
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2.8 Molecular biology summary
21
2.1 Background.
Although the first case of presumed Hirschsprung’s disease was noted in the literature as early
as 1691 (Leenders and Sieber  1970), it was not until Harald Hirschsprung presented his case series in
Copenhagen in 1886 that the clinical syndrome was recognised.  Hirschsprung consolidated this
description with a further report in 1904.  (Hirschsprung, 1887). Notwithstanding this important work,
Hirschsprung failed to appreciate the underlying pathophysiological problems.  He was correct
however in appreciating that this was a congenital condition. Hirschsprung and those who followed
him seemed convinced that the dilated bowel was the problem.
Swenson in 1949 in brilliant clinical and experimental work demonstrated that the contracted,
and apparently normal bowel was in fact the cause of the problem. (Swenson 1948).  In the process he
described the operation still named after him.  This proved highly successful in treating what had up
until then been an intractable, and often fatal problem. Earlier optimistic attempts at cure by
sympathectomy such as that described by Wade and Royle (Wade 1927) were in the process
conclusively shown to be misguided.
At the same time, Whitehouse and Kernohan (Whitehouse, 1948), and in the following year
Bodian Stevens and Ward (Bodian 1949) demonstrated conclusively that the contracted bowel was
aganglionic.  Observations of aganglionic bowel had been previously made in Hirschsprung’s disease
patients during the early part of the century, but due to the lack of understanding of the basic
pathophysiology of the condition, this was not recognised as a regular and crucial feature of the
condition.  These two developments : the appreciation of the significance of the spastic segment, and
of its association with aganglionosis were decisive in allowing further progress in the understanding of
Hirschsprung’s disease.  The operations which we still use to treat this condition today were basically
developed during the following ten years, along with contributions from Rehbein and State, whose
operations are no longer widely used.  (Swenson 1948, Duhamel 1960, Soave 1966,.)
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2.2 Genetics.
Further understanding of the mechanism of Hirschsprung’s disease was possible now that
there were strict criteria for diagnosis. There were no longer series contaminated by acquired and other
forms of megacolon.  Bodian Carter and Ward in 1951 were able to carry out a systematic genetic
study of the condition on what was at last a firm theoretical basis. In the early sixties Bodian and
Carter (Bodian 1963) described a case series with observations on the epidemiology.  This was
followed up by a further report nearly 20 years later,  “Children of those treated surgically for
Hirschsprung’s disease”. This study pointed out the relatively high risks to children of those who had
been successfully treated for Hirschsprung’s disease. Two of four offspring of long segment patients
were either certainly or probably affected, while only two offspring (one of each sex) of ninety nine
short segment cases  were affected. (Carter 1981) Risk to offspring was not a problem that had been
much in evidence in the era before successful treatment was possible. (We are now getting to the era
when the very long term outcomes for these individuals is demanding attention. This problem will be
addressed in the later chapters of this thesis.) At nearly the same time Eberhard Passarge working in
the United States described further details of the epidemiology. He collected 63 index cases of his own,
and reviewed the work of previous authors, including Bodian and Carter from 1963, Madsen et al from
Denmark (1964), and Althoff from Bremen (!962). Passarge found a 3.6% overall risk to sibs of
affected individuals. This was higher (7.2%) if the index case was female, but only 2.6% if the index
case was male. 10% of Passarge’s patients had long segment disease, which he defined as extending to
the hepatic flexure or beyond. Two of these six long segment patients had affected siblings, suggesting
a much greater risk in families with long segment disease in the index case. After reviewing his own
cases, Burnard’s, (Burnard 1950) and the others mentioned above, Passarge concluded that HSCR had
an incidence of between 1/4,000 and 1/10,000 live births.  A number of case series then followed
which expanded on the familial risks and associated conditions, observed some abnormal karyotypes,
and confirmed the strong link with Down’s syndrome.  In 1990 Badner and others published their
careful genetic review of the condition establishing how it could be transmitted as both the sex
modified  autosomal recessive condition, and an incompletely penetrant autosomal dominant.
A more recent population based review by Rajab and Freeman in Oman showed an incidence
somewhat higher than most (1/3,070) associated with a very high level of consanguinity -  75% was
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estimated from case notes - and clustering of cases in a small segment of the total population. (Rajab
1997) Possibly the relatively high incidence of the condition in this series is due to expression of an
autosomal recessive phenotype, to an altered genetic background, or even to environmental factors.
The relative incidence of DS in this series is also low, consistent with an elevated background rate of
HSCR.
2.3 RET
What is it?
Genetic, karyotype and animal model clues.
Human screening.
RET is a receptor tyrosine kinase encoded by a gene of 20 or 21 exons (depending on splice
variants) on chromosome locus 10q11. The acronym stands for REarranged during Transfection,
referring to the fact that this gene was noted to be activated following an in vitro rearrangement. It was
noted to be re-arranged and constitutively activated in a large percentage of thyroid papillary
carcinomas. (Santoro 1992) Normally ligand binding is required for receptor dimerisation, which in
turn causes autophosphorylation, and activation of a multi-component intracellular signalling cascade
(Ras, shc, grb, and possibly others).
Martucciello et al in 1992 reported a case of a girl with total colonic aganglionosis associated
with interstitial deletion of the long arm of chromosome 10. [46 XX del 10 (q11.21 q21.2)]
Martucciello noted that this interval includes the MEN2a locus, but that the mechanism was not
known. (Martucciello 1992) Yin et al reported Hirschsprung’s disease associated with interstitial
deletion of the long arm of Chromosome 10 in 1993 (Yin L. 1993).  Fewtrell and others in 1994 also
reported a case of interstitial deletion of long arm of Chromosome 10 (del (10)(q11.2q21.2). (Fewtrell
1994) These informative cases were then able to guide linkage studies such as the report in 1993. (Luo
1993)  This study analysed a total of 21 affected and 23 unaffected individuals in five Hirschsprung’s
disease pedigrees.  The study showed a pattern of transmission consistent with an autosomal dominant
model.  The observed recombinations helped restrict the smallest interval in which the Hirschsprung’s
disease gene could be.  Luo’s group had access to three additional cytogenetically visible deletion
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cases of HSCR in addition to their own reported case of an interstitial deletion of Chromosome 10.
This allowed them to localise the  site of the Hirschsprung’s disease gene to a region of 250 kilobases
in chromosomal band 10q11.
Fortuitously at this time, a RET knockout mouse had been prepared.    Most of the mice
homozygous for the RET knockout demonstrated severely dysplastic kidneys and all showed total
intestinal aganglionosis. (Schuchardt 1994). It was already known that the RET gene was localised to
10q11.  The Ret knockout mouse work in itself made RET a prime suspect in Hirschsprung’s disease.
The localisation of RET expression to a number of areas, importantly including the developing wall of
the gut provided the smoking gun. Consistent with the observation of severe renal dysplasia from the
Ret -/- mouse, Ret was also shown to be expressed in the developing kidneyi. (Avantaggiato 1994)
Two other linkage studies were published within weeks of Luo and Ceccherini. Angrist
Kauffman, Slagenhaupt et al analysed transmission of  microsatellite markers in five multi-case
affected families. (Angrist 1993) This study showed close linkage between the Hirschsprung’s disease
phenotype and marker D10S176.  Lyonnet et al, also in August 1993, using similar methods mapped a
locus for a dominant form of Hirschsprung’s disease to Chromosome 10q 11.2. (Lyonnet 1993) These
authors (and others) had noted that the MEN2 syndrome had already been mapped to this region and
was in fact known to be caused by distinct mutations in the RET gene.
These reports were soon followed by the first reports of screening of the coding portion of the
gene itself. (Romeo 1994, Edery 1994, Angrist 1995)
At the beginning of 1994, the position was summed up in an editorial in “Nature” headlined,
“One Gene – Four Syndromes”. It was pointed out that mutations in a single gene seem to give rise to
four distinct conditions.  These were familial  medullary thyroid carcinoma (FMTC), MEN 2A and
MEN 2B, as well as Hirschsprung’s disease.  How one gene could account for such differing
phenotypes it is still being worked out in detail, but in general, disabling mutations of RET (for
                                                          
i Ret expression was also shown in a number of other structures, notably in the developing spinal cord
and ventral part of mid brain. A signal was also seen in the genital eminence and in the developing
liver.
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instance deletions, premature stop codons, or point mutations which reduce tyrosine kinase activity)
cause HSCR. Specific mutations associated with MEN2a, MEN2b or FMTC result in loss of a cysteine
residue. The resulting “unbalanced” cysteine is thought to then be available to constitutively dimerise
the RET receptor in a way that mimics the dimerising effect of the RET ligand. As dimerisation
activates the receptor, the cell is left in a state of permanent stimulation. How mutations such as C620R
(reported in several families associated with both HSCR and MEN2a [Svensson, 1998, Mulligan
1994]) and C618R  (Caron, 1996) can be simultaneously associated with both gain and loss of function
is harder to explain.
2.3.2 Review of RET screening results
Collected results of fourteen RET mutation detection series from 1994 to 2001 are
summarised in Table 2.1. Reviewing 80 HSCR patients (35 familial, and 45 sporadic) screened for
HSCR in 1994, Attie et al found mutations in RET in half of familial patients whether long or short
segment. (Attie 1994) By contrast in sporadic HSCR, she again found mutations in 50% of long
segment  HSCR, but in only 2 of 12 short segment patients. Calculating a penetrance for RET
mutations overall from her multi-case families she assigns males a 72% penetrance for RET mutations,
and a 51% penetrance for females. Interestingly, Attie finds a male preponderance in long segment
disease in her RET mutation families, with equal numbers of male and female having short segment
disease, from a sample of 55 individuals. This contrasts with clinical series which report overall 4:1
male female ratios, with ratios approaching 1:1 for long segment disease, and in some series an even
greater male preponderance for short segment disease. It seems that in families carrying a RET
mutation, having two “X” chromosomes not only reduces the chance of having the mutation expressed,
but reduces the severity of the phenotype when it is expressed.
The overall incidence of RET mutations in these fourteen series is 127 out of 566 cases, or
22.4%. Given that several of the series cited in Table 2.1 below are highly selected, the expected
incidence of RET mutations in population based series is likely to be even lower.
A preliminary survey of RET sequence variants is described in chapter 9.ii
                                                          
ii Hofstra discusses criteria for assessing pathogenicity of a sequence variant. Seven criteria are
discussed.
26
Ref Sample size Number
mutations
Comment
Angrist (1995) 80 8
Attie, Pelet (1995) 80 33
Edery (1994) 19 6
Gath (2001) 29 3
Hofstra (2000) 95 20
Inoue(2000) 15 10 only very long segment tested
Mulligan(1994) 5 5 exon 10 only: HSCR, +/- MEN
Munnes(2000) 6 5 multi-case families only
Romeo(1994) 27 6
Sancandi(2000) 57 8
Sakai (1998) 1 1 Ondine’s curse/HSCR
Shimotake(2001) 1 1 TIA
Svensson(1998) 69 5 population based
Yin (1994) 82 16
TOTALS 566 127
Table 2. 1 RET mutation screening papers.
Distribution of mutations across exons.
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Figure 2. 1 Distribution of mutations in published RET screening series. (The series of Mulligan
concentrating on exon 10 has been excluded. A further five mutations in exon 10 were published
in this paper.)
In the collected series mutations have been found across the whole of the RET gene. This
contrasts with MEN2, where mutations in specific codons of RET have been identified. In these
fourteen series, 566 patients were screened to find 127 mutations, including 5 silent or intronic changes
of uncertain significance, one silent change shown to interfere with proper editing of RET mRNA, and
three whole gene deletions. Although exons 17, 15, 10, and 3 are most frequently reported as the sites
of mutations, no exon is significantly more involved than average. (Average mutations per exon, 3.75:
                                                                                                                                                                     
1.) De novo mutations are likely to be pathogenic.
2.) segregation of the mutation with the disease in a pedigree.
3.) absence of the mutation in controls.
4.) significant amino acid change.
5.) occurrence of the change in a highly conserved region, either between species, or between related
proteins.
6.) effect demonstrated in vitro or in vivo model.
7.) previous inclusion of the mutation on a disease database. (!)
(Hofstra 1997)
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all exons are within 2 SD of the mean.) The distribution of mutations is similar for both long and short
segment disease.
Inoue et al (2000 ) and Shimotake (2001) et al report either mutations in exons 15 or 17 of
RET in total intestinal aganglionosis, or frameshift mutations which result in a severely truncated
protein. Eight patients in this group have either extensive small bowel involvement or total intestinal
aganglionosis. All eight have one of the above changes.  Of Inoue’s fifteen very long segment patients,
there were only five without RET mutations, and three of these have deafness with or without
hypopigmentation, suggesting SOX10 mutations (see below). Only one of five TIA’s had no RET
mutation, while three of six TCA patients had no RET mutation. (Inoue 2000) There seemed to be a
tendency to more males with the very longest segment disease, as noted in OC, and discussed in
chapter 7.
There have also been cases where individuals carry mutations in more than one gene. (Tohoku 1999,
Svensson 1998)
Non random assortment of RET polymorphisms.
In his paper describing linkage of HSCR to a missense mutation in the EDNRB gene in the
Mennonite kindred of Eastern America, Puffenberger et al noted a non random assortment of an Eag I
polymorphism at ala 45 (A45A), carried in 59% of affected Mennonites, and only 24% of
untransmitted chromosomes in that kindred, and in 21% of control chromosomes χ2 = 12.08.
(Puffenberger 1994b) Ceccherini 1994) This observation of an association between A45A and HSCR
has since been confirmed by Fitze (Fitze 1999) and Borrego. (Borrego 2000) By contrast Borrego et al
also found a significant under-representation of rare alleles G691S and S904S in exons 11 and 15
respectively of RET. Griseri et al found an under-representation of S836S in exon 14 in HSCR, but an
over-representation of this allele in medullary thyroid cancer. Sancandi et al found a smaller than
expected frequency of de novo mutations in RET, but they did find a high frequency of an allele rare in
the normal population,  R982C in exon 18. This occurred in four patients of  57, suggestive of a
causative role. (Griseri 2000, Sancandi 2000)
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RET mutations then, are associated with about 50% of long segment disease, particularly the
very long segment disease, and much less of the short segment disease, while certain RET
polymorphisms are shown to be non-randomly associated with the HSCR phenotype, some apparently
protective, and others causing increased risk. There is more to HSCR than RET sequence variants.
Clearly other genetic, environmental or stochastic factors are important.
We can now understand that the results of Carter et al (Carter 1981) who found a risk to
offspring of affected long segment parents approaching 50%, as the effect of mutations in RET, which
behaves as an incompletely penetrant autosomal dominant, and is found more often in long segment
than in short segment cases. RET mutations are found in about 50% of familial cases, but the majority
of all cases are unexplained by RET mutations, while RET polymorphisms are clearly important
susceptibility alleles.
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Importantly the international RET mutation consortium reported on an analysis of mutations
in RET associated with MEN 2 in 1996. (Eng 1996) They were able to identify mutations at specific
codons predisposing to specific patterns of MEN 2 related neoplasia. See  2.2 for details. This analysis
is important, because specific mutations have been found in RET in families with both HSCR and
MEN 2 phenotypes.  Mutation were found in MEN 2 families in codons 609, 611, 618, 620, 634, 768,
804, and 918, encompassing exons 10, 11, 13, 14, and 16 of RET.
Mutation Phenotype
Any mutation codon 634. Phaeochromocytoma, hyperparathyroidism
CGC at codon 634 Familial medullary thyroid carcinoma (FMTC) NOT seen.
codon 768 FMTC
codon 804 FMTC
codon 918 MEN2b
codon 620 (TGC -> CGC) HSCR and MEN2a (5 families.)
codon 618 HSCR and MEN2a (1 family.)
Table 2. 2 RET genotype - phenotype correlation. (Eng 1996)
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2.4 Other genes.
2.4.1 GDNF
What is it?
Animal knockouts
Human screening
GDNF was first characterised by Lin et al in 1993 (Lin 1994).  It is a 211 amino acid protein
weakly related to the TGFβ  super family. In common with the other members of the TGFβ  super
family it contains seven conserved cysteine residues. Cellular processing results in secretion of a 134
amino acid mature protein, which forms a disulphide linked homodimer in solution.  It was mapped to
the chromosomal locus 5p13.1-p12 by Schindelhauer et al in 1995 by FISH. (Schindelhauer 1995)
This localisation was refined to 5p13.1-p13.3 by Bermingham et al  using a combination of FISH and
cell hybrids. (Bermingham1995, Quoted in OMIM 600837)  Interestingly there are no reports of
deletions of this locus in human Hirschsprung’s disease, nor reports of linkage arising from any
previous linkage studies.  GDNF was shown to be expressed by dopaminergic neurones in the
substantia nigra and basal forebrain in both adult and embryonic rats (Schaar 1993) raising the
possibility that GDNF may have a role in the treatment of Parkinson’s disease and related conditions.
It was also shown to be expressed during embryonic development of the kidney. RET and GFRα1 are
expressed in the growing ureteric bud, GDNF in the mesenchyme (Srinivas 1999). The paper of
Srinivas et al describes manipulation of the RET ligand complex in the mouse model, producing
variable renal abnormalities, less severe than those produced by RET knockout in the mouse
(Schuchardt 1994) It is of interest then, that renal tract anomalies are not more commonly observed in
HSCR.iii Pichel et al (Pichel, 1996) showed kidney defects in both homozygous and heterozygous
GDNF knockout mice,  about 35% of the adult heterozygous mice showing a wide range of renal
defects, while homozygous GDNF knockout mice showed renal agenesis or very severe dysplasia. The
                                                          
iii Screening of a multi-case vesico-ureteric reflux (VUR) family for mutations in RET, GDNF, and
GFRα1 failed to show any abnormalities. Shefelbine SE. Khorana S. Schultz PN. Huang E. Thobe N.
Hu ZJ. Fox GM. Jing S. Cote GJ. Gagel RF. “Mutational analysis of the GDNF/RET-GDNFR alpha
signalling complex in a kindred with vesicoureteral reflux.” Hum. Genet. 102:474-8 (1998). The
author is unaware of any evidence linking RET or GDNF mutations to common renal tract anomalies,
for instance VUR.
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fact that Ret and Gdnf knockouts do not show quite identical phenotypes may be due to the existence
of alternative Ret ligands. This idea is supported by the observation of Sanchez (Sanchez 1996) that
while Ret -/- mice have an absent superior cervical ganglion, Gdnf -/- mice have only a small reduction
in volume of their superior cervical ganglion. Perhaps some other ligand is more important than Gdnf
in development of the superior cervical ganglion? In fact we now know that a variety of ligands may
bind to Ret, through the intervention of a family of co-receptors, discussed below.
In Pichel’s paper intestinal aganglionosis was not noted in the heterozygous mice, while
homozygous knockout mice showed whole intestinal aganglionosis.  Sanchez and co-workers observed
similar findings, noting a dilated duodenum which they interpreted as pyloric stenosis. (Sanchez 1996 )
It is more likely however that the dilated duodenum in these mice simply represents a transition zone at
the proximal end of the aganglionic segment. Moore et al in 1996 also demonstrated the same enteric
and renal phenotype in the mouse. (Moore 1996) More recently Shen et al have noted aganglionosis,
very similar to human HSCR in about 20% of heterozygous Gdnf knockout mice. (Shen 2002)
Sanchez and co-workers further observed GDNF expression using their transgenic mouse
construct. GDNF was expressed at embryonic day 8.5 in the nephrogenic cord, primitive gut and first
branchial pouch.  Soon after that, expression could be seen in the developing nervous system; in the
ventral region of the mid brain and hind brain and in the ventral and dorsal regions of the mid/hind
brain junction.  There is also evidence for GDNF expression in the craniofacial mass, the umbilical gut
as expected,  the mesonephros, and the proximal regions of fore and hind limbs.
Meng et al showed a paracrine effect of Gdnf in the heterozygous Gdnf mutant mouse model.
Mutant mice showed depletion of spermatogonial stem cells. If this finding translates to reduced
fertility in humans with GDNF variants, it may help account for the rarity of GDNF mutations in
HSCR. (Meng 2000, quoted in OMIM Reference 600837.)
In spite of the lack of karyotype evidence or linkage, GDNF therefore became a prime
candidate gene for Hirschsprung’s disease after its identification as a RET ligand in 1996.  The first
GDNF mutation screening publications came out soon afterwards.  A summary of all the published
mutation screening results of GDNF in HSCR to date is included in the table below. (Table 2.3)  It will
be seen at once that GDNF mutations are rare.  They constitute approximately 1.5% of  the 638
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previously published patients.  They may be neither necessary nor sufficient to cause the disease .
(Salomon, 1996).  A further 150 patients have been screened for GDNF sequence variants in the
presence of either : idiopathic slow transit constipation, Ondine’s Curse,  neuronal intestinal dysplasia
or  phaeochromocytoma.  In these 788 patients twelve unrelated individuals were found to have
sequence variants. Only one of these was a de novo mutation (in Hirschsprung’s disease).  Four
individuals showed the R93W sequence variant.  This variant was not seen in 970 control
chromosomes.  Two other sequence variants were seen twice.  D150N was seen once in association
with Down syndrome/HSCR, and once with short segment aganglionosis.  R143R was seen twice,
once in association with a cytogenetically visible RET deletion. Five of ten GDNF sequence variants
were seen in association with other genetic or karyotype abnormalities.
Do the described GDNF sequence variants constitute a significant association with
Hirschsprung’s disease ?  Are they predictive of any particular phenotype ? A GDNF mutation study is
described in chapter 9.
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Author Number
screened
Number
sequence
variants
Method HSCR type Mutation Exo
n
Control
alleles
Martuciello 55 2 SSCP TCA R143R
492 g->A (het)
2
SSCP “classic” I211M
630 C->g
2
Gath 41 0 SSCP - - - 300
Hofstra 95 1 DGGE short segment D150N 2 160
Borrego 1 0
Ivanchuk 36 2 sequence TCA, dev. delay 429g->A, R143R
+del 10q11.2 - q21.2
2 30
TCA 460A->T T154S (?causative) 2
Salomon 173 3 D150N +Trisomy 21 2 180
P21S. Associated with shared RET
linked haplotype
1
Multicase
4/5 affecteds long
segment.
R93W + (RET exon 11 2142g->A,
S649S )
2
Angrist 106 1 sequence short segment;
malrotation
R93W +RET mutation (2379delC) 2 196
Inoue 15 0 sequence all TCA - -
Munnes 6 families 0 - - -
Shimotake 1 0 sequence TIA - -
Svensson** 78 0 pop. based.
Kostjens-
Frederikse
1 0                     +22q deletion
Amiel 2 0 SSCP Ondine’s/HSCR
(2)
Sakai 28 1 HSCR T -> C 25bp upstream exon 1 3’
UTR
Totals 638 10 (1.6%)
Other Diagnoses:
Knowles 16 0 CSC idiopathic slow transit constipation
Svensson 25 0 Ondines
Martuciello 43 0 IND*
Amiel 5 1 SSCP Ondines R93W
Marsh 45 0 ¶ MEN & related
tumours
Woodward 61 1 MEN related
tumours
R93W 2 104
* IND: Intestinal neuronal dysplasia; CSC: chronic severe constipation; TIA: Total intestinal
aganglionosis; 3’ UTR: 3’ untranslated region (of the gene); DGGE: denaturing gradient gel
electrophoresis. ¶ MEN: Multiple endocrine neoplasia
**: PJ Svensson, personal communication.
Table 2. 3. Summary of results of screening for GDNF sequence variants in HSCR. Results of
screening for GDNF sequence variants in associated conditions are also shown at bottom for
comparison.
2.4.2 Importance of GFRa1
Pichel et al in 1996  observed that Gdnf and C-Ret were expressed in similar places, in the
budding ureter and the enteric ganglioblasts. (Pichel, 1996) They further noted that mutations in both
these genes produced similar phenotypes and speculated that Gdnf may be involved in C-Ret mediated
signalling during both  enteric nervous system development and kidney organogenesis.  Treanor
demonstrated the interaction of Gdnf with Ret via a membrane bound co-receptor called GDNF family
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receptor Alpha 1 (GFRα 1). (Treanor 1996)  Subsequent work by Tomac in 1999 demonstrated that
disrupting GFRα 1 produced a similar phenotype to Ret and Gdnf knockouts, but without effects on
dorsal root or sympathetic ganglia. (Tomac 1999) In addition they showed that these mutations (in
GFRα 1) reduced the neuro-protective effect of GDNF.
GFRα1 then seemed a good candidate gene for HSCR. Surprisingly, two large series failed to
show any evidence for mutations in GFRα1 in HSCR. (Myers 1999, Angrist 1998) It remains to be
seen whether it has any phenotype modifying effect. This question is addressed in part in chapter 9.
2.4.3 NTN and other TGFβ related proteins
GFRα1 is the first of a series of membrane bound glycosyl-phosphatidylinositol linked
proteins to be identified in association with RET. GFRα2, GFRα3, and GFRα4 have also been
identified recently, but without evidence of involvement in HSCR. The TGFβ related protein, neurturin
(NTN) interacts with RET via GFRα2. GFRα2 has been investigated as a candidate gene for HSCR,
and like GFRα1, no mutations have been found in this gene in HSCR. (Vanhome 2001) The NTN gene
has been localised to human chromosome 19 (Hueckeroth 1997) . It is closely related to GDNF. A
mutation in NTN has been demonstrated in one case of HSCR.(Doray 1998) Further TGFβ related
proteins (Artemin, Persephin) are now known. Artemin interacts with RET via GFRα3. The co-
receptor for Persephin is GFRα4. (OMIM 603886, OMIM 602921, Lindahl 2001) There is no
evidence that mutations in the genes for artemin and Persephin are important in HSCR.
In summary then, homozygous absence of functioning GDNF in the mouse resulted in total
intestinal aganglionosis, renal agenesis or severe dysplasia, and changes in dorsal root and sympathetic
ganglia.  Interestingly these phenotypes are not identical between Ret knockouts and Gdnf knockouts
or between Gdnf knockouts and Gfrα1 knockouts.  Ret knockouts in particular demonstrate renal
dysplasia rather than complete agenesis.  This may suggest alternative signalling pathways in renal
development.  The very broad expression of GDNF through the developing rodent brain suggests that
other neurological associations  with Hirschsprung’s disease will be found, perhaps even in non-
syndromic patients.  In fact Hirschsprung’s disease is associated with a variety of neurological
abnormalities. Several of these (Down syndrome, Ondine’s Curse, mental retardation and
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microcephaly similar to Goldberg-Shprintzen syndrome.) are discussed at greater length in subsequent
chapters. (Graivier 1966, Goldberg 1981, Haddad 1978). The molecular basis for these conditions is
not yet fully understood.
2.4.4 RET downstream signalling.
A number of downstream signalling proteins are known to interact with RET in mediating the
effects of signalling. Logically, it is possible that downstream proteins that interact with RET in the
signalling cascade might also cause HSCR when mutated. Angrist has tested this hypothesis for one
such protein, GRB10, and has not found any evidence of either genetic linkage, or mutations. (Angrist
1998b ) The GRB10 gene is found on chromosome 7. The author is unaware of either linkage analysis
or reports of chromosomal rearrangements linking HSCR to this locus.
2.4.5 Endothelin related genes.
There are three endothelin related genes.  These are known as endothelin 1, 2 and 3.  They are secreted
as inactive pre-pro-peptides, which are edited in two steps through to a 21 amino acid active
compound.  Sakurai et al  described isolating the potent vaso-active compound, endothelin 1, from
fluid in which porcine aortic tissue was cultured.  Inoue et al in 1989 then mapped endothelin to three
separate genetic loci, noting the sequence differences between loci and calculating the slight amino
acid variation between the three compounds. (Inoue 1989) Bloch et al and then Gopal Rao et al in 1989
localised the gene for endothelin 3 to 20q13.2-q13.3. (OMIM reference 131242)  The raw peptide is
processed to the active compound in two steps.  The first step is by a furin like peptidase, and the
second step is by an enzyme known as endothelin converting enzyme 1. (Pingault 2001) This enzyme
is active in processing all three endothelins.  Matsuoka  demonstrated  that the endothelin converting
enzyme gene is localised to chromosome 1, specifically 1p 36.1.  This result was later confirmed by
them, and the location refined to 1p36.1 using FISH. Others mapped the gene slightly differently in the
same band. (Albertin 1996)
Endothelins bind to two receptors.  The endothelin 1 specific receptor is known as the
endothelin A receptor, and the relatively non-selective receptor is known as the endothelin B receptor.
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Arai in 1993 mapped the human endothelin B receptor to chromosome 13. (Arai 1993) The endothelin
B receptor is a G coupled transmembrane receptor, with seven transmembrane helices.
Chromosomal clues.
In 1989 Lamont reported three cases of interstitial deletions of chromosome 13, between
segments 13 q 22.1 and q 32.1. (Lamont 1989) Two of these three cases had Hirschsprung’s disease.
The Hirschsprung’s was short segment in both cases.  The authors commented that Hirschsprung’s had
not previously been described in association with 13 q deletion.  Interestingly the second
Hirschsprung’s case was felt to have had a possible apnoeic episode at eighteen hours.  No further
hypoventilation is reported to support the diagnosis of central hypoventilation however.  All three
cases showed cytogenetic evidence of deletion of at least part of chromosome 13q22.  Subsequently
Bottani et al in 1999 reported one case with Hirschsprung’s disease and deletion of 13q32.3 -q33.2.
This boy was mentally retarded with Hirschsprung’s disease. (Bottani 1999)  In fact the endothelin B
receptor locus is now known to reside in 13q22.  It is possible that the karyotype in this case has been
inaccurately interpreted, or that there is more than one influence at work in this child.  Khong in 1994
diagnosed a further case of Hirschsprung’s associated with umbilical cord ulceration, intestinal atresia
and Hirschsprung’s disease. (Khong 1994) Van Camp  in 1995 diagnosed one case of 13q deletion
(deletion 13q 21.2 to 13q32).  This  paper then went on to map the deletion using micro-satellite
markers.  The deletion was however very large.  The patient himself was a six year old boy with
features of Waardenburg’s syndrome (WS): unilateral iris heterochromia, sensorineural deafness and
delayed development.  Dystopia canthorum was not present.  The patient did not have Hirschsprung’s
disease.  Because of the linkage between Hirschsprung’s disease and WS the authors collected seven
multi-case  Shah – Waardenburg families and performed a linkage analysis on the hypothesis that a
WS locus would be found in 13q. (Van Camp 1995) The study was unable to demonstrate any linkage
between Hirschsprung’s disease, or WS to 13q.  They concluded that they could not exclude a rare
cause of WS on 13q, but positive evidence was not present.  Subsequently Weigel  in 1998 published a
case of retinoblastoma and Hirschsprung’s disease, having an interstitial deletion of 13q (q13.2-q22).
(Weigel 1998)  In 2001 Shanske reported a final case of Hirschsprung’s disease and features of WS
and other abnormalities in a patient with deletion of 13q. (Shanske 2001)
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Alterations in coat colour associated with aganglionosis had been shown in a number of
animal models. Work on the molecular genetics of these models went on simultaneously with the
human work described below, and there was a very fruitful interaction between the human and animal
work.iv
Endothelin B receptor.
In 1994 Eric Puffenburger and his co-workers  in Cleveland, Ohio published a very large
study using linkage analysis in 3700 members of the Mennonite community in the Eastern United
States. (Puffenberger 1994a) This family has a somewhat higher amount of in- breeding than other
communities, and suffers several inherited conditions including Hirschsprung’s disease.  Genealogical
analysis of the families revealed a single common ancestral couple for all affected offspring.  Linkage
analysis mapped the gene responsible to Chromosome 13q 22 associated with specific microsatellite
markers.  In addition this study revealed preliminary evidence of modifier loci at  Chromosome 10q11
(the RET locus) and Chromosome 21q22.  There were 61 Hirschsprung’s disease probands altogether.
Some of these had other phenotypes associated with the WS, including both pigmentation anomalies
and sensory neural hearing loss.  There were also some affected with Down’s syndrome. Interestingly,
some members of this kindred displayed the pigmentary disturbance and deafness without
Hirschsprung’s disease. In addition, analysis of marker transmission in this kindred demonstrates a
recessive rather than a dominant transmission.
In December of 1994 Puffenburger and co-workers published a work decisively implicating
the endothelin B receptor in the WS / HSCR of the Mennonites. (Puffenburger 1994b)  Endothelin B
receptor gene was mapped very close to one of the polymorphic markers linked in their previous
papers to the Hirschsprung’s locus.  Polymorphisms in the endothelin B receptor locus again linked
with the Hirschsprung’s phenotype, and provided independent evidence for the role of the endothelin B
receptor. Even in this kindred, the linkage with endothelin B receptor polymorphisms was not absolute,
                                                          
iv Interestingly, a recent report in Applied Animal Behaviour Science, (vol 73. pp. 93) and reported in
New Scientist magazine, demonstrates that the position of the hair whorl on the head of cattle is
strongly correlated to cattle’s ability to tolerate novel situations. Will we see further examples of
dermal markers of neural development?
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giving evidence of some genetic heterogeneity.  The endothelin B receptor gene was screened by a
single strand conformation polymorphism analysis  and sequencing.  Sequence analysis revealed a G to
T transversion  in exon four (W276C) corresponding to a change in a highly conserved tryptophan
residue in the fifth transmembrane helix of the seven transmembrane helices of this G protein coupled
receptor.  This sequence change was seen in the Mennonite probands but not in ninety controls.
W276C was shown to account for 64% of Hirschsprung’s disease in this kindred.  By analysing the
zygosity of the mutations in males and females, they were able to calculate a penetrance for the
mutation.  Homozygous males were 85% affected, while heterozygous females were only 8% affected.
Homozygous females and heterozygous males had intermediate risks (60% and 33% respectively)
Puffenberger and his team then went on to demonstrate that the mutant was functionally important by
assessing the intra-cellular calcium response to stimulation of mutant receptors in transfected cells.
The stage was now set for a wide spread screening of the endothelin B receptor gene in both sporadic
and familial Hirschsprung’s disease in the wider population.  A number of papers came out starting in
1996 doing just this. At the same time great strides were being made in understanding both naturally
occurring and targeted mutation rodent models of aganglionosis.
Kusafuka, Wang, and  Puri in Dublin in 1996 reported two novel mutations in  41 isolated
Hirschsprung’s disease patients.  Both mutations produced stop codons expected to produce a
truncated and non-functional protein. (Kusafuka 1996) Auricchio et al. from Italy, also in 1996
reported on the results of mutation screening in seventeen individuals, showing  two novel mutations in
endothelin receptor B.  Interestingly both these sequence variants were transmitted from healthy
parents, but were not found in any normal individual. (Auricchio 1996) Amiel showed four sequence
variants out of 175 probands.  All these four variants however were also present in the healthy parents.
(Amiel  1996) Amiel proposed from his finding of heterozygous mutations in these four cases of non-
syndromic Hirschsprung’s that heterozygosity of EDNRB mutations predisposes to isolated
Hirschsprung’s, while homozygosity predisposes to more complex disease including features of WS.
Hofstra screened 40 individuals finding one sequence variant in the endothelin B receptor in three
individuals. (Hofstra 1997) This variant (G57S) was also present in four of 180 control chromosomes
however. Svensson in 1998 then found no more examples in another 230 control chromosomes from a
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Swedish population, after describing a family with the same sequence variant in three members only
one of whom was affectedv. (Svensson 1998) Inoue screened 37 individuals finding two sequence
variants, one of which was also found in the control groups and may have been a polymorphism.
(Inoue 1998) In total 10 sequence variants were found in 296 individuals (approximately 3%).  Clearly
the endothelin B receptor has a role in the aetiology of Hirschsprung’s disease, but equally clearly the
majority of cases are still unaccounted for.
Animal models of endothelin related genes.
Naturally occurring rodent models of Hirschsprung’s disease had been known from the sixties
(eg. Bielschowsky 1962, Lane 1966).  These included the lethal spotting mouse, the piebald lethal, the
dominant “dom” mouse, and the spotting lethal rat .  These strains were associated with white or
piebald coat colours.  There is no literature to indicate whether they also suffered from deafness.
Aganglionosis has also been observed in a number of other mammals, most notably in the “overo”
piebald horse, or “Paint Horse”. (Hultgren 1982, Yang 1998)
Nagahama et al (Quoted by Cass in Holschneider’s textbook.) noted abnormalities in the three
dimensional structure of the ganglionic bowel as high as the duodenum of the spotting lethal (sl) rat.
The spotting lethal rat shows a total colonic aganglionosis, and sometimes a shorter segment
aganglionosis. Cass asks whether the diffuse subtle abnormalities in this animal’s gut imply diminished
function. (Cass 2000)  If these histological abnormalities described by Nagahama are also present in
humans, they raise the question whether we can detect any functional correlates in human HSCR
patients. This question is addressed in chapter 8.2
Kurihara  in 1994 created an endothelin 1 knockout mouse. (Kurihara 1994) This animal
showed severe craniofacial abnormalities, amongst other features, but not Hirschsprung’s disease.  It at
least suggested the importance of endothelin to neural crest development. Subsequent experiments
demonstrated that when endothelin 3 was knocked out the animal looked very similar to the lethal
spotting mouse.  Subsequently the endothelin B receptor was also knocked out in the mouse with a
similar result of piebaldism and aganglionosis.  This animal looked similar to the piebald lethal mouse
                                                          
v Three out of five members of this family have mutations in both RET and EDNRB, but only one (a
boy) has Hirschsprung’s.
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(Cass DT 2000, Hosoda K 1994).  Meanwhile a painstaking programme of  back cross and linkage in
the spotting lethal rat had identified an aganglionosis locus in this animal at the endothelin B receptor
gene.  Subsequent cloning and sequencing  revealed a  301 base pair deletion in this animal.
(Ceccherini 1995) These experiments confirmed the importance of the endothelin B receptor and its
ligand in normal neural crest development in mammals at a time when these genes were just beginning
to be appreciated in the human condition.    As such they provided valuable encouragement to those
who were searching for human mutations in these genes.
Endothelins.
Endothelins 1 , 2 and 3 were already known to bind to endothelin B receptors (Elshourbagy,
1996. Maggi, 2000).  Endothelin 1 knockout animals had been shown to have craniofacial, and
autonomic problems, but not aganglionosis. Leibl et al. have shown that endothelin 3 expression is
concentrated in the mouse caecum, while endothelin B receptor is expressed on migrating neuroblasts.
(Leibl 1999) The animal model work previously referred to demonstrated that Endothelin 3 could be
involved in aganglionosis.  It therefore became a target for researchers searching for human
Hirschsprung’s associated genes.  Several papers now appeared reporting the results of mutation
screening in endothelin 3. (Hofstra, 1996).  He found one homozygous mutation in exon 3 (CYS  159
PHE) in exon 3 of the endothelin 3 which was presumed to affect the proteolytic processing of the
immature peptide.  The family was consanguineous, and had a previously affected child with
Hirschsprung’s, depigmentation and deafness.  A child in whom the mutation was found was severely
affected with total intestinal aganglionosis, sensory neural deafness, and pigmentary defects. (Shah
Waardenburg Syndrome).
Endothelin 3 mutation screening studies.
As noted above  Baynash et al (Baynash 1994) produced a recessive phenotype of
aganglionosis and piebald coat colour  by targeted disruption of the mouse endothelin 3 gene. Baynash
noted that the edn3 deleted construct did not produce a more severely affected offspring when mated
with the naturally occurring ednrb deficient mouse, confirming that edn3 mutations act by interaction
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with endothelin B receptor.  Edery et al  in 1996 demonstrated the first such mutation in human
Hirschsprung’s disease. (Edery 1996) This mutation replaced the two base pairs (GC) by a T , thereby
modifying the 120 downstream amino –acids and resulting in a premature stop codon.  Although this
girl’s parents were unrelated, the mutation was homozygous.  Hofstra  in 1996 published results of
mutation detection in endothelin 3. (Hofstra 1996) He found one individual with combined
Hirschsprung’s disease /WS phenotype out of 40 individuals.  This child had a G to T change,
converting phenylalanine 159 to cysteine.  Although the child was not from in-bred parents, he was
homozygous for this mutation.  Bidaud in 1997 published a patient with a G to A change, causing (A
17 T). (Bidaud 1997) This mutation was inherited from the child’s normal mother, leaving the child
heterozygous for the mutation.  While the child had HSCR, there were no features of WS. A further
heterozygous point mutation was discovered. Two patients of 174 had homozygous truncating
mutations. Both these patients showed features of WS. (There were four children with WS in the
series.) In 1999 Pär-Johan Svensson published a result of a mutation screening in a group of Swedish
Hirschsprung’s disease patients. (Svensson 1999) They picked up one mutation in endothelin 3.  This
was the insertion of  a G nucleotide in exon 2, (c.262insG), causing a premature stop codon two
codons further on.  This child was heterozygous for the change and again had no features of WS.
At this point a consensus seemed to be arising that heterozygous mutations in endothelin 3
might be sufficient to cause Hirschsprung’s disease, but would be insufficient to cause the full blooded
features of WS .  It seems however that the position is a little more complicated.  Pingault and others in
March 2001 presented a patient who had a heterozygous endothelin 3 mutation with long segment
Hirschsprung’s disease, heterochromia and deafness. (Pingault 2001)  This child had a mutation
(C169X) in the ET like peptide of distal pre-pro-endothelin .  Mutations in this region are thought to
interfere with the normal editing of the pre-pro endothelin, as they interfere with a disulphide bond,
importantly changing the structure of the pre-pro endothelin.  There is some reason therefore for
thinking that this is an important mutation.  This family had three affected members.  DNA was
available on two of the members.  Both the affected carried the mutation.  Both affected and two
unaffected members of the family were heterozygous for this mutation.  Unlike the earlier cases, the
individuals not only had long segment Hirschsprung’s disease, but also the features of WS.  This
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family was also screened for mutations in the endothelin B receptor, SOX 10 and RET.  No causative
mutations were found in any of these genes to explain the disease in this family.  A further study
published by Sakai in the European Journal of Paediatrics of March of 2000  found no mutations at all
in endothelin-3 in 28 patients, while finding two disease causing mutations in the same group in the
endothelin B receptor gene. (Sakai 2000)  For comparison in the same group of 28, four disease
causing mutations were found in the RET  proto-oncogene.  The mutation studies published so far
confirmed that endothelin 3 mutations are a rare cause of Hirschsprung’s.  They may be associated
with long or short segment disease.  They are incompletely penetrant.  They seem more likely to result
in the combined Shah Waardenburg syndrome when homozygous, and HSCR alone when
heterozygous, although this is not an absolute rule.
2.4.6. SOX 10
A naturally occurring aganglionic mouse model arose at the Jackson labs, and was described
by Lane and Liu in 1984. (Lane 1984)  This mouse model had aganglionosis, a white belly spot and
white feet.  The aganglionosis was transmitted as a dominant trait.  Homozygotes were embryonic
lethal before day 15.  Lane and Liu mapped this trait to mouse Chromosome 15.  Pingault and others in
1997 established homology between mouse Chromosome 15 and human Chromosome 22q12 – q13.
(Pingault 1997) They localised the ‘dom’ locus more precisely between markers and proposed some
candidate genes.  Southard-Smith in 1998  proposed Sox10 as a candidate gene for the ‘dom’ mouse
trait on the basis of its location, and its expression pattern in melanocytes and enteric glia. (Southard-
Smith 1998) Sox 10 is a transcription factor related to the testis determining gene SRY. (SOX stands
for Sry related bOX ). It includes a characteristic stretch of DNA known as the HMG domain. It maps
to Chromosome 22q13.  It has a broad expression in the peripheral nervous system, including the
enteric nervous system, cranial and sympathetic ganglia and peripheral nerves during development.
Southard-Smith and collaborators went on to describe a mutation of the Sox10 gene in the
‘dom’ mouse causing premature termination of the protein.  They demonstrated disrupted expression
of both Sox 10 and the endothelin B receptor in ‘dom’ mutant embryos.
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Herbarth et al  soon after confirmed the frame shift mutation which caused the truncated
protein. (Herbarth 1998) Pingault et al in 1998 found four Sox 10 mutations in fifteen WS/
Hirschsprung patients. (Pingault 1998) Interestingly one of these four patients had hypoganglionosis
on rectal biopsy rather than aganglionosis.  Eight other syndromic patients with Hirschsprung’s disease
did not have Sox 10 mutations and neither did thirty-four unrelated patients with non-syndromic
Hirschsprung’s.  Touraine et al  in 2000 screened twelve unrelated WS Hirschsprung patients.
(Touraine 2000)  They discovered mutations in three of these patients.  Each of the mutations was a
truncating mutation.  Two of the three patients had extensive aganglionisis.  In only one was the
aganglionosis short segment.  These three patients were picked for the study by virtue of the fact that
they had a progressive neurological problem.  It is not clear whether the other nine WS type 4 families
were also studied.  It is interesting that all the mutations were terminating mutations.  The authors
refer to a further paper by Inoue et-al in 1999, who described a patient with WS, severe neurological
problems (with both central and peripheral neuropathy) and Hirschsprung’s disease. (Inoue 1999)
Again this patient had a heterozygous mutation in SOX 10 that deleted the stop codon and created a
protein that was 82 amino acids longer.  The authors comment that seven out of  eleven SOX 10
mutations known to them arose de-novo in the  probands.  This might be expected of a gene expected
to be lethal, or at least to severely restrict the carrier’s ability to reproduce. Tomiyama H et al in 2001
studied sixteen patients with very long segment Hirschsprung’s disease, at least involving the whole
colon.  They found RET mutations in ten of these, and  a SOX 10 mutation in one of the sixteen.
(Tomiyama  2001)
In summary, in humans , as in the ‘dom’ mouse , SOX 10 mutations act in a dominant
manner.  They seem more likely to be associated with long segment aganglionosis, and are nearly
always associated with WS phenotypes.  In addition, they are associated with more diffuse
neurological abnormalities.  Reported mutations in SOX 10 have most often been of a type resulting in
major structural alterations to the protein.  Mutation screening for SOX 10 in non-syndromic
Hirschsprung’s is unlikely to be productive.
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Lee et al in 2000 showed that SOX 10 activates transcription of the microphthalmia gene
(MITF) required for melanocyte development. (Lee 2000 )  Lang et al (Lang 2000) demonstrated that
Pax 3 (Paired box 3 , another developmental gene implicated in some types of WS) interacts with SOX
10 to regulate RET expression.  These studies are starting to explain the molecular basis of the
phenotype of inactivating SOX 10 mutations.
2.4.7 Putting it together:
The neural crest arises as folds lateral to the neural plate towards the end of the second week
of gestation. Cells from the neural crest then migrate widely giving rise to derivatives in a wide variety
of tissues, including: sensory neurones of  dorsal root ganglia of spinal nerves, sensory neurones of
many cranial nerves, post ganglionic neurones of both sympathetic and parasympathetic systems,
including not only the enteric nervous system, but also elements of the cardiac, coeliac, mesenteric and
other plexuses. In addition it contributes to a wide variety of other tissues in the head and elsewhere,
most notably melanoblasts. (Gray’s Anatomy 1989)
Bolande in 1974 proposed the concept of a neurocristopathy, noting the common origin of a
range of benign and malignant tumours in cells of neural crest origin, as well as HSCR. (Bolande,
1974) Horstädius in his 1950 book summarised much work originating from before the second world
war. (Horstädius 1950) Amongst other things he had shown that the neural crest gives rise to the
enteric nervous system and to pigment cells. Ledouarin had shown that the gut microenvironment
could induce normal enteric nervous system differentiation in these neural crest derived cells.
(Ledouarin 1986)
A number of authors including Pachnis, Martuciello, and Attie-Bitach had shown that RET is
expressed by enteric neuroblasts, as well as in the developing kidney, and at other sites in the
developing cranial ganglia and spinal cord. (Pachnis 1993, Martuciello and Tam in Holschneider 2nd
ed., Attie-Bitach 1998) Taraviras showed that a functioning RET gene was necessary and sufficient for
GDNF and neurturin mediated signalling to maintain cultured neural crest derived cells. (Taraviras
1999)
The Liverpool group have shown that the expression of endothelin 3 is controlled in both time
and space in the developing gut. The localisation of endothelin 3 expression to the ileo-caecal region is
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fascinating given the tendency of long segment case transition zones to cluster at this level.
(Woodward 2000, Leibl 1999 )
Hearn et al have shown that GDNF acts to increase ganglion cell proliferation in avian
embryos. Endothelin 3 has a variable effect depending on ganglion cell density, but it seems that its
general effect is to inhibit differentiation of migrating neuroblasts, so allowing adequate numbers of
clones to remain to populate the whole gut. (Hearn 1998)
To summarise, we can infer that mutations in RET make the migrating neural crest cell
relatively insensitive to the proliferative signal provided by GDNF, and possibly other ligands
including neurturin. Mutations in GDNF have the same effect by failing to properly stimulate the RET
receptor. Mutations in ET-3 allow early maturation of migrating neuroblasts, resulting in an
insufficient population of dividing stem cells distally, while mutations in EDNRB have a similar effect
by making the migrating neuroblast relatively insensitive to ET-3. ECE-1 mutations act by making less
available ET-3. SOX 10 has effects on the expression of RET and possibly other proteins important in
neuroblast development. The WS phenotype suggests that these will include endothelin related
proteins. Mutations in SOX 10 may result in decreased expression of RET and possibly other proteins.
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Gene Locus Described mutations
RET 10q11.2 yes
GDNF 5p13.1-p12 yes
GFRα1 10q26
GFRα2 8p21
GFRα3 5q31
NTN 19p13.3 yes
Persephin 19p13.3
Artemin 1p33-p32
EDNRB 13q yes
ET3 20q13.2-q13.3 yes
ECE1 1p36.1 yes
SOX10 22q13 yes
SMADIP1 2q22 yes
L1CAM Xq28 yes
Table 2. 4 Summary of selected actual or hypothesised HSCR related genes, and chromosomal
loci. Linkages to chromosomes 9q31 and 21q22 are not mentioned as no specific gene has been
implicated at these sites. That these may not be the only genes involved in HSCR is suggested
both by the diversity of HSCR associated syndromes mentioned below, and also by the fact that
mutations in these genes accounts for less than half of all cases of HSCR. An additional locus on
chromosome 21 is suggested by the association with Down syndrome, which will be discussed
below, and in chapter 4.
2.5 Associated conditions.
Smith’s “Recognisable Patterns of Human Malformation.” mentions ten syndromes that are
occasionally or frequently associated with HSCR. The frequent associations are given as:
Down Syndrome, Smith-Lemli-Opitz Syndrome, WS. (WS associated with HSCR is now understood
as due to mutations in endothelin 3, endothelin B receptor, or SOX 10, as discussed in the section
above. Mutations in PAX 3 are associated with WS type 1, which also shows dystopia canthorum.)
The occasional associations are given as: Aarskog Syndrome, del 13q (now understood to be
due to deletions of the endothelin B receptor gene.), microcephaly, (one form of which is discussed in
chapter 6.) holoprosencephaly, small thumbs, major mental retardation in those with deletions
extending into 13q32 (presumably by a contiguous gene effect), Fryn syndrome, Metaphyseal
dysplasia (McCusick type), Nager syndrome, and Senter Kid syndrome. (Senter Kid syndrome
includes deafness, ichthyosis, and occasional HSCR.)
Large series vary in the frequency with which they report associated malformations. Many
report Meckel’s diverticulum for instance, whereas this is a common finding in the general population,
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and may not be reported by all. Ikeda and Goto reported a nation-wide survey of 1628 patients in 1983.
14.0% were reported as having a concomitant condition. 2.9% of the patients had DS. This is a
relatively low rate. (Ikeda 1984) Reding et al report 29% of 59 HSCR patients having an associated
anomaly, and Rajab and Freeman report 27%, while Swenson reports 11.2% in 501. (Reding 1997,
Rajab 1997, Swenson 1973) DS is the single commonest reported association. Amiel and Lyonnet in
an excellent recent review of the genetics of HSCR list 34 named syndromes associated with HSCR.
(Amiel 2001) Parisi adds three more in her review. (Parisi 2000) There are several recurring features in
these otherwise disparate conditions. Cleft palate is common to a number of the conditions, as is
agenesis of the corpus callosum, limb defects, mental retardation, and heart defects.vi Neural crest
related conditions are prominent, and have already been mentioned.
Smith-Lemli-Opitz syndrome (SLOS) is a rare condition presenting a series of features with
some overlap with DS, including a high incidence of congenital heart defect, duodenal atresia, and
HSCR. (OMIM 270400) A number of cases of HSCR have been reported in association with SLOS
(For instance, Patterson 1983, Kim 1985, Cass 1990.) SLOS is now known to be due to mutations in
the 7-dehydrocholesterol reductase gene. Affected children have low serum cholesterol, and elevated
serum 7-dehydrocholesterol level. This specific metabolic abnormality promises further understanding
of the biochemical mechanisms of HSCR. Lipid metabolism is also disordered in DS. In DS however,
cholesterol is high. (Bocconi 1997) In particular, the phenotypic similarity between DS and SLOS
suggest that a similar biochemical mechanism may be at work. vii
In fact Down syndrome is the associated condition of major clinical importance. It will be
discussed in some detail in the section below. Waardenburg Syndrome has been alluded to in the
section above dealing with endothelin pathway genes and SOX10. WS type I is due to PAX3
                                                          
vi For instance, the report of Say and Smith combines several of these features in a child with short
segment HSCR, who may have a variant of the Toriello-Carey syndrome. (Say 1996)
vii In fact RET is known to be anchored to the cell membrane in “lipid rafts”, which have been shown
to be essential for GDNF signalling. (Work quoted in Encinas 2001) It is interesting to speculate that
the cholesterol metabolism abnormality in SLOS may alter the composition of these lipid rafts, thus
upsetting GDNF signal transduction. The lipid metabolism abnormalities of DS may have a similar
effect.
If this is true, why then don’t all SLOS patients get HSCR? Perhaps certain polymorphisms in
the transmembrane domain of RET make them especially susceptible (or resistant) to membrane lipid
changes. It would be theoretically possible, although practically difficult to test all SLOS/HSCR
patients for the distribution of such polymorphisms, and collecting sufficient cases would take
considerable time. Testing the equivalent hypothesis for DS would be much more practical.
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mutations, features dystopia canthorum, piebaldism and deafness is not associated with HSCR and will
not be discussed further. (OMIM reference #193500 )
2.5.1 Down syndrome.
Down in 1866 published a description of Down syndrome, (“Observations on an ethnic
classification of idiots.”) based on the erroneous “Darwinian” assumption that Europeans were more
highly evolved than other races. (Down 1866) Here the Mongoloid slant of the eyes in Down
syndrome suggested that the mental retardation of these children was due to a regression to a more
primitive type (the “Mongoloid “type.), hence the synonym “Mongolism”, by which trisomy 21 was
known until the latter half of the twentieth century. Lejeune in 1959 put the understanding of this
condition on a more modern footing with the recognition of the role of trisomy 21. (Lejeune 1959)
The incidence of DS is given by Lancaster as 12.2 per 10,000 in Australia from 1981 to 1994.
(Lancaster 1997) In general DS is associated with advanced maternal age, rising to 3.75% at 46 years.
(Gardner-Medwin 1988) However various subgroups of DS are not associated with advanced maternal
age. About 5% of DS is due to an “atypical” karyotype. Half of these are Robertsonian unbalanced
translocations, the other half are other complex rearrangements of chromosomes giving trisomy 21, or
of mosaicism. About 5% of the children develop trisomy from mitotic errors, and, having a duplication
of one of the chromosomes of one parent, potentially can express two copies of recessive genes.
(Antonarakis 1993) Some of the atypical karyotypes result in triplications of less than the complete
chromosome. These karyotypes potentially give us the ability to map disease loci associated with
chromosome 21. Korenberg’s group has done this for congenital heart disease associated with
DS.viii(Barlow 2001) .
HSCR is also a recognised association of DS. Many authors have noted the co-occurrence of
DS and HSCR.  (Bodian 1963, Swenson 1973, Passarge 1967, Badner 1990, Garver 1985, Gravier
1966, Ikeda 1984, Rajab 1997, Quinn 1994.) Passarge, reviewing HSCR series to 1966 found an
incidence of 2.05% of DS in HSCR (24 cases in 1163.) Swenson found an incidence of 3.2% (16 of
493 HSCR patients) in his series including patients at several US centres from 1947 to 1973. Quinn et
al find 17 (13%) DS children in 135 HSCR presenting over a 17 year period. Quinn’s group of
                                                          
viii One of the four patients in Barlow’s group is also informative for the HSCR gene region.
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DS/HSCR had a similar distribution of length of aganglionosis to other HSCR, but the male to female
ratio was 12:5. In addition, half (9/17) of these children had other major congenital anomalies.
When DS is looked at as a risk for HSCR, Kallen gives a rate of 0.56% in 5,581 DS patients.
(Kallen 1996) Torfs gives a rate of 1.4% of 2,894 DS patients (Torfs 1998), while Buchin et al give a
rate of 2.1% in a referred population. (Buchin 1986) Aquino et al note one (0.8%) HSCR patient in 127
surviving Italian DS patients. (Aquino 1998) In general there is a rate of 1% of DS affected by HSCR.
This represents a 50 times risk compared to the general population.
Korenberg and others, and Rahmani and others mapped the DS critical region to 21q22.2. In
his large scale linkage analysis of 3,700 Mennonites who are part of a kindred carrying an EDNRB
mutation, Puffenberger not only mapped an HSCR locus to 13q22 (the EDNRB gene), but also
mapped possible modifier loci to 10q11 (the RET gene locus), and (weakly) to 21q22, the DS critical
region, as mapped by Korenberg (Korenberg 1989a, 1989b) and Rahmani (Rahmani 1990).
The mechanism of the high risk of HSCR in DS is not known. The possible mechanisms fall into
several categories:
1.) Interaction of an extra dose of a normal gene on chromosome 21 with a weak
susceptibility allele elsewhere, so that a disease causing threshold is crossed. Some of the known RET
polymorphisms would represent candidates as weak disease alleles for instance. Salomon has reported
a case of a DS/HSCR child also carrying a supposed susceptibility allele in the GDNF gene which may
represent this mechanism. (Salomon 1996)
2.) Interaction of an extra dose of a normal gene on chromosome 21 with an environmental
factor, such as high temperature, or some other teratogen. The author knows of no evidence in support
of this hypothesis.
3.) The homozygous over-expression of a rare susceptibility allele on chromosome 21. Such
an over-expression might come about through reduction to homozygosity of a gene in a mitotic
recombination error, or in a meiotic error with crossover. No evidence of such a reduction was found
in a study of the inheritance of chromosome 21 markers. (A Chakravarti, personal communication, and
unpublished results.) Were this to be the mechanism, the frequency of such an allele would have to be
consistent with the observed 1% risk to DS children. This implies an allele frequency of 1%, which
further implies that 1/10,000 pregnancies (or half all HSCR children) would be homozygous by simple
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Mendelian inheritance. Linkage analysis does not suggest such an important contribution from any
chromosome 21 gene. A further possibility might be that double homozygosity (three identical copies)
of a weaker susceptibility allele is required. To produce a HSCR frequency of 1% in DS, such an allele
would need to have a frequency of approximately 22% in the general population. Being weaker, such
an allele need not make an important contribution to disease susceptibility in the non trisomic
population.
The DS/HSCR phenotype is examined in chapter 4, and ways of using this clinical resource to
map HSCR loci on chromosome 21 are further considered.
2.5.1.1 Outcome in Down syndrome.
DS/HSCR children have recently been considered to do badly after definitive surgery for
HSCR. Quinn et al were able to follow up 13 of their DS/HSCR patients for a mean of eight years after
surgery. They found that only three of these children had a satisfactory result from surgery, in that they
had normal, or near normal bowel function. They counselled caution in offering more than a
defunctioning stoma to these children. In addition, they highlighted the high rate of HAEC in these
children. (Quinn 1994) By contrast, Caniano et al had earlier claimed that only one of eight survivors
of 13 DS/HSCR they had treated was unsatisfactory. Six of these eight had had “satisfactory”
definitive surgery. The need to give a saline enema once or twice a week was apparently not
considered problematic. (Caniano  1990) Shono and Hutson in 1994 retrospectively studied 110 of
their HSCR patientsix. Outpatient follow up data was obtained on 91 more than six months post
operatively. Perhaps surprisingly, only 48% were felt to have completely normal bowel habits. (Shono
1994) This paper raises the possibility that earlier follow up studies on HSCR overall may have been
insufficiently critical of results. Judged against Shono and Hutson, the results of Quinn et al look a
little less dismal, but we may wonder at the results claimed by Caniano. A reappraisal of results in
DS/HSCR is needed. A much larger group of DS/HSCR children is followed up in chapter 5, and
factors contributing to the success or failure of their surgery are considered.
                                                          
ix Including both DS/HSCR and non DS/HSCR. There were eight with DS of 110.
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2.5.2 Goldberg/Shprintzen syndrome
In 1981 Goldberg and Shprintzen described a brother and sister with HSCR, microcephaly,
cleft palate, and retardation. (Goldberg 1981) A number of case reports followed, not all of whom had
HSCR, and in many of whom the retardation was not severe. In retrospect, the children reported as
“Goldberg-Shprintzen syndrome” made a heterogeneous population.
Ohnuma et al reported a child with typical features of those later described by us (Mowat
1998) in association with chromosome 2 interstitial deletion. Ohnuma reports that nine of ten
individuals reported to that date (Ohnuma 1997) had abnormal CT brain scans. The child reported,
who had the typical facies of those reported by Mowat, had short segment aganglionosis, and diffuse
abnormalities of the brain, including loss of brain parenchymal volume, and hypoplastic corpus
callosum, amongst other features. The chromosomes were reported as normal in this patient. The six
children reported by Mowat defined a syndrome, some of whose molecular features are discussed in
chapter 6. Five of these six children had HSCR.
2.5.3 Haddad Syndrome (Ondine/Hirschsprung’s Disease) and other autonomic and sensory
disturbances.
When Bolande classified the neurocristopathies in his 1974 paper, he included HSCR and a
variety of benign and malignant tumours that were thought to take origin from a defective neural crest.
The association with central hypoventilation was not included. Haddad published his observations of
three cases of HSCR and OC in 1978, followed shortly afterwards by a number of others, for instance
that of Bower and Adkins (Bower 1980). It was clear that OC belonged in the spectrum of the
neurocristopathies.
OC results in hypoventilation, most pronounced during sleep, with relative insensitivity to
hypercarbia, and a lesser insensitivity to hypoxia, in the absence of other abnormalities of the cardio-
respiratory system. OC, (also known as congenital central hypoventilation syndrome [CCHS]), is
named after a figure from Germanic mythology.x Ondine’s curse properly refers only to the condition
where hypoventilation is restricted to the sleeping state. As stated above, OC and HSCR were first
                                                          
x Retold in “Sintram and his Companions, and Undine.” De La Motte Fouque. Publishers: Wells
Gardner, Darton & Co. Ltd, London. Fourth Edition, 1925.
52
reported together by Haddad in 1978. (Haddad 1978) Both are uncommon, and their co-occurrence
suggests a common aetiology, probably involving a fault of neural crest development.
D Weese-Mayer in the USA has collected a large data set derived from her central
hypoventilation patients. She has concluded that 16% of her OC patients have HSCR. Further, she has
demonstrated that symptoms of general autonomic nervous system dysfunction were more common not
only in the OC sufferers themselves, but also in relatives of those affected with OC, than in controls.
(Weese-Mayer 2001) Marazita et al in 2001 performed a genetic segregation analysis of this group and
concluded that OC was the most severe manifestation of a general autonomic disturbance. There is
most likely co-dominant Mendelian inheritance of a major gene for autonomic dysfunction. (Marazita
2001) It is unclear what this gene may be.
There has been a report of a mutation in exon 12 of RET in an OC/HSCR case. (Sakai 1998 )
Amiel et al also reported two RET mutations in 14 OC patients. Seven of these were Haddad syndrome
patients. There was one mutation in each group. Amiel et al felt that the available evidence, including
that published in their paper, supported a polygeneic inheritance for OC. (Amiel 1998) Bolk et al
carried out a screening program for mutations in RET, finding no mutations in 14 OC patients. (They
did find a familial pericentric inversion in chromosome 2 in one patient.) (Bolk 1996b) There has been
a report of an endothelin-3 frameshift mutation in OC, but in general there have been few positive
results from gene screening in OC. (Bolk 1996) This is surprising given the relatively frequent co-
occurrence of these two conditions.
It is even more surprising given that Burton et al in 1997 showed a decreased sensitivity to
inhaled CO2 in RET knockout mice. CO2 sensitivity in homozygote knockouts was approximately half
that in heterozygotes, which was about 60% of normal. (Burton 1997) Kurihara et al had earlier noted
that the endothelin-1 homozygous knockout mouse was unable to draw it’s first breath. (Kurihara
1994) Other genes are known (MASH-1, rnx) which result in disorders of respiratory control when
damaged in mice. (Dauger 1999, Shirasawa 2000) Although there is no other evidence linking these
two genes with human HSCR, they are candidate genes for human OC, and perhaps as modifiers for
HSCR.
There is evidence however for linkage of a 9q31 locus (near, or identical with the Riley-Day
dysautonomia locus) with HSCR. (Bolk 2000) Riley-Day (or Familial Dysautonomia) patients exhibit
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a range of mainly autonomic derangements, with overlap with features observed in HSCR. Indeed
HSCR and Riley-Day have previously been reported together. (Azizi 1984) The Riley-Day gene is
therefore a strong candidate as a HSCR modifying gene.
While EDNRB and ET3 mutations are known to be associated with abnormalities in
pigmentation and hearing, most HSCR do not have clinically obvious deafness or piebaldism. Cheng et
al have shown abnormalities not only of oto-acoustic emissions in HSCR children compared with
controls, but also of abnormalities in vibration sensation. Abnormalities in oto-acoustic emission were
so common in fact in Cheng’s patients that they are not consistent with an origin in mutations in
EDNRB or ET3. Three patients with severe clinical hearing impairment in this group may have
WS.(Cheng 2001)
Knowles et al studied 33 patients with slow transit constipation. Three were found to have a
family history of HSCR, and twenty were found to have a family history of constipation. These 33
patients were tested for sweat response, and for sensory response to heat and cold. 15 of the 33 were
found to have either a sensory deficit, an autonomic deficit, or both. (Knowles 1999) This paper is
important not only for demonstrating three families with a family history link between HSCR and slow
transit constipation, but for showing some cases of slow transit constipation to be part of an autonomic
neuropathy.
Forty one cases of Haddad syndrome had already been reported in the English literature at the
time of starting this thesis. These case reports are summarised and discussed in chapter 7. Haddad
syndrome presents a challenging spectrum of problems, and these children represent a subgroup of
more severely affected HSCR. The widespread autonomic disturbances related to OC, and the
ventilatory abnormalities associated with RET knockouts suggest that HSCR patients should be
carefully screened for subtle autonomic abnormalities. This issue is explored in chapter 8.
Kelly et al reported coexistent HSCR and oesophageal achalasia in male sibs. Both had short
segment disease, although one had an ileo-anal anastomosis for severe NEC. (Kelly 1997) Kelly quotes
Faure in 1994 who reported abnormal oesophageal manometry in patients with TCA. (Faure 1994)
Aslam et al have reported an abnormal turnover of colonic mucin even in the ganglionated bowel of
HSCR. (Aslam 1998) It seems likely from these reports that HSCR is most safely regarded as a
generalised disorder of the bowel. Predisposition to NEC may have as much to do with autonomic
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control of mucous defence, and of motility, than it does with technical aspects of surgery. Some of
these questions are also addressed in chapter 8.
Overall, the autonomic neuropathies are a diverse and overlapping group of conditions, of
which HSCR is one of the more common. It is likely that these conditions will be polygeneic, sharing
some genetic background, with some genes specific to particular conditions.
2.5.4 Other conditions.
Twins
Sarioglu et al reported a pair of discordant monozygotic twins. (Sarioglu 1997) Previously
Moore et al in 1979 had reported a pair of monozygotic twins discordant for HSCR. Identity was
established by the shared placenta, and by identical HLA and blood group antigens. The affected twin
had a sigmoid transition zone, while the unaffected twin had a normal rectal biopsy. (Moore 1979)
Reding et al in their series of 59 patients reported one discordant monozygotic twin pair. (Reding
1997) The author is aware of a further pair of (presumably) monozygotic twins in Nottingham
discordant for HSCR. (L Kapila, personal communication.) These rare cases are fascinating in the light
of our increasing genetic knowledge. Are these cases due to the imprinting of crucial genes in one twin
but not the other? Or is this just a stochastic effect on a common genetic background? This question
remains unanswered, but the same genetic mechanisms presumably are important in affecting the
penetrance of mutations in the known HSCR genes.
Hydrocephalus.
Okamoto et al reported a case of hydrocephalus and HSCR in a patient with a mutation in L1CAM,
(See Table 2.4.) and referred to another patient with X linked hydrocephalus and HSCR. Interestingly
this mutation, which involved a frameshift, was also present in the apparently healthy mother. In
common with a number of other HSCR associated conditions, there was agenesis of the corpus
callosum in the patient. The two separate cases suggest that the L1CAM mutation may not be a random
association with HSCR. (Okamoto 1997) In addition, it is known that a cellular adhesion molecule
exists in the DS critical region, (DSCAM, OMIM 602523) which may also be a HSCR candidate gene.
It remains to be seen what (if any) involvement polymorphisms in cellular adhesion molecules (CAMs)
have in modifying the phenotype of HSCR.
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2.5.5 Reports of karyotype anomalies
DS involving both partial and complete trisomy 21 has been reported in association with
HSCR on many occasions. This association is discussed in chapters 4 and 5.
 A number of cases of deletion of 2q22 were summarised by Lurie (Lurie 1994), one of whom had
HSCR. A further case is reported in this thesis, and more have been reported since the work reported in
chapter 6. These cases strongly suggest a HSCR susceptibility gene at 2q22. Work to localise this
interval is described in chapter 6.
Tetrasomy 9. Melaragno et al reported a patient with tetrasomy 9p, Dandy-Walker cyst, and
HSCR. This report is interesting in view of the subsequent report of 9q31 linkage, but is presumably
related to HSCR by a different mechanism (Bolk 2000)
Deletions of the long arm of chromosome 10 have been reported with HSCR, and are
discussed in the section dealing with RET mutations above. Deletions of the long arm of chromosome
13 have similarly been reported, and are associated with damage to the endothelin B receptor gene, and
are discussed in the section dealing with endothelin mutations.
Michaelis et al reported an interstitial deletion of 20p from 20p11.22 - p11.23 in a patient with
HSCR and autism. (Michaelis 1997) None of the genes summarised above are localised here.
Kerstjens-Frederikse et al in 1999 reported HSCR and multiple dysmorphic features, including
paroxysmal hypoventilation, in association with a deletion in 22q11.2 (Kerstjens-Frederikse 1999).
Assuming the boundaries of the deletion have been correctly assessed in this patient, it is possible that
this deletion may have a downstream effect on the SOX10 gene at 22q13, (See Table 2.4 ) or it may
mark a new HSCR locus. In their review Amiel and Lyonnet mention a case of partial trisomy 22
(22pter-q11)
Additional chromosomal anomalies summarised by Amiel and Lyonnet include several cases
involving 17q21: four cases with del 17q21, and four cases with dup 17q21-q23. They also summarise
single case reports of: mosaic trisomy 8, XXY karyotype, and partial duplication 2q. A case of
Turner’s syndrome (XO) is discussed in chapter 3.
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2.5.6 Children presenting late.
Chronic constipation is common around the world, and may present a severe challenge to treat
and to diagnose. (de Araujo Sant'Anna 1999, Stewart 1999) Keuzenkamp-Jansen et al found that only
66% of 137 chronically constipated patients followed up a median of four years after treatment were
considered cured of their constipation. (Keuzenkamp-Jansen 1996) When should we biopsy these
children? In children with chronic constipation failing to respond to medical treatment the question of
late diagnosed HSCR will often arise. The author is not aware of good evidence supporting any
particular criterion for performing rectal biopsy to exclude HSCR in children outside the neonatal
period. In 1998 Ghosh and Griffiths set out the results of their attempt “to develop criteria to prevent
unnecessary rectal biopsies in constipated children.” (Ghosh 1998) While this review looked at rectal
biopsies from 141 people, there were only 17 HSCR cases in the group. Only three of these 17 children
were referred after the neonatal period. The authors conclude that if the onset of symptoms was after
the neonatal period, a biopsy is unnecessary. Given that the author is aware of a trickle of anecdotal
cases who present with HSCR throughout life, this conclusion seems facile, especially as the neonatal
history is often forgotten in older children. Even if HSCR is only rarely diagnosed in later life, it is
surely important not to exclude it out of hand. In addition, Ghosh’s conclusion assumes that late
diagnosed HSCR is identical to classical HSCR. This was not proven.xi A more valid way to address
the problem of whom to investigate would be to analyse a large series of late presenting HSCR. Such a
series is discussed in chapter 3.
2.6 Alternative theories of aetiology.
Although HSCR has been shown to be the result of mutations in a number of genes, over half
the cases are not associated with known mutations. It is possible that environmental or other influences
might interact with these genetic factors. Several investigators have speculated on these factors.
Hershlag  et al investigated an association between CMV and HSCR. (Hershlag  1984) Tam et
al investigated HSCR patients, and reported finding CMV antibodies in serum. (Tam 1992) Kuroda et
al and Kobayashi et al investigated the possibility of an auto-immune aetiology. (Kuroda 1991,
Kobayashi 1995) Kobayashi demonstrated abnormally strong staining to ICAM 1 and MHC class II
antigen on hypertrophic nerve trunks and in small ganglia of the transition zone of HSCR, and on
                                                          
xi For instance, perhaps there is an acquired form, by analogy with Chaga’s disease?
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hypertrophic nerve trunks in the aganglionic colon. They compared this with controls, and speculated
that there might be an immunologic role in the pathogenesis of HSCR. The studied children were said
not to have HAEC. We await confirmation, and further understanding of these results.
Larsson et al found no correlation between maternal hyperthermia in pregnancy, and HSCR in
the offspring. (Larsson 1989) Rajab and Freeman looked at 85 children with HSCR born over five
years in Oman. Because Oman suffers a very hot and humid seasonal climate, a seasonal effect was
studied as well as looking for differences in incidence in warmer regions. No effect of temperature was
found.
In Rajab’s series, mothers of HSCR patients were however significantly older than the local
population  (p<0.001), but there was no paternal age effect. (Rajab 1997) Goldberg came to a similar
conclusion on a very small series in 1984. (Goldberg 1984) She reported that 4 of 7 HSCR children
born to mothers over 30 years old were first born, compared to 17% of all births to mothers over 30
being first born. If an age effect is present, it is evidently not great. This issue is addressed in chapter 3.
Finally, a small group of patients present with the HSCR/ colonic atresia combination. These
patients were reviewed by the author in 1997. (Croaker 1997) It is possible that the atresia, whether in
ileum or colon, acts as a physical barrier to migration of ganglion cells in these cases.
2.7 Summary
At the start of this work it was already clear that HSCR was polygeneic, and that RET was
probably the most important single gene. Defects in the endothelin signalling system are also
important. This understanding had been immensely helped by interaction between clinical observation,
animal models and human genetics. Mutations in some of these genes are pleomorphic, having
differing effects in different tissues.
It was clear at the start of this project that more than half of all HSCR cases still could not be
accounted for by mutations in any single known gene. Several recurring chromosomal aberrations
suggest where we should investigate further. In addition it is possible that polymorphisms in known
genes may be more important than previously appreciated. It is still possible that environmental factors
may play a part. How these genetic and other changes relate to the very broad spectrum of associated
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conditions is not yet understood. In particular, the spectrum of autonomic and other neurological
disturbances is not well defined.
2.8 Molecular biology summary
A number of molecular biological techniques are referred to not only in the literature review,
but also in the body of this thesis. It is appropriate here to give a brief overview of the subject as it
relates to this thesis.
As is well known, DNA (deoxyribonucleic acid) is the molecule by which heritable
characteristics are passed on in all higher organisms, excepting for some viruses. The last half century
has seen the development of techniques for purifying and storing DNA, and for reading its sequence.
Although originally a purely chemical method of sequencing was used, currently the Sanger
method is standard. This simple method described by Frederick Sanger and others, uses very similar
techniques and concepts to those used in PCR, but with the addition of small quantities of artificial
nucleotides that terminate the polymerase reaction randomly so that a series of partial copies of the
source DNA are formed whose length depends on the identity of the terminal base. The resulting
fragments are separated by length on a polyacrylamide gel, and the sequence interpreted.
For nearly all genes of interest the DNA sequence must be amplified by some technique
before a sequencing reaction can be performed on it. Before the introduction of PCR in the 1980’s,
genes of interest were introduced into bacterial plasmids using restriction enzymes. The bacteria could
then be allowed to multiply, being harvested after a suitable interval. Their DNA was then purified,
and the gene of interest sequenced.
Kary Mullis won the 1994 Nobel Prize for chemistry for his invention of the technique of
polymerase chain reaction (PCR) (Sakai RK 1988), which is now a mainstay of the molecular genetic
laboratory. This technique uses a heat stable DNA polymerase (usually from the organism
thermophilus aquaticus, hence “taq” polymerase.) to replicate a given DNA sequence by means of
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repeated cycles of denaturation and replication in a temperature cycling machine. The DNA sequence
to be amplified is defined by short DNA molecules (usually about 20 base pairs long) complementary
to each end of the fragment of interest, which act as starting points for the taq. Given complete
doubling at each cycle, 30 cycles of PCR would theoretically yield 230 = 1,073,741,824 copies of the
original molecule. This quantity of identical DNA molecules can then be routinely manipulated by
standard laboratory techniques to obtain sequence and size information.
In the work described in this book, two types of DNA fragments are amplified:
1.) Fragments of genes coding for particular functional proteins.
2.) Non coding segments of DNA that are known to be highly variable in length - the so
called microsatellites. Because the lengths of the microsatellite alleles is usually stable between
generations, these can be used as markers to check for transmission or non-transmission of parts of
chromosomes.
1.) In dealing with large numbers of fragments of genes coding for proteins that are potentially
involved in disease pathogenesis it is desirable to use a cheap and quick method to sort samples that
are likely to have sequence variants. There are a number of such methods available. The most widely
used, and possibly the least sensitive, is SSCP (Single Stranded Conformational Polymorphism)
screening, described by Orita and others in 1989 (Orita 1989). This method relies on the fact that a
single stranded sample of DNA will adopt a folding pattern (conformation) that depends upon its
sequence. Differently folded samples of the same size are expected to migrate through a gel under the
influence of an external electric current at different speeds, giving  different patterns of bands. Bands
that are different to the usual for a particular segment are then investigated further by sequencing.
SSCP is a type of gel electrophoresis. It is performed on polyacrylamide gel. (Hence PAGE -
PolyAcrylamide Gel Electrophoresis) DNA samples in polyacrylamide gels can be visualised by either
silver staining or radioactive labelling and autoradiography.
Sheffield et al showed that for DNA samples of 200 base pairs or less, the sensitivity of SSCP
averages 79%. They allow that particular details of the polymorphism and surrounding base sequence
60
may influence this sensitivity. Very small samples under 100bp were also felt to be less reliably
analysed using this method. (Sheffield 1993)
2.) Microsatellites are also run on PAGE as single strands, but in this case the sizes of the alleles
are compared, usually between family members. In this way we are able, for instance, to define an
interval that has been lost in a chromosomal deletion. Microsatellites are also importantly used in
linkage analysis to search for linkage between chromosomal locations and particular disease states. The
concept is that in multi-case families with HSCR or other conditions which are transmitted in a simple
way, one looks for markers which are transmitted with the condition. Linkage between a chromosomal
locus and the disease state is calculated using the LOD score (Defined as log10 ratio [probability that
linkage is real/probability that linkage is random])
Sequence variants that have been identified on sequencing can sometimes be confirmed by a
change in the ability of a restriction enzyme to digest the given fragment. If a search program, such as
that available on ANGIS (Australian National Genome Information Service), identifies a restriction
enzyme recognition site near the putative sequence variant, then it is possible that the sequence change
will change the ability of the enzyme to cut the strand at that point. Amplification of the fragment,
followed by digestion with the appropriate restriction enzyme will allow the recognition of a restriction
fragment length polymorphism (RFLP). This method is useful for rapid estimation of the frequency of
some common polymorphisms, and for confirming DNA sequence changes (where applicable) where
the sequence data may be unclear.
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3.1.) Aims:
1.) To characterise the clinical composition of NSW HSCR patients.
2.) To ascertain clinical material for the study of rare associated conditions.
3.) To provide a resource to support follow up and genetic studies.
4.) To study the reason for late presentation of HSCR.
3.2.) Materials and methods:
 Cases presenting to NSW paediatric units from 1st January 1975 to 1st January 1995 were
ascertained by retrospective review of medical records. Nearly all cases presenting after this time up to
1st December 1998 in NSW were also ascertained. Some patients presenting to the Royal Alexandra
Hospital, Camperdown between 1975 and 1960 were also ascertained.
Case series were notified to us from Monash Medical Centre, Melbourne, and from individual
consultants in Queensland. Complete ten year case series are available for Bristol Children’s Hospital,
and for the Nottingham Hospitals. Other individual cases were notified by treating physicians on an ad
hoc basis.
The case series for NSW and the ACT for the period 1st January 1975 to 31st December 1998
is considered to be largely complete, and this is referred to as the reference series. As this is a
retrospective review, not all data of interest has been available in the case history notes. The analysis
below is concerned with the reference series unless otherwise indicated. Associated clinical diagnoses
are those given in the case history notes and correspondence in most cases. Cases from outside the
reference series are used in the study of late presenting cases, and in subsequent chapters.
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3.3.)  Results: Details of NSW HSCR population.
3.3.1) Incidence. (Yearly and per capita.)
380 patients belong in this group: a rate of nearly 16 per year over the study period. The
overall birth rate for NSW and the ACT for the year 1994 was 92,768  (Day. 1994).  During this year
there were 18 new HSCR cases born, a rate of approximately 1 in 5,100 live births. With the long term
average incidence of HSCR at 16 per year, the incidence is close to 1 in 5,500 live births.  (See Fig. 1.)
HSCR by year
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Figure 3. 1 Incidence of HSCR in NSW and the ACT by year.
3.3.1.1 Potential errors in counting.
While not all the children in this group were born in NSW, it is assumed that, while some
children have moved into the state to be included in this review, some children with HSCR will move
out of state, roughly balancing the numbers. For instance 12 children on the database were born in the
Pacific Islands, and came to Sydney for treatment. Two children give Victorian addresses, and the
addresses of 11 are unknown. The potential scale of this error is therefore not large. Nonetheless, as
children leaving would have needed to be diagnosed late to avoid appearing in NSW medical records,
and because NSW is numerically the biggest state, it is likely that the incidence estimate may be
inflated slightly by movement of population. Children who have died before transfer to one of the
participating paediatric units have not been counted by the retrospective case review method,
potentially resulting in under-counting of case incidence. The observed incidence of 1/5,500 is close to
other large series estimates (Torfs 1998) and is probably very close to the true incidence.
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For comparison, the incidence of Down syndrome, commonly associated with HSCR,
averaged 126 per year during the same time period. (approximately 1 in 740 live births.) On average
1.5 children are born with the combination DS/HSCR per year, or 1% of all DS. This association is
discussed in detail in chapter 4.
3.3.1.2 Seasonal incidence.
There is no significant difference in incidence of HSCR births at any time of year. All
monthly totals are within 2 SD of the mean. (Fig 3.2. over page) In fact the observed monthly
incidence closely parallels the overall NSW monthly birth rate. (Day 1994) There was no attempt to
look for geographical clustering of cases, nor for clustering by different social backgrounds.  xii  Patients
came from a variety of ethnic backgrounds, predominantly from Europe and the Middle East, and the
Asia - Pacific region. Ethnicity is entered for 222 patients, of whom “Aboriginal” is given for 6. This is
consistent with the estimate of 2.9% for the percentage of Aboriginal confinements given by Day for
1994, giving the same per capita incidence of HSCR as in the overall population. No further attempt
was made to estimate specific ethnic incidence rates given the difficulty of isolating total birth rates for
each group.
HSCR by month of birth
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Figure 3. 2 Incidence of HSCR by month of birth.
                                                          
xii Work done by the author in Nottingham showed a significant clustering of constipated children in
areas with post codes associated with higher socio-economic deprivation indices. There was no such
clustering in a control group of HSCR patients, nor in a group of hernia patients. (“Social disadvantage
as a factor in childhood constipation.” Keon C, Ledger R, Croaker GDH. Poster at BAPS, London,
July 2001.)
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3.3.2) Maternal age, parity, birth weight, gestational age, and apgar scores.
HSCR gestations averaged 39.2 completed weeks in 342 cases where the data was available.
The range was 27 weeks to 42.5 weeks. This is identical to the NSW mean gestation for 1994. There
seems to be no tendency to prolonged gestation in this group.
The average birth weight was 3.39 kg in 333 children for whom a birth weight is available.
Both birth weight and gestational age were available in 329. From this it was calculated how many
standard deviations from the mean weight for age the children were. The average birth weight SD of
all the HSCR children was 0.07, implying that there is no significant difference in HSCR birth weight
from normal.xiii Similarly, there is no tendency for long segment aganglionosis children to be smaller
for gestational age than short segment children. Down syndrome children are however smaller, as
expected, and this is discussed in Chapter 4. There is a tendency for children less than 3 kg birth
weight to be more female: 48M: 21F compared with 195M:39F in those 3 kg and over, but this is not
statistically significant. There is also a tendency for proportionally more of the smaller children to have
TCA, but again this is not statistically significant. (9/69 children under 3 kg have TCA, while 15/235
children over 3 kg birth weight have TCA.)
32 children were born before 37 weeks gestation in this group. Their length of aganglionosis
was not significantly different to the overall group (there were 5 with TCA), but they did suffer from a
greater range and frequency of associated conditions than the overall group. Amongst these there were:
7 with Down syndrome, three with breathing disorders: one with Ondine’s curse, one who died of
“SIDS” aged three months, and one child with medium chain acyl CoA dehydrogenase deficiency with
retardation and evidence of central hypoventilation, one with Turner’s syndrome, and one with Smith-
Lemli-Opitz syndrome. Altogether there were 17 out of 32 premature children with another major
associated malformation, not related to the effects of prematurity.
The maternal age range in the series was 13 years to 42 years, with an average age of 27.8
years calculated from 272 where the data is known. This includes mothers of DS/HSCR children as
                                                          
xiii Data calculated using British normal values, rather than Australian values.
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well as mothers of HSCR children. This almost identical to the mean maternal age of 28.4 for all NSW
and ACT confinements for 1994. (Day 1997)
Because of an earlier report that suggested that HSCR children born to mothers 30 years and
over were more likely to be first born (Goldberg 1984), I looked at the proportion of first born HSCR
children born to mothers 30 years and over, and at the proportion of all HSCR children who were first
born. These figures were then compared with those given in Day, as above. There were 70 children
born to mothers over 30 where all data is to hand. 25.7% were first born, almost identical to the NSW
average of 26.2%. If children born to mothers of all ages are compared, the result is unchanged: 37.6%
of HSCR children are first born, compared to 39.5% of all NSW children sampled in 1994.
Because HSCR is a neurocristopathy with a link to Ondine’s Curse, (see section 3.3.4.1)
apgar scores were recorded where possible, to test the hypothesis that there is a diffuse autonomic
neuropathy with a tendency to altered arousal and hypoventilation in all HSCR children. Apgar scores
at one minute were available on 115 non-syndromic individuals who also had no congenital heart
defect. 84.3% had an apgar greater than 6 at one minute. This is nearly identical to the figure reported
by Day for all NSW pregnancies in 1994, and includes all gestational ages. The average apgar score
calculated for long segment patients is almost identical to the score calculated for short segment
patients. (8.38 and 7.77 respectively, calculated over 103 non-syndromic patients. Only 1 of 14 long
segment patients had an apgar score below 7, as opposed to 15 of 89 short segment patients.) As
expected, the average apgar is lower for the complicated HSCR patients (DS, CHD, other syndromes.),
than for the uncomplicated HSCR: 6.86 compared with 7.85 for all uncomplicated HSCR. (p < 0.005)
There is no evidence of an abnormal apgar score in non-syndromic HSCR.
3.3.3) Family history, Length of aganglionosis and sex ratios.
3.3.3.1) Family history and length of aganglionosis.
A family history of HSCR was available in 45 patients, (45/380 or 11.8%) who belonged to
34 kinships. There are 25 extended HSCR families; there are four parent-child families; there are 13
sibships; and there are 3 doubtful histories. Usable data on the length of aganglionosis is available on
342 individuals. The distribution of aganglionosis is shown in the chart below. The distribution is
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typical of other published series. A peak of incidence is noted in the sigmoid, and a smaller peak in the
region of the ileo-caecal valve. (Fig. 3.3) There is a trend to longer segment of aganglionosis in
familial cases. Regarding long segment aganglionosis as having a transition above the splenic flexure,
10% of sporadic cases have long segment aganglionosis, while 16.2% of familial cases have long
segment aganglionosis.
3.3.3.2) Sex ratios.
There were 73 females and 307 males in the group, a ratio of 4.2:1, comparable to other
published series. There was one genetic male intersex case, a case of MIS deficiency, and one case of
genetic female intersex, a case of Smith-Lemli-Opitz syndrome. These individuals have been counted
with their genetic sex.
3.3.3.3) Sex ratios in subgroups.
The sex ratio in longer segment aganglionosis is closer to equality than the overall sex ratio:
16F: 22M (1.4:1), while the short segment sex ratio: 53F: 289M (5.4:1) is more male, with little
difference between those children with low rectal transitions (below the peritoneal reflection: M:F =
4.7:1), and those with sigmoid transitions. The sex ratio for long segment cases with a transition
between splenic flexure and ileo-caecal region is M:F = 0.9:1 (17 cases), while there are 15 children
with the very longest segment aganglionosis, > 10 cm above the ileo-caecal valve. The male: female
ratio in this group is 2:1 This difference in sex ratios between long segment and very long segment
disease is not significant by χ2. (Two children in the database had total aganglionosis of the small
bowel, both were male. One was from the reference group, one from Queensland. The sex ratios are
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calculated from reference group cases only, to avoid the possibility of ascertainment bias.)
Sex ratio vs length aganglionosis.
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Figure 3. 3 Variation of sex ratio with length aganglionosis. (Low rectal: below peritoneal
reflection; standard: to splenic flexure; long: to 10cm above ileo-caecal valve; small bowel: all
more proximal cases.) Raw data shown below.
Length Number Ratio Sex
Low rectal 7 4.6 F
32 M
Standard 44 5.0 F
219 M
Long 11 1.2 F
13 M
Small
bowel
5 1.8 F
9 M
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Figure 3. 4 Distribution of lengths of aganglionosis in NSW HSCR reference group. “Low”
means rectal below the peritoneal reflection, so that no levelling biopsy done at laparotomy was
positive.
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3.3.4) Associated features.
3.3.4.1 Recognisable syndromes.
Overall there were 72 children of 380 who were felt to show a recognisable syndrome. 40 of
these were Down syndrome. Making up the other thirty two patients were twelve girls and twenty
boys. This difference in sex ratio between syndromic and non syndromic HSCR (excluding Down
syndrome) children is highly significant by χ2  test (p<<0.01). Eight of thirty one with a known
transition zone had long segment aganglionosis (TCA in seven). Specific cases are discussed below,
and summarised in Table 3.1. (over page.)
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Named Diagnoses Number affected.
Down syndrome 40
Developmental delay (non-Down syndrome: with or without other
features.)
28
Gastro-oesophageal reflux 25
Structural cardiac anomaly (non- Down syndrome) 17
Vesico-ureteric reflux 14
Undescended testis 12
Hypospadias 9
Ondine’s curse. (Congenital central hypoventilation syndrome) 5
“Goldberg-Shprintzen” like syndrome. 4
Cleft palate (with or without other features.) 4
Smith-Lemli-Opitz 2
Cerebral palsy 2
Tracheomalacia 2
Micrognathia 2
MIS deficiency 1
Laurence - Moon - Biedl syndrome (?) 1
Medium chain acyl CoA dehydrogenase deficiency 1
Ano-rectal malformation (with duodenal stenosis) 1
Late infantile spinal muscular atrophy 1
Hereditary multiple exostoses 1
Talipes 1
Hereditary haemorrhagic telangiectasia 1
Table 3. 1 Selected HSCR associated conditions from the NSW/ACT reference group. Diagnoses
are not exclusive.
3.3.4.1.1) Goldberg-Shprintzen like syndrome. (SMADIP1 mutation associated syndrome.)
This condition was recognised in 4 of 380 children in the reference group, or 1%. Most, but
not all individuals with the condition suffer HSCR. Aside from this, it involves microcephaly,
profound developmental delay, a characteristic facies, and a variety of malformations including cleft
palate and congenital heart disease amongst others. One of these patients had an interstitial deletion of
chromosome 2q22. It is of particular interest, and is dealt with in more detail in Chapter 6.
3.3.4.1.2a) Ondine’s Curse and HSCR (Haddad syndrome)
Five such patients were recognised out of 380 in the reference group. One of these patients
had been referred from outside the reference area. Unless some of these children suffered undiagnosed
neonatal SIDS, and are buried undiagnosed, the incidence in NSW is therefore 4 in 24 years, or 1% of
HSCR. This group is discussed in detail in chapter 7.
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3.3.4.1.2b) Possible autonomic disturbances.
 A number of other children had episodes recorded in their medical histories suggesting either
mild ventilatory control abnormalities, or other autonomic dysfunction. Nine children (apart from those
with Ondine’s curse) had ventilatory control problems, of whom one died of SIDS at 3 months, one
child had an abnormal sleep study, one child was noted to suffer from breath holding attacks and one
required prolonged post operative ventilation (45 hours) for reasons that are unknown. Apnoeic
episodes were noted in the other five children.xiv
One patient was recorded as having no tear production from one eye and one child was
recorded as having an episode of transient poor peripheral perfusion without obvious precipitating
cause. Gastro-oesophageal reflux was recorded in 25 children altogether, in one of whom it was noted
to coincide with oesophageal dysmotility.
Nine children were noted to have a squint; nystagmus was recorded in one child with deafness
and pigmentary disturbances. Three children with Ondine’s curse were noted to have a variety of
pupillary and extra-ocular problems, to give a total of thirteen.
3.3.4.1.3) Deafness with or without pigmentary anomalies.
Twelve children (3%) are recorded as suffering from deafness. Heterochromia (See Fig 3.4)
(or very pale irides) was recorded  in three of these. Nine of these children have associated mental
retardation, four due to Down syndrome. Formal audiometry was often not recorded, and conductive
deafness is also possible in some, especially in Down syndrome, which has a high incidence of otitis
media. Only one of these twelve children had long segment disease. This child had both total colonic
aganglionosis, autism, severe retardation, and very pale irides. There were five girls and seven boys.
Figure 3. 5 Pigmentary anomalies consistent with Waardenburg syndrome. Iris heterochromia in
a chronically constipated child (right). Wide inner canthal distance suggests a PAX 3 mutation.
White forelock (present lifelong) in the child’s father (left.)
                                                          
xiv The author speculated on the possibility that the Apgar score might reflect a tendency to later
apnoeic episodes. Apgar scores of HSCR patients have been discussed in section 3.3.2.
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3.3.4.1.4) Karyotype anomalies.
3.3.4.1.4.1) Down syndrome.
Down syndrome was present in 40 of 380 children with HSCR, or 10%. These children are of
particular interest, and are discussed in detail in chapters 4 and 5.
3.3.4.1.4.2) Miscellaneous karyotype anomalies.
No chromosome 10 anomalies were noted. One chromosome 13 anomaly was noted.
a.) Unbalanced translocation: 46XY t(4:13) with 4q tri
Although this child has partial trisomy of chromosome 4q, it is likely that the HSCR
phenotype in this child is due to interference with the endothelin B receptor locus on chromosome
13q22. Microcephaly, cerebral palsy, congenital heart disease, dysmorphic facies, undescended testes
and complex eye problems are recorded, but there is no data on deafness or pigmentary anomalies in
this child.
b.) Interstitial deletion chromosome 2: del 2q14.3 - q23.5 This child suffered from the Goldberg-
Shprintzen like syndrome mentioned in section 3.3.4.1.1, and discussed in detail in chapter 6.
c.) One child suffered from mosaic Turner's syndrome. The child’s mother was herself affected
with HSCR. While the Turner’s syndrome may be coincidental, the association has been reported
before, at least as a mosaic, (XO/XX/XXX) by Passarge. (Passarge 1967.) As HSCR is a sex modified
multifactorial condition with a lower risk in females, it is conceivable that loss of one X chromosome
may increase HSCR risk.
d.) Uncharacterised chromosomal anomaly. One child born in 1982 suffered from multiple
congenital anomalies (developmental delay; hypospadias; dysmorphic facies; muscular VSD; possible
deafness, and strabismus). No photograph is available to compare with other syndromic appearances.
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3.3.4.2) Renal tract anomalies.
39 patients of 380 were coded as having renal tract abnormalities. Eight of these had UTI
only. There were 14 of 380 (3.5%) with vesico-ureteric reflux. 3 had problems relating to bladder size
or configuration, with one suffering from giggle incontinence in addition. It is not clear whether these
bladder problems were congenital or acquired. There were two cases who suffered a degree of renal
impairment, which also may have been (at least in part) acquired. There was one reported duplex
kidney, one reported dysplastic kidney, and one ectopic kidney. There were three with haematuria or
proteinuria. There were three with hydronephrosis of unspecified origin. One child with several other
VATER features was also noted to have a small kidney and HSCR involving the descending colon
(post mortem diagnosis). Three of those with structural abnormalities of the renal tract also had
undescended testes.
The overall sex ratio in those with renal anomalies was 10 females, to 29 males. 24% of those
coded as having renal tract anomalies had long segment disease (transition above splenic flexure) as
against 10% of the non-renal group who had long segment disease. This difference, while suggestive,
is not significant by χ2 test.
3.3.4.3) Undescended testes.
Patients with UDT were of interest because one of our HSCR patients suffered also from MIS
(Mullerian Inhibitory Substance) deficiency. MIS is a protein distantly related to TGFβ which is
involved in descent of the testis amongst other roles. (See section. 3.3.4.6) 12 patients definitely, and
one patient possibly were shown to have UDT. This compares with the general rate of UDT in the
population of 1.58% (Hutson) 5/13 were associated with Down syndrome. This rate is not significantly
different to the general population.
3.3.4.4) Cardiac anomalies.
Cardiac anomalies (including murmurs that were otherwise uncharacterised) were found in
65, of whom 28 had DS. The sex ratio was M:F = 7:1 overall. Of these, 17 children who did not have
DS had a structural cardiac anomaly documented. This represents 5% of the non-Down syndrome
HSCR population. There were four girls and 13 boys. Three of the seventeen had total colonic
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aganglionosis, with aganglionosis extending well into the small bowel in two. Two more had a splenic
flexure transition. The others had short segment disease. Brief details are given in the Table 3.4.
ID Other Associated Features length of aganglionosis family history of
HD
Sex
39 ?small VSD 41cm above I-C valve f
660 AS/AI ileal f
260 ? Laurence - Moon - Biedl syndrome.
Polydactyly; ASD (large); myopia
recto-sigmoid junction f
177  A-V canal; duodenal atresia;
brachycephaly;  SLOS.
sigmoid ? f
141 hypospadias; abnormal facies;
muscular VSD
Descending colon m
144 "trivial" VSD. rectal yes m
43 Ebstein's anomaly. splenic flexure m
627 "Shprintzen’s" (see chap 6.) pulm.
atresia; VSD; mitral stenosis.
rectal m
48 VSD sigmoid m
619 mild pulmonary stenosis mid small bowel. yes m
140 PS and small muscular VSD. rectal - ultrashort yes m
45 TGA sigmoid m
279 VSD, PDA unknown m
277 pulmonary stenosis r-s junction m
305 PFO noted early, but later echoes
normal
sigmoid m
679 ASD; (has cutis laxa intermedia) splenic flexure m
692 ASD/VSD recto-sigmoid m
Table 3. 2 Details of patients with structural cardiac lesions.
3.3.4.5) Developmental delay.
28 children of 380 were classified as having developmental delay, other than that due to
Down syndrome. Five of the 28 were felt to have primarily behavioural problems. Three of these have
been called ADHD.xv The degree of developmental delay in these three is questionable. One child was
felt to have problems with gross and fine motor control, but there was no concern with speech or
academic development. Of the remaining 22 with a clear intellectual deficit, the majority in fact have
developmental delay as part of a syndrome, or in the context of multiple problems. Four of these
children were identified as having a syndrome linked to a chromosome 2 locus. (See chapter 6.) One
has Ondine’s Curse. (See chapter 7.) Two were felt to have Smith-Lemli-Opitz syndrome. Two showed
features of WS. One had mosaic Turner’s syndrome. The remaining children suffered from a variety of
conditions. Six of the children had structural cardiac problems. The children with developmental delay
showed a more even sex ratio than non-syndromic HSCR: M:F = 18:10 (1.8:1)
                                                          
xv One child in fact had been in prison by the time of late follow up for a rather extreme form of
behavioural disturbance: he tried to burn down his parents house!
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If those with behavioural disturbances alone are excluded, the ratio is similar: M:F = 14:8.
Five have a positive family history of HSCR. The distribution of lengths of aganglionosis in the
developmentally delayed children is typical.
3.3.4.6) Miscellaneous anomalies.
MIS deficiency. One male intersex child was shown to be a compound heterozygote for
mutations in MIS, causing a complete MIS deficiency syndrome, as well as having short segment
HSCR. This case has already been reported. (Cass 1992) The testes were undescended, and there was
persistence of Mullerian structures.
One child in the series had associated colonic atresia. The colon distal to the atresia was
aganglionic, while the proximal colon was ganglionated. The atretic segment involved the transverse
colon. Interestingly this child also suffered from a  transverse deficiency of the right forearm, with a
shortened forearm, and rudimentary finger stubs. In one other sibship in the series, the sister of a
HSCR patient suffered from limb reduction.
The likely explanation of the combination of abnormalities in this child is that the colonic
atresia presents a physical barrier to ganglion cell migration. (Akgur 1993) Bowel atresia has been
hypothesised to be due to an intra-uterine vascular accident, (Louw 1966) while there has been an
increase in rates of limb reduction abnormalities reported in children of mothers who smoke. (Czeizel
1994) The mother of this child smoked during pregnancy, but there is no other history of drug
ingestion in pregnancy, and in particular no history of vaso-active drug ingestion, such as cocaine or
amphetamine.
Intra-uterine exposure to nicotine may be the unifying cause of all three malformations in this
child. If this is true, the time of the insult is tightly constrained by the fact that ganglion cells had not
yet progressed past the transverse colon at the time of the atresia. On the other hand, the insult
occurred late enough to allow formation of rudimentary finger stubs. These factors suggest either that
the event occurred at the twelfth week of gestation, or that there was more than one event, or an
underlying genetic tendency to both colonic atresia and limb reduction. The sibship in which limb
reduction was seen in one sib, and HSCR in another may or may not be relevant to this child, as it is
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assumed that HSCR in this child is secondary to the atresia, which is clearly not the case in the other
family.
3.3.4.7) MEN 2 and related conditions.
No child with a MEN 2 related malignancy is known to be enrolled in the reference series.
There are two individuals known to us from NSW with a codon 620 RET mutation who present with
both HSCR and FMTC. These patients were made known to us specifically because of this association,
and were born well before the study period. There is one child from the reference series with a mid-
transverse transition zone, and neuronal dysplasia of the appendix, who was felt to have oral mucosal
neuromata. No further information is available to support a diagnosis of MEN2b.
No children in this series were noted to have a thyroid abnormality of any sort at the time of
ascertainment.
3.3.4.8) Hypospadias.
Nine of 308 males suffered hypospadias, a rate of 2.9%. This compares with the estimated
population incidence of approximately 0.3%. These children tended to be small, averaging 0.5 SD
below the mean birth weight for gestational age. In four of the children, hypospadias was the only
associated feature noted. In the others a combination of major malformations was recorded. Four had
structural cardiac lesions of varying severity, one had Down syndrome, one had an uncharacterised
dysmorphic appearance and one had interstitial deletion of chromosome 2, with multiple
malformations.
3.3.4.9) Duodenal atresia.
Duodenal atresia or stenosis was seen in 10% of Down syndrome /HSCR patients. There were
two patients with duodenal atresia or stenosis in 340 non-DS patients. One of these was thought to
have Smith-Lemli-Opitz syndrome type 2, and the other had an ano-rectal malformation, HSCR with a
descending colon transition, a hypoplastic gall bladder, and duodenal stenosis.
Other anomalies are noted in Table 3.1.
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3.3.5) Enterocolitis
The overall rate of HAEC was 100 of 380. (Definite: 64, possible: 30, probable: 6) + 2 with
disuse colitis of defunctioned limb. Of those without Down syndrome, there were a total 87 of 340
(26% definite, probable and possible.)
The rate in DS is higher. (definite: 8, possible: 4, probable:1) + 1 with disuse colitis of defunctioned
limb. (See Chapter 4) Down syndrome total 13/40 (33%)
The rate of HAEC was the same in HSCR diagnosed early and late. (Late diagnosis being later than 90
days. See next section.)
3.3.6) Late diagnosed HSCR
3.3.6.1) Background: 
Could late presenting HSCR be a genetically separate form of disease? One possibility is that
ganglion cells may be present throughout at birth, but then disappear for some length, for reasons that
may be genetic or environmental. If late diagnosed HSCR is a separate condition, then we might expect
a different sex ratio, a different family history rate, a different distribution of length of aganglionosis, a
different pattern of associated conditions, and possibly a different post-op course. In addition, it is
likely that the incidence of late presenters would be constant. If, on the other hand, late presentation is
due solely to failure of early diagnosis, then we would hope to see earlier diagnosis in our overall
group as well as a decreasing incidence of late diagnosis with increasing awareness of the disease over
the last 30 years. Swenson et al reported a median time between onset of symptoms and diagnosis of 3-
6 months. In addition he reported that only 94% of patients had delay in passage of meconium.
(Swenson 1973) Klein and Philippart reported that the mean age of diagnosis had declined from 18.8
months in the 1960’s to 2.6months in the 1980’s. (Klein 1993)
3.3.6.2) Materials and methods:
For the purpose of this study, late presenting HSCR was defined as HSCR that was diagnosed
at 90 days or more of life, irrespective of gestation. In the reference group 289 patients of 348 for
whom we have an age of diagnosis were diagnosed at less than 90 days of age. (83%). We then queried
the entire database for late presenting HSCR. 100 such patients were found.
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3.3.6.3) Results:
A series of 100 patients in whom the diagnosis was made at more than 90 days were identified
from the HSCR database. In two thirds of these a history of first passage of meconium had been
obtained. In only half of these (one third overall) was there a history of delay in passage of meconium.
3 children had long segment disease, including one with TCA, (who presented at 3 months.) A further
6 had transitions between the sigmoid apex and the splenic flexure. Overall there was less long
segment disease in this group than in the early presenting group, however one child was diagnosed at
three months with an ileal transition zone..
As seen in Figure 3.6, there has been a noticeable decline over 25 years in the rate at which
HSCR affected children are being diagnosed late. This seems to be stabilising, so that 60% of children
diagnosed in the first year are diagnosed in the first week.xvi There has been no change in sex ratio of
late diagnosed HSCR as the average age of diagnosis has improved.
Figure 3.6 shows the percentage of all HSCR who present in the first week of life as a percentage of
those who present in the first year. The improvement in rates of early diagnosis is clear. Before 1970
ascertainment was very low, and part of the low rate of early diagnosis is possibly artefactual. (The X
axis is 5 year periods beginning in the given year.)
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Figure 3. 6 Percentage of children diagnosed in the first week of life compared to the number
diagnosed by the first birthday, by five year periods beginning in the given year.
                                                          
xvi Expressing the percentage in this way corrects to some degree for distortions in recent years from
very late presenters who may not yet have presented.
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The sex ratio of late presenters in the reference group is 4:1, nearly identical to the 4.2:1 of the overall
group . Overall the sex ratio in the whole late presenting group is 2.7:1, significantly different to 4.2:1
as in the overall group. This latter difference may represent an ascertainment bias.
A family history of HSCR was noted in the early diagnosed group from the NSW reference
series in 28 of 288 cases (10%). Interestingly in the 55 late diagnosed from the reference group, there
was a positive family history in 13%. The same pattern was noted in the overall group of 100 late
diagnosed, with a 16% positive family history, two thirds of whom were siblings. The incidence of a
positive sibling history in the late diagnosed group is significantly greater than in the reference series
of all HSCR. (p < 0.001).xvii
There is a similar range of associated conditions in these children as in the early diagnosed
group, with 17 being developmentally delayed, and 12 of these having Down syndrome, a similar
percentage to the overall group. In spite of the late presentation of these children there was no increase
in the rate of incidence of HSCR Associated Enterocolitis (HAEC). There were ten patients with
definite episodes, and a further seven with possible episodes of HAEC.
Late diagnosis does seem to have had a small effect on the growth of these children in that
weight (corrected for gestational age) in late diagnosed HSCR was -0.378634634 SDxviii below average
at the time of operation, while weight at time of definitive operation in early diagnosed HSCR was
close to normal, being 0.08952 SD below average. The SD was calculated on 13 late diagnosed HSCR
for whom we have the weight at time of operation, and 19 early diagnosed HSCR for comparison. The
difference was not statistically significant. There was a slight tendency to be lower on percentiles with
increasing length of diagnostic delay, but again, and surprisingly, this was not statistically significant.
                                                          
xvii In at least one case known to the author, the late diagnosis was only made after the birth of a
younger, more obviously affected sibling.
xviii SD: Number of standard deviations below the population mean calculated using an Excel macro
based on British population data.
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3.4 Discussion.
3.4.1) Late diagnosed HSCR.
The first and obvious conclusion from the existence of 16% of the HSCR population who are
diagnosed late, is that this is a condition that is not inevitably fatal if untreated. It is of note that rates of
incidence of late presenting HSCR have fallen consistently over the last 25 years. Even allowing for
the shorter time elapsed since the birth of the more recent birth cohort, there is a significant effect. This
is confirmed by the shift to earlier diagnosis even in those under one year of age at diagnosis. This is
what would be expected if late presenting HSCR were not a distinct disease, but the same disease
presenting late for technical or social reasons.
The low incidence of long segment disease is not surprising, but it is of interest that some
children  with long segment disease should manage for prolonged periods without problems. Weaning
is often associated with the onset of symptoms in these children, and this is reflected in the high rate of
breast feeding recorded amongst the mothers of the late diagnosed group, compared to the early
diagnosed group.
The high rate of positive family history is of interest. In some cases known to the author, the
diagnosis was only considered in a chronically constipated child after the birth of a new, and clearly
affected sibling. This phenomenon raises the possibility that there is an ongoing HSCR population in
the community undiagnosed, for want of an affected sibling! More generally it may reflect a failure on
the part of clinicians at one time to take an adequate family history, or to consider its implications if
they did.
Encouragingly, we have not shown any increase in risk of development of HAEC in late
diagnosed HSCR. Neither have we seen a significant average growth failure in these children, although
they do have a tendency to be small. The cost of late diagnosis in terms of suffering and possibly also
in the more subtle effects of chronic ill health is harder to quantify.
The incidence of late diagnosed HSCR has been falling as the awareness of HSCR has
increased over the last 30 years, and perhaps as the availability of speciality trained paediatric surgeons
has increased. There is no evidence that late diagnosed HSCR is genetically or pathologically distinct
from other HSCR. These children are slightly lower on percentiles at operation than their earlier
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diagnosed brothers. But there are few other differences. The main unresolved issue with late diagnosed
HSCR is when to submit the child with chronic severe constipation to anaesthetic and biopsy. Some
would advocate a very non-interventionist approach to biopsy. (Ghosh & Griffiths) On the basis of the
current series of 100, the author does not feel that this is appropriate. The development of clinical
indicators for the investigation, classification and management of chronically constipated children is a
pressing need.xix
3.4.2) General demographic features of Australian HSCR.
Specific features of these results have already been discussed in the appropriate sections
above. The per capita incidence of HSCR appears comparable with that given in the literature from a
variety of locations and ethnic groups. There is no seasonal peak, and the rate appears to have changed
little over the last 25 years. Similarly, there is no evidence for a maternal age effect, or an effect from
birth order. xx The high rate and variety of associated anomalies are consistent with the polygeneic
model of disease put forward by others. (Passarge 1967, Badner 1990.) Of particular interest is the
more equal sex ratio observed in some syndromic forms of HSCR. This not only supports the
polygeneic model, but suggests that more than one different genetic pathway may be involved. Of
equal interest is the fact that renal tract anomalies are not more common. We know that RET mutations
are relatively common even in sporadic cases of HSCR. Damage to this gene in the rodent leads to
severe renal anomalies. We know from rodent knockout studies that proper expression of RET and its
ligand, GDNF, is also important for the normal development of the kidney. Renal defects were seen in
both homo- and hetero-zygous GDNF knockout mice. (Schuchardt 1994, Pichel 1996.) By contrast,
renal tract anomalies are only rarely seen in human HSCR. We do not know why this is.
                                                          
xix The author has been reviewing a large series of constipated children, and has established a link
between low social class and constipation. (This work was presented as a poster at BAPS in 2001.
“Social disadvantage as a factor in childhood constipation.” C Keon, R Ledger, GDH Croaker 2001)
Even in the absence of HSCR, these children are slightly smaller than non-constipated “normal”
children. At retrospective review of case notes for all rectal biopsies, there are in fact few features that
reliably predict a positive biopsy. Explosive decompression after PR examination is probably the best
single indicator. (S Rajak, D Croaker. Unpublished audit. Nottingham 2000) Low social class might be
regarded as a weak negative indicator for a positive biopsy. It is possible that the non-invasive
modalities discussed in chapter 8 will have a role to play in the assessment of the chronic severely
constipated child, and in deciding who to send for further investigation and biopsy.
xx A paternal age effect has not been looked for, as a suitable comparison group is lacking. In fact the
mean paternal age is 30.8 years, and is not obviously elevated.
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The ratio of male to female in TCA is consistent with the majority of these cases being due to
RET mutations with approximately 70% penetrance in males, and approximately 50% penetrance in
females. There is a somewhat higher frequency of males in the very longest segment aganglionosis in
our series. Further case reports of TIA (Shimotake 2001, Tomiyama 2001, Saxton 2000, Inoue 2000,
Shim 1999, Finaly 1999, Shimotake 1997, Ziegler 1993, Zerella 1993, Lopez Gutierrez 1991, Fodstad
1990, Ziegler 1987, McKinnon 1977.) confirm the impression that there is a male preponderance at
this level of aganglionosis, with a sex ratio of 1.6:1, (32M:20F) similar to that for TCA with small
bowel transition in our series. In addition, Inoue (Inoue 2000) notes that male patients tend to have
more severe aganglionosis than females with identical mutations in RET. There were five mutations in
the tyrosine kinase domain of RET in Inoue’s group of 15 very long segment patients. Shimotake
(2001) reports a further homozygous mutation in RET exon 17 with TIA. Interestingly there have been
few reports of renal abnormalities in this group of patients, suggesting differences between humans
and the rodent knockout model.
McKinnon and Cohen (McKinnon 1977) suggested that TIA was autosomal recessive and
genetically distinct from other forms of HSCR on the basis of six sibships. The example of the RET -/-
mouse, and the GDNF -/- mouse seemed to support this idea, except that few examples have been
found of  humans homozygously mutant in RET at any level of aganglionosis, and no examples of
homozygous GDNF mutations are known to the author.  The imbalance of the sexes in this most severe
phenotypic form of HSCR may be due to the additive effects of RET mutations and lacking a second X
chromosome, or it may be partly due to specific RET mutations in the tyrosine kinase domain of RET,
as the penetrance of RET mutations is known to be sex modified. (Shimotake 2001, Shimotake 1997).
In addition there are reports of WS phenotype in TIA, and there are a small number of reports of
SOX10 mutations in very long segment aganglionosis consistent with mutations in this gene.
(Tomiyama 2001).
Bodian and Carter (Bodian 1963) reported a male predominance of 7.2:1 in aganglionosis
where only the rectum was involved. We have not observed this increased male predominance at the
shortest lengths of aganglionosis, but even in a series of 380, only a few extra (or fewer) females with
rectal length aganglionosis would be required to alter the sex ratio appreciably.
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There has been a feeling amongst surgeons that HSCR was rare or even non-existent amongst
premature infants. This study shows that that belief is not true. In fact babies born very prematurely are
a little more likely to suffer from an associated syndrome, but HSCR is not excluded by prematurity.
Down syndrome in particular is associated with prematurity, and carries a high risk of HSCR.
3.4.3 Associated conditions.
This large series confirms previous series which show a highly significant association
between HSCR and a number of other conditions. Previous series report rates of associated conditions
between 11.2% and 29%, as noted in chapter 2 (Section 2.5). There are 174 separate diagnoses in 380
patients shown in Table 3.1. These associated conditions can be put into three groups:
1.) Conditions with a significant non-random association with HSCR.
DS is the most common and significant such condition. In our series it affects 10% of the
HSCR patients. Some rarer conditions such as Ondine’s Curse and Smith-Lemli-Opitz syndrome type
2 also are clearly recognised to have a non random association with HSCR, and those associations are
seen again in this series.
2.) Conditions which are common in the general population, and which may or may not be
related to HSCR.
Meckel’s diverticulum is such a condition. A number of urological conditions are also
common. Vesico-ureteric reflux has been seen in 14 of 380 patients, or 3.7%. Kramer writing in
Kelalis, King & Belman’s textbook of urology quotes several authorities to arrive at an incidence of
vesico-ureteric reflux of less than 1% in the general population. (Kramer 1992) In particular, Ransley
found 7 cases of reflux in 535 otherwise apparently normal neonates (1.3%). Our incidence of 3.7%
must be regarded as a minimum, as reflux was not routinely looked for, and may not have been
recorded in every instance. While it is tempting to think that this high incidence of vesico-ureteric
reflux may reflect a defect in the RET-GDNF signalling system expressing itself as an abnormality of
the vesico-ureteric junction, it is also possible that this may be secondary to surgery, or to chronic
colonic distension. There has so far been no evidence of linkage to RET in vesico-ureteric reflux
families. (Shefelbine 1998)
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Ten children (2.6%) were recorded as having had at least one episode of urinary tract
infection (UTI) recorded. (A further thirteen had vesico-ureteric reflux, and may have had UTI to bring
them to notice.) This compares with 1 - 1.4% quoted by Rushton in Kelalis King and Belman for the
incidence of neonatal bacteriuria, with symptomatic UTI being one third to one tenth as common.
(Rushton 1992) Again, this figure is almost certainly lower than the true incidence. Some of these
infections are likely to relate to surgical instrumentation as well as to any underlying abnormality.
Twelve children are recorded as having UDT. One patient has clinical and molecular genetic
evidence of MIS deficiency, raising the possibility that there may be a link between MIS deficiency
and HSCR. Twelve children is 3.1%, similar to the rate given by Kogan for term neonates. (Kogan
1992) There is therefore no evidence that UDT is more common in HSCRxxi.
3.) Conditions which are rare, and which may be aetiologically important or may be a random co-
occurrence with HSCR. Our patient with medium chain acyl CoA dehydrogenase deficiency may be
such a patient. It is impossible however to be certain whether such conditions have an impact on HSCR
susceptibility when they are themselves rare.
3.5 Summary.
The incidence of HSCR in the NSW population from 1975 onwards has been shown to be
consistent with other published series. It shows no seasonal variation. HSCR children on average are
born at the same gestational age as other children from the study area. In particular, and contrary to
surgical folklore, there seems no tendency to very late gestation. They are born to mothers who are the
same age as other mothers in the study area, and are as likely to be first born as other children. The
significant incidence of a positive family history is again highlighted.
The sex ratio in HSCR is again shown to vary with length of aganglionosis: short segment
cases being more male, and long segment cases more equally distributed, with the caution that very
long segment cases may again show a moderately increased male predominance.
There has been a gradual decline in the incidence of late diagnosed HSCR, which presents as
a condition identical to early diagnosed HSCR. Delayed passage of meconium is often not present in
                                                          
xxi In addition, screening of several of the UDT/HSCR children for the mutations seen in the child with
the MIS deficiency (who was a compound heterozygote) showed no abnormality. G-C Yang. Personal
communication.
85
the history, or has been forgotten by the time of presentation. A family history is surprisingly often
present in these children.
The variety of associated conditions seen in HSCR highlight the genetic heterogeneity of the
condition. Some of these specific conditions will be studied in more detail in later chapters. Syndromes
associated with developmental delay are the most common and important of these conditions. Down
syndrome accounts for two thirds of the children with clinically severe developmental delay. Colonic
atresia by contrast, appears to be related to the development of HSCR by a very specific anatomic
mechanism (physical block to migration) unrelated to the development of other neurological structures.
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4.1 Hypothesis.
As there are no known HSCR susceptibility genes on chromosome 21, DS must act to
increase risk for HSCR by over-expression of some undescribed gene on chromosome 21. Other
described genes in HSCR have pleiotropic effects and recognisable phenotypes. The author proposes
that HSCR associated with DS will result in a specific phenotype of either DS or HSCR or both. This
phenotype may help guide genetic searches on chromosome 21.
4.2 Introduction:
A number of authors have contributed to our understanding of the genetic basis of HSCR
(Badner 1990, Bodian 1963, Passarge 1967)  , but this understanding advanced greatly in 1994 with
the identification of the RET proto-oncogene as an important part of the aetiology of the condition
(Luo Y 1993, Romeo 1994, Edery 1994.), and with subsequent genetic discoveries (Chakravarti 1996,
Edery 1996, Pingault 1998, Wakamatsu, 2001). However mutations in these genes only account for a
minority of cases, and offered no clear understanding of the relationship of HSCR to DS, which had
long been  noted  (Passarge, Graivier L).  While noting the presence of DS at rates from 2.9% (Ikeda)
to 13% (Rajab, Quinn) of all HSCR patients, earlier collected series have given little overall
information about this sub-group of patients which might give clues to the underlying molecular
genetic mechanisms at work, not only in DS, but in other forms of the disease. DS children have an
approximately fifty fold increase in incidence of HSCR, with 1 - 2% suffering the condition compared
to the population incidence of about 0.02% (Torfs). This increase in risk suggests that Chromosome 21
contains HSCR susceptibility genes, specific alleles of which produce the DS/HSCR phenotype, either
alone or in combination with other susceptibility factors. Certain conditions, for instance congenital
heart disease (CHD), and duodenal atresia (DA) are present at an increased frequency in both DS and
HSCR patients, suggesting common underlying susceptibility factors.
Can the distribution of these conditions in DS children throw light on the underlying
mechanisms of HSCR susceptibility?
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4.3 Materials and Methods:
Patients were drawn from two sources:
1.)All new patients presenting with HSCR since the first of January 1975, in the
states of New South Wales and the Australian Capital Territory, Australia have been ascertained, first
by retrospective review, and for 1997 - 1998, by prospective data collection through the Australian
Paediatric Surveillance Unit (APSU). In addition, the medical records of the Royal Alexandra Hospital
for Children were searched back to 1960.
2.) Further cases have been collected from elsewhere in Australia, the UK and New
Zealand by contact with colleagues, and by publicity through the Down syndrome and Hirschsprung's
disease parent support groups in Australia. We have tried to ascertain all DS/HSCR children from the
Eastern and Southern coasts of Australia by these means. An attempt was made to contact the families
of all living patients for further detailed information. Fifty two of ninety patients' families were
followed up in this way. Information collected has been stored and analysed using a computerised
database (Microsoft "Access" version 2), and spreadsheet (Microsoft “Excel” version 4).
4.4 Results:
4.4.1 Epidemiology:
380 HSCR patients were collected from NSW in the period beginning 1/1/75, and ending
31/12/98. (The "reference group.") Information on this group of patients forms the base of the dataset
from which our group of HSCR/DS patients is taken. There are 340 non-DS patients in this group, of
whom 274 are male, and 66 female; a sex ratio of 4.1:1. There are 40 DS/HSCR patients in this group
of 380 (10.5%), with a sex ratio of 4.7:1 (33 male, 7 female). This slight difference in sex ratio
between the DS/HSCR reference group, and the non-DS/HSCR reference group is not significant by χ
2 analysis. A further 50 DS/HSCR patients were collected more widely. In the larger group of
DS/HSCR patients, not limited by the time and geographical restrictions of our reference group, there
are 90 patients, including 68 males and 22 females a sex ratio of 3.1:1. This difference in sex ratios
with the non-DS reference group is also not significant by χ2.
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Consistent with DS overall, DS/HSCR patients have parents who were significantly older than
the parents of non-DS/HSCR children. Similarly, the DS/HSCR children had shorter gestations, and
lower birth weights. These figures are consistent for both the reference group of DS/HSCR and the
overall group of DS/HSCR. Details are given in Table 4.1. The average maternal age of the DS/HSCR
patients was 30.9 years. The average maternal age of non DS/HSCR was 27.2 years, in 234 cases
where the data is available.
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DS
Reference
Group
Number** All DS Number** Non-DS (Reference
Group.)
Number**
Number 100% 40 100% 90 100% 340
      Male 82.5% 33 75.6% 68 80.6% 274
      Female 17.5% 7 24.4% 22 19.4% 66
Birth weight kg  (+/-
S.D.) (All)
3.189 34 3.0485
(0.6322)
76 3.400 (0.607) 273
      Male BW 3.223 29 3.112
0.6110
57 3.450 (0.581) 218
      Female BW 2.986 5 2.856
0.6723
19 3.198 (0.668) 55
Gestation (complete
weeks) (Both sexes)
38.11 40 38.1 78 39.3 301
      Male 38.0 33 38.1 60 39.4 242
      Female 38.6 7 38.3 18 39.1 59
Maternal age. (years) 31.29 38 30.94 70 27.28 234
Paternal age. (years) 35.33 30 34.29 56 30.17 206
Birth order. (Average)
(Range)
2.16 (1- 7) 37 2.44(1 - 7) 71 2.12 (1 - 8) 155
Fam. Hist. HSCR 0% 0 4.4% 4/90 13.2% 45/340
Percentage diagnosed
by 1 week.
50% 48.8%* 41/84 52.7%
 Table 4.1. Showing similarity between reference DS/HSCR group, and total DS/HSCR group, as
well as selected comparisons between DS and non-DS/HSCR patients.
*For comparison: 13/84 were diagnosed at more than 3 months of age.
** Number for whom information available.
Nearly half the group (41 of 83) had been diagnosed with HSCR by one week of age, an age
of diagnosis comparable with non DS/HSCR in our series. Only seven of 83 were still undiagnosed at
one year of age, and four of those were born before 1975. One child born in 1970 was diagnosed at
post mortem. There was no significant increase in delayed diagnosis amongst the DS/HSCR group as
compared to the general HSCR group. There was a weak association between age of diagnosis and
length of aganglionosis, in that no patient who had aganglionosis extending beyond the sigmoid was
undiagnosed for longer than 60 days.
4.4.2 Karyotype:
We have evidence of an unbalanced Robertsonian translocation in four, and  a fifth had a
pericentric inversion of chromosome 21 with breakpoints (p11 2q21.2). in association with trisomy.
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There are not sufficient informative chromosome rearrangements in this group to allow us to restrict
the possible site of a HSCR susceptibility gene on chromosome 21.
4.4.3 Length of aganglionosis:
The severity of the HSCR as measured by the length of the aganglionic segment is similar to
the severity of our non DS reference group (See Fig 1). There is no difference in proportions of long
and short segment disease between DS/HSCR and our reference group of HSCR. (χ2 = 0.372267)
Only three patients have total colonic aganglionosis (TCA), and one of these three was
brought to our notice specifically because of the length of aganglionosis, and therefore tends to bias the
length distribution. Of those nine of ninety DS/HSCR patients overall with aganglionosis to the splenic
flexure or beyond, only one is female. There is no evidence in this small sample of a trend to more
equal sex ratio with increasing length of aganglionosis. Likewise, the length distribution in the 43
patients who had a structural cardiac lesion was similar to the overall DS group. There were four
children of these 43 with aganglionosis extending to the splenic flexure or beyond, of whom one was
female.
The authors have not reviewed the histology for the presence of neuronal intestinal dysplasia
(NID) in the proximal bowel, however two children with DS/neuronal dysplasia alone have separately
been brought to the attention of the authors.
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Fig. 4.1 Bar graph showing length of aganglionosis, and comparing this between DS/HSCR (red
bars), collected Ondine’s Curse/HSCR cases (blue bars), and the Sydney reference group of
HSCR without either of these concomitant conditions (yellow bars). The table shows numbers of
individuals with known long segment (to splenic flexure or beyond) and short segment HSCR in
both groups, with the calculated χ2 value.
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4.4.4 Family History:
Four DS/HSCR patients from three families had a positive family history of HSCR, a rate of
4.7%. Two of these four patients were twins, probably monozygotic.i One DS/HSCR patient died with
total colonic aganglionosis, and five years later had a (non DS) brother with sigmoid length
aganglionosis, without other problems.  The final patient has short segment disease, and multiple
affected relatives over several generations. This patient also has a sister with an acoustic neuroma.
Sixteen of the patients (17.8%) have families that admit to a family history of constipation,
compared to 15% of the non DS/HSCR families with a family history of constipation. This compares
to reported rates of constipation in the general population in the range 10% - 30% (de Araujo
Sant'Anna 1999, Probert 1994, Stewart 1999). There is no significant difference in incidence of
constipation between the groups.
There is one DS/HSCR family which also has multiple different chromosomal rearrangements
in different members: a brother with Klinefelter's syndrome, and a mother and sister with a balanced
autosomal translocation.
4.4.5 Associated conditions:
Patients suffered from a range of DS associated conditions, of which the most common and
most significant was congenital heart disease (CHD). 43 of 90 (48%) are regarded as suffering
structural cardiac lesions. These children were far more likely to be male than expected for the CHD of
Down syndrome (sex ratio 8:1 in the reference group, 4.4:1 in the whole group.)
A further 13 had murmurs and unconfirmed suspicion of CHD. Of the 34 with unequivocally
normal hearts, two had DA, and there was one with ectopic pancreatic nodules on the fourth part of the
duodenum. Six of nine patients with duodenal atresia or stenosis had CHD. These conditions also co-
existed in one DS/hypoganglionosis patient. (Total nine of 90 had duodenal atresia/stenosis/ectopic
pancreas.) Only 22 had DS/HSCR alone with no other associated major diagnoses recorded.
CHD was associated with DA and costo-vertebral anomalies, but overall there was no
increase in other associated conditions in the DS/HSCR/CHD group. Two children had oesophageal
                                                          
i Interestingly there are two other patients in the group were also part of twin sibships, and a fifth has
twin sibs, although not a twin himself. The incidence of twinning is discussed in section 3.3.4.7.
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atresia, one with, and one without fistula (OA/TOF). Four Meckel's diverticula were noted, although
ascertainment for this relatively common condition is probably not complete, and 4/90 should be
regarded as a minimum incidence. Table 2.  shows the relative frequencies of selected associated
conditions, in "normals", in those with DS, with HSCR, and with both conditions, using large scale
population based data gathered in California. (Torfs)
                                                                                                                                                                     
94
Selected features General Population (Torfs) HSCR alone DS (Torfs) DS/HSCR
Down syndrome - 10% 100% 100%
HSCR 0.014% 100% 1.4% 100%
Retardation - 6.9% (Non-DS) 100% 100%
CHD 0.5% 5.1% 56% 48% (43/90)*
DA 0.02% 0.6% 4.6% 9%  (9/90)**
Renal tract anomalies. 0.13% 6.0% 1.8% 9% (8/90)
UDT 0.19% 2.1% 7.2% 5.9%
Strabismus - 2.7% - 10.5%
Deafness - 2.4% - 9.4%***
OA/TOF 0.03% 0% 0.7% 2.2% (2/90)
*Major structural abnormalities.
**9/85 (10.6%) when stenosis and ectopic pancreas cases are included.
*** Excluding known glue ear.
Table 4.2. Comparison between groups with and without HSCR, DS or both for frequency of
associated features. Figures for normal population, and DS alone are from the paper of Torfs &
Christianson, on a basis of 2894 DS births, and 2,490,437 non DS births in the state of California,
USA (Torfs). The DS/HSCR group contains the 90 patients reviewed in this paper, and the
HSCR group is 340 non-DS, HSCR patients who presented in NSW from 1/1/75 to the end of
1998.
Figure 4.2 is a Venn diagram showing the incidence of DA in HSCR and DS. Figures for the
incidence of HSCR are taken from the authors’ survey. The incidence of DS is estimated from the five
yearly Australian incidence for 1990-1994 given in Lancaster. (Lancaster)  The figure for the incidence
of DA is an estimate based on the 20 year review of DA at the Children’s Hospital, Westmead,
Australia, presented by at the annual meeting of the Royal Australasian College of Surgeons in
Melbourne, May 2000. The state-wide incidence of DA was calculated on the basis that HSCR cases
and DA cases were equally distributed between paediatric units around the state. It will be seen that
there is a significant association between HSCR and DA. DA occurs in about 1% of DS patients in
NSW, while Torfs gives a higher estimate for California (4.6%). In those 380 patients with HSCR
from the same demographic base there were 40 patients with DS/HSCR. Four of these forty (10%)
have DA. This tenfold increase in risk is not significant by χ2 , but is certainly suggestive. Similarly
HSCR patients have a 0.5% chance of DA, which increases to 10% in the presence of DS.ii This
                                                          
ii Of the NSW duodenal atresia group referred to (Singh et al), about 30% have DS, and about 38%
have CHD. The CHD is equally distributed between those who have DS, and those who do not. The
approximately 75% incidence of CHD in the DS/HSCR/DA group may therefore represent a simple
additive risk from DS and DA, however, the risk of CHD in the group DS/DA is only 50%. HSCR
remains as a potential additive risk factor for CHD, but again very large series are required to settle this
point. In DA overall there is a slight female preponderance. In our group, eight of nine are male. The
most mildly affected (arguably) individual with ectopic pancreatic nodules on duodenum was female.
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increase in risk is highly significant (p << 0.001) and is based on the known association of DS with
DA.
Figure 4.2. Interaction between HSCR susceptibility and other DS associated conditions. This
Venn diagram shows the overlap between the features of HSCR, DS, and DA. For children with
DS, also having HSCR gives them a ten times increased risk of also being born with duodenal
atresia. (p = 0.168553) (HSCR Figures for NSW/ACT for the period 1975 to end 1998 from the
authors survey. Figures for DA extrapolated from figures compiled by Rebecca Dickson and
presented at AAPS, Melbourne, 2000. Figures for DS births are estimates based on figures for
1990 - 1994 given in Lancaster, Hurst, Day, Huang, and Shafir: “Congenital Malformations
Australia 1993 and 1994.”)
In the “reference group” of HSCR, 17 children have CHD and HSCR alone - about half the number as
have CHD, DS and HSCR - while 26 of 40 with DS/HSCR have CHD, including all those with DA.
HSCR and DS are independent risk factors for CHD, but it is not clear that they form additive risks, as
they do for DA. These proportions of CHD are not maintained in the full series of 90. The proportion
of CHD in DS/HSCR falls to 48% in the full series from 67%, and only five of nine (with a possible
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sixth) DA patients have confirmed CHD. One patient with DA and CHD, but without DS, had Smith-
Lemli-Opitz syndrome, a condition with a somewhat similar phenotype to DS.
32 of 90 children were noted to have at least one episode of enterocolitis. There was no
increase in risk with either increased length of aganglionosis or the presence of CHD. The rate of
HAEC in our reference group of non-DS/HSCR was approximately 15%, compared with 35.5%
(32/90) in the DS group.
4.5 Discussion:
HSCR forms one of the less common major anomalies associated with DS. It is noteworthy
(see Table 2 and Figure 2.) that several of the associated features of DS, chiefly developmental delay,
duodenal atresia, and congenital heart disease, are present at an increased frequency in the reference
HSCR population, suggesting common susceptibility factors. This paper notes some interesting
clustering of features in these patients.
Table 1 shows that the demographic features of the 90 collected cases are nearly identical
with the 40 population based patients. The slight difference in sex ratios and cardiac defects probably
represents greater ascertainment of cardiac affected patients in the population based series, due to
better ascertainment of children who died.
In length of aganglionosis and sex ratio our group of DS/HSCR is nearly identical to our
Australian reference group of HSCR . (See Fig 1.) Not all HSCR patients do share the same clinical
spectrum of aganglionosis and sex ratio. Ondine's Curse/Hirschsprung's disease is clearly different
(Croaker 1998, and chapter 7).
4.5.1 Incidence and associated features:
It has long been known that children with DS are at increased risk of HSCR, conversely,
children with DS make up a substantial minority of HSCR patients (Graivier 1966). The reported rate
of DS in series of HSCR patients varies from  2.9% (Ikeda 1984) to 13% (Rajab 1997 , Quinn 1994).
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The reasons for the differing rates of DS/HSCR in these series are unclear but may be related to the
differing racial backgrounds. This factor may also explain the apparent differing rate of DA in DS
between California and Australia, communities with different ethnic mixes. Differing maternal ages in
different cultures may also influence the overall rate of DS. Our DS/HSCR mothers are on average
four years older than our HSCR mothers, who are almost exactly the same as the average mother in
Australia during the study period. (Day 1997)
Differing rates of consanguinity in these series may contribute differing background rates of
non DS associated HSCR, by increased rates of autosomal recessive forms of HSCR The rate of
incidence of HSCR in DS is approximately 1%, varying from 0.56%  of 5,581(Kallen 1996) , to 1.4%
of 2,894.(Torfs 1998) , to 2.1% in a referred population. (Buchin 1986)   This represents an
approximately 50 fold increase in risk of HSCR to DS children compared to the general population, for
whom the risk is approximately 1/5,000 live births (Torfs 1998).
It is clear from both Table 2, and Fig 2 that DS and HSCR give additive risk for the
development of DA during intra-uterine life. About 1% of DS children have HSCR, and about 6% of
DA have HSCR, but >10% (4/30) of DS/ DA have HSCR. Five of nine patients with all three
conditions also have a documented structural heart defect. Accepting that one patient for whom
evidence of (claimed) CHD is lacking really has CHD, and that the patient with ectopic pancreatic
tissue on the duodenum does not have a condition related to DA, then 6/8 children with DA/DS/HSCR
also have CHD. This suggests a clustering of these features, but definitive proof awaits collection of
even larger numbers.
Duodenal obstruction or stenosis occurred at ten times the rate in our group of DS/HSCR as it
did in overall Australian DS patients, and at nearly four times the rate reported by Kallen (Kallen
1996). Buchin in his 1986 series reports a rate of DA with DS of approximately 5% (9 of 187), and a
rate of HSCR with DS of approximately 2% (4 of 187). Even on Buchin’s high estimate of the
incidence of DA/DS, our series has nearly twice the incidence if HSCR is added. In a smaller series,
Surana, Quinn and Puri report three of seventeen DS/HSCR patients with co-existing DA. Combining
the series, we have 12 DA/DS/HSCR out of 107 DS/HSCR. These proportions approach significance
at the 0.05 level.
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(p = 0.075747 by χ2.) From this and from our own figures, it is therefore suggested that this
combination should be regarded as a distinct syndrome, and that rectal biopsy should be considered in
all DS children with DA, particularly in the presence of CHD. In practical terms, the small discomfort
and risk of rectal biopsy, is far outweighed by the risk of performing a duodenal anastomosis in the
presence of unrecognised and unrelieved distal obstruction.
In addition, factors associated with HSCR seem to be skewing the sex ratio of the cardiac
defect patients from the female preponderance normally seen in DS (Pinto1990), to one more typical of
HSCR. It seems likely that CHD susceptibility factors and DA susceptibility factors interact with
HSCR by different mechanisms, which do not produce the more equal sex incidence, long segment
disease more typical of RET mutations. (Seri M 1997, Tomiyama H 2001)
There is no significant difference between the rate of positive family history of HSCR in our
reference group and in our DS/HSCR group (P~0.1). Two of 20 cases collected in Ohio, USA,
(A Chakravarti, personal communication.) are familial. Taking these two series together, there are six
familial cases in 110 DS/HSCR, compared with a rate of 13.2% for our reference group. (Table 1)
Multicase HSCR families are already reported with one of the affected also suffering from DS. In
several cases these families have now been shown to carry mutations in specific genes, including,
GDNF (Salomon 1996), a RET ligand. Mutations in the RET proto-oncogene may have pleiotropic
effects, including susceptibility to tumours of the MEN2 group. In distinction to this, it is interesting
that DS is known to be associated with a high incidence of hypothyroidism, (Cutler 1986, Karlsson
1998) and a low incidence of neuroblastoma (Satge 1998). Neuroblastoma is a condition which is very
common in Ondine’s Curse/HSCR (Croaker 1998). None of our 90 DS/HSCR patients are known to
have neuroblastoma.
There was an increase in patients with deafness in the DS group. All of these were short
segment disease, but numbers are too small to conclude that deafness is associated with a modifying
effect on length in DS/HSCR. We have no definitive proof that all these are sensorineural deafness
cases, however we have excluded those who are known to have deafness accountable for by otitis
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media. (common in DS). No patients had a history of pigmentary disorders to support the diagnosis of
endothelin pathway or SOX10 mutations.
The mental retardation associated with DS is shown in this paper to be unassociated with any
modifying effect on length of aganglionosis, however this is unproven for non DS retardation. It is of
interest that Brooks and others  (Brooks)  have noted a more even sex ratio in syndromic forms of
HSCR. This more even sex ratio is not seen in DS/HSCR.
4.5.2 Karyotype and genetic considerations:
The underlying mechanisms of the relationship between DS and HSCR remain undiscovered,
however with increasing knowledge of the genetic arrangement of chromosome 21 candidate regions
are becoming apparent. Three such regions on chromosome 21 are the S-100b gene, found at 21q22.2-
q22.3, and known to produce early maturation in neural cell lines (Satge 1998); the DSCAM gene
known to be involved in the development of neural pathways in the embryo (OMIM reference
602523); and the NCAM2 gene, found at 21q21, which is known to slow cellular migration in vitro.
(Paoloni-Giacobino 1997) An extra dose of any or all of these genes could upset the delicate process of
enteric neuroblast proliferation and migration. An extra dose of S100b may explain the low incidence
of neuroblastoma in DS. (Satge) S100b is found at a locus which is part of the DS “critical region”
(Korenberg 1989, Rahmani 1990) and which has already tentatively been mapped as a HSCR modifier
locus by Puffenberger and others (Puffenberger 1994). Barlow et al in 2001 described four cases of DS
with partial trisomy and CHD. One of these cases also suffered from HSCR. (Barlow 2001) This case
suffered from triplication from 21q22.13 to qter. This seems to exclude the NCAM2 gene as a
candidate, while leaving S100b and DSCAM.
The author predicts that polymorphisms in S100b or DSCAM will be found to non-randomly
segregate with HSCR. Of these two, S100b has the most intuitively obvious mechanism for
contributing to the HSCR phenotype when expressed to excess. Both DS and SLOS patients suffer
alterations in lipid metabolism, which have been alluded to in chapter 2.iii The overlap in phenotype
between these two conditions suggests that alterations in membrane lipid composition may also be
                                                          
iii In section 2.5. “Associated conditions.”
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involved. A possible mechanism would be by altered transmembrane receptor interaction with
membrane lipids, and consequent functional alteration.
Korenberg and  her co-workers were able to localise a critical region for the development of
CHD in DS patients by the study of translocation trisomy patients with distal breakpoints (Korenberg)
Even with such a common association, however, localisation is imprecise. HSCR is approximately 20
times less common than CHD in DS patients, so this approach is even more difficult. In our own
group, five patients with unusual karyotypes were identified. Two of these had Robertsonian
translocations, which do not significantly add to our understanding. The third had a pericentric
inversion with breakpoints (p11 2q21.2). This is consistent with Barlow’s case, excluding NCAM2 as
a candidate gene for HSCR.iv
As Robertsonian and other "atypical" karyotypes make up approximately 5% of the DS
population, our sample is typical in this respect (Mutton 1996, Stoll 1998). As distal partial trisomies
are very rare, a very large population would be required to localise the HSCR associated region by this
method.
One possibility is that rare recessive alleles are being reduced to homozygosity during the
non-dysjunction that gives rise to the trisomy. The author was involved in work to test this hypothesis
and localise any such areas during work in the laboratory of Aravinda Chakravarti at Cleveland Ohio
in the summer of 1995. No common area of reduction to homozygosity was found. Ten individuals had
a maternal meiotic nondysjunction, and were not reduced to homozygosity at any point. One patient
had a mitotic nondysjunction, and was reduced to homozygosity for the whole of chromosome 21. No
region could be localised from these results.  (Lab work on these 11 individuals by S Bolk.) No
evidence of reduction to homozygosity was found in limited work on further cases brought from NSW.
4.5.3 Congenital heart disease :
The reference series suggests little additive risk for the development of CHD from HSCR and
DS. Torfs claims that up to 56% of DS have CHD (Torfs 1998), which is comparable to the rate
                                                          
iv We cannot ascribe the HSCR phenotype to the effect of a breakpoint at 2q21.2, as trisomy 21
presumably acts to produce the DS phenotypes by an increase in product from chromosome 21 genes.
A break in a gene at 2q21.2 would not normally be expected to produce the same phenotype as that
usually produced by a 50% dosage increase in genes at that locus.
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(27/40) in our reference group, and greater than the rate (43/90) in our overall group. Ascertainment
bias may explain the relative lack of CHD in the larger series. As a number of patients were contacted
through the parent support organisation, and mortality is high in DS/HSCR/CHD, there are possibly
some missed cases of this combination.
The group of DS/HSCR were analysed to attempt to determine whether the presence of
specific associated features was associated with longer or shorter segment disease. There was no
evidence that susceptibility to CHD acted as a modifier for length of aganglionosis, however numbers
were small. There was also a male preponderance in the 43 patients in the DS/HSCR/CHD group
(4.4:1). This is noteworthy in view of a previous report that found a female preponderance of CHD in
DS (62% females), due to the increased susceptibility of females to AVSD (Pinto 1990). AVSD is the
major cardiac defect in our DS/HSCR children (24/43), as it is in DS overall. However, in contrast to
the series of Pinto & Nunes, only three of our twenty four children with an AV canal defect were
female. This is highly significant.
The incidence rate of CHD in the HSCR reference group was ten times the incidence in the
population group cited in the report of Torfs, while the incidence of CHD in the DS/HSCR group was
similar to the rate in Torfs' DS group, which was one hundred times the general population rate. (See
Table 2) The types of CHD seen in our HSCR reference group were different to those seen in
DS/HSCR. Hofstra et al have reported a mutation in an endothelin pathway protein, ECE1,
which is associated with both HSCR, VSD and facial dysmorphism in their patient, but not deafness or
retardation.(Hofstra 1998) ECE1 is located on chromosome 1p36, is clearly a very rare cause of
HSCR, and is unlikely to be involved in the DS mechanism of HSCR and CHD susceptibility.
4.5.4 Neuronal dysplasia:
Although our medical records were not interrogated for neuronal dysplasia (NID), we did
become aware of one patient who had diffuse hypoganglionosis and DS, without HSCR. This patient
also suffered from DA, and CHD amongst other associated conditions. A further patient had neuronal
dysplasia without HSCR, as defined by abnormalities in specific neuropeptide staining. It is possible
therefore that DS predisposes to HSCR and NID by similar mechanisms. The most likely mechanism,
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in the author’s opinion, is that over-expression of S100b protein causes premature maturation of
ganglion cells, that may lead to diffuse hypoganglionosis, or complete aganglionosis if sufficient
dividing clones are removed, for instance by the additive effect of a second HSCR susceptibility allele.
4.5.5 Neuroblastoma
It has been reported that neuroblastoma is not seen in DS children.(Satge 1998) This
observation also lends (circumstantial) support to the idea that an agent promoting neuroblast
maturation is present in these children. By contrast, neuroblastoma and non DS HSCR have been
reported together on a number of occasions, particularly in the context of Ondine's curse (Croaker
1998 [& Chapter 7.]) .
4.5.6 Enterocolitis:
Our DS/HSCR patients have a rate of HSCR associated enterocolitis approximately twice that
of the reference group. This condition is associated with neither length of segment, nor with the
presence of CHD. It is known that DS have abnormalities of immune function, (Nair 1984) and it is
possible that this high rate reflects immune changes rather than an intrinsic difference in the HSCR.
Aslam and co-workers have suggested that the onset of enterocolitis can be predicted by a low colonic
mucin turnover while the child is still asymptomatic. (Aslam 1998) It could be that DS/HSCR children
have a more defective mucosal defence than other HSCR children, in addition to more general immune
abnormalities. This question could be addressed specifically by comparing mucin turnover in
DS/HSCR and HSCR children.
4.7 Summary:
1.) Available data on DS/HSCR supports the polygeneic model of aetiology of HSCR in DS
as in non-DS individuals, possibly acting by over-expression of protein(s) which cause early
maturation of ganglion cells, or which delay ganglion cell migration. Either of these mechanisms may
then act to lower the threshold for expression of other HSCR susceptibility genes of low penetrance.
The sex ratio and distribution of aganglionosis in DS/HSCR is similar to other cases of HSCR,
suggesting a common pathway. The sex incidence of CHD in DS/HSCR however is different to the sex
incidence of CHD in other DS children, and CHD itself may be more common, suggesting disease
modification by HSCR susceptibility alleles.
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DA is significantly more common in DS/HSCR, than in DS, and OA/TOF appears also to be
more common. DS and HSCR give additive risks for DA. The available data suggests that
CHD/DA/DS/HSCR are clustered. Rectal biopsy is suggested in children who present with the
combination DS/DA, particularly in the presence of CHD.
2.) The associated high rate of HAEC may be due to differences in immune function in DS
patients.
3.) Large international collaborative series are needed to definitely establish the phenotypic
patterns of HSCR and its relatively rare but significant associated conditions such as DS, DA
,OA/TOF, Ondine’s curse and others. The author recommends an international collaboration like that
undertaken so successfully in the investigation of MEN2. (Eng C 1996)
4.) The author predicts that polymorphisms in S100b will be found to non-randomly segregate
with HSCR.
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Chap 5. Factors affecting outcome in Down Syndrome
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5.1 Introduction.
Swenson’s introduction of the concept of resection of the spastic segment, introduced in the
1940’s was the first major breakthrough in the treatment of HSCR leading to great improvements in
mortality. (Swenson 1999 ) Surgical treatment has since been refined so that in the new millennium
management is aimed not merely at low mortality, but at good quality of life over a normal life span.
Down syndrome Hirschsprung disease (DS/HSCR) contributes approximately 10% (Ikeda
1986, Quinn 1994, Rajab 1997)  of the cases of HSCR overall, yet these patients suffer a
disproportionate amount of morbidity and mortality. The best way of achieving both low mortality and
optimal quality of life is not yet settled for those with DS/HSCR. These children are often beset by
multiple problems, notably congenital heart disease, that threaten survival. Previous reports (Quinn
1994) suggest that long term continence is doubtful, but there is little in the way of large scale follow
up in the literature.
The aim of this chapter is to present follow up data on a series of DS/HSCR patients large
enough to be informative. The length of follow up was from 5 months to 36 years. The author has
collected a series of 90 patients, starting from a defined population, (See chapter 4.) and was able to
contact 50 survivors. The overall mortality was assessed, and then data concerning these patients
clinical features at birth, operative procedures, and subsequent clinical course was collected. This study
reviews the mortality of DS/HSCR over the last four decades, and assesses long term bowel function
with a view to establishing criteria for deciding for or against a permanent stoma early in life.
5.2 Materials and Methods:
The patients reviewed in this chapter are those from chapter 4 who could be contacted for
follow up. Follow up was conducted by face to face interview if possible, and by phone interview if
not.
Follow up data on 50 DS/HSCR patients was collected by this means. A standardised
questionnaire was administered, which was modified to include information on which to calculate a
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continence score. Subsequently several questions were also included to assess the families adjustment
to their child’s illness.
The families of patients were asked for information about bowel function and continence,
weight, height, general health, and social adjustment. For forty patients we scored continence using the
score devised by Holschneider (Holschneider 1992). If the child was able to pass flatus without soiling
he was regarded as being able to distinguish flatus and faeces. If he asked appropriately for the toilet,
he was considered to have rectal sensation. If the parents were unsure, he was graded as zero.
Information collected has been stored and analysed using a computerised database (Microsoft
“Access” version 2).
5.3 Results:
5.3.1 Mortality:
There are ninety DS/HSCR children on our database. Seventeen of these children (17%) are
now known to be dead. Death rates (at least for Australian children) have progressively improved over
the last thirty years for children with this combination of anomalies, so that only 6% of those born in
the 90’s have died at the time of review. (See Fig 5.1.) All the deaths occurred in infancy or early
childhood. Twelve of the dead had associated congenital heart disease, and two had associated
duodenal atresia or stenosis. Twelve of fifteen children who died with known lengths of aganglionosis
had aganglionosis confined to the recto-sigmoid region.
Mortality for DS/HSCR by decade: Overall and 
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Figure 5. 1 Showing progressive decline in DS/HSCR associated mortality over 4 decades,
consistent between NSW region with full ascertainment, and whole group, with less than
complete ascertainment.
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5.3.2 Follow up:
We have been able to contact 50 of the 73 survivors  for follow up. A continence score has
been calculated for forty of these. We have no follow up on 23 children. These children have the same
rate of CHD and long segment disease as the rest of the group, although half are female. Of these 23,
19 are abroad or interstate, two have refused requests for information, and two live in NSW, Australia,
but are lost to follow up. Table 5.1 gives a summary of the group statistics.
No on database DS/HSCR Alive Contacted Definitive Operation Median age at follow up
92 90/92 (2 DS/NID) 73/90 50/73 49/50 80 months
Table 5. 1 Showing numerical breakdown of DS/HSCR cases known to the authors. Two cases of
DS associated neuronal dysplasia are not included in the analysis that follows.
Forty-eight of those contacted have had definitive treatment for their condition. Follow up
averages 83.7 months after surgery, (Range: 5 months - 435 months), with an average age at follow up
of 95 months. (Median age at follow up: 80 months.) Two individuals have had no pull through: one
was still awaiting surgery at the time of contact, and one has been satisfactorily treated by dilatation,
laxatives and washouts since biopsy proven diagnosis in 1960.
5.3.2.1 Growth and general health:
Information on height is available for 27 individuals, and on weight for 37. Information was
gained by weighing under supervision in outpatients in some cases, but most were weighed and
measured at home by parents. When this information is plotted on Down syndrome normal growth
curves (Cronk 1988), there is no evidence of long term growth failure. As the children aged they were
less likely to have been admitted to hospital in the 12 months before contact, but data on total hospital
admissions is not available.
A comment was obtained on the parent’s perception of the child’s general health at
the time of interview. Forty-nine answers were obtained. I have classified these answers as “positive”,
“positive with reservations”, and “concerned”.  Thirty-two were generally positive, and felt their child
was well, eleven were positive but had specific reservations, often not related to the child’s bowel
habit. Only six had an overall pessimistic attitude to their child’s health.  There is no correlation of this
answer with either age or continence score. All those six children whose parents had major concerns
about their children’s health had co-existing CHD. Parents were then asked about restrictions to their
lifestyle due to their child’s illness. Answers were obtained from thirty-nine families. Twenty-six
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admitted to no restriction of lifestyle or activity, while 13 had some degree of difficulty due to their
child’s illness. Those with least concern about the child’s overall state of health were also least likely
to feel that their child restricted their lifestyle.
5.3.2.2  Constipation:
At the time of interview parents were asked whether their children were constipated. (Table
3.) There is an apparent trend to report increasing constipation with age although this is not statistically
significant by χ2 test. Twenty-one families were asked at a second interview an average of twenty-one
months after first interview about their children’s bowel habits. Thirteen gave the same report of
constipation as at the first interview. Two reported less constipation, and six reported more
constipation.
5.3.2.3  Continence:
Continence was assessed in 40 cases by administering a questionnaire based on the continence
score of Holschneider  (Holschneider 1992. See Appendix Table 5.2 for details.), and in a further ten
by asking the parents about soiling, constipation, and their assessment of continence. Parental
assessments correlated closely with the Holschneider score. (A score of ten or more out of a possible
14 was regarded as social continence.)
 Three children had returned to stomata at the time of follow up due to a combination of
recurrent obstruction and incontinence, associated with enterocolitis in one case. All three had short
segment disease, and two are known to have had a transition zone below the peritoneal reflection.
The results of plotting continence score against age are shown in  Fig 5.2 a-f.  (over page)
While no child younger than five and a half years had a score consistent with social continence, there
was a trend to increasing continence with increasing age. Only ten out of forty (25%) had a continence
score of 10 or more. Eight children were rescored at an average age of 97 months, after a mean interval
of 20 months from first contact. Three had an improved continence score, four were static, and one had
a worse score. Mean improvement was 0.25 points.
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Figure 5. 2 Continence score shown against age at follow up for 40 patients in whom the score was
calculated. (One outlier at 36 years of age is not shown for clarity.) Note that no children under 5 years
of age have social continence. Correlation coefficient 0.365.
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Figure 5. 3. Patients divided into those with and without CHD. Note that only 4 of 22 (18.2%) with
CHD have scores of 10 or more, while 6 of 16 (37.5%) with no CHD have scores of 10 or more. While
suggestive, the difference in proportions is not significant by χ2. Both groups show a tendency to
improve with time.
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Figure 5. 4 Continence score shown plotted against age at which patient walked unassisted for 34
patients in whom both the age of walking and the continence score are known. Children who are slow
to walk are also slow to gain continence. General developmental assessment before pull-through
should be included in the child’s operative assessment.
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Age and continence score showing male and 
female separately
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Figure 5. 5 Continence score shown against age at follow up for 40 patients grouped by sex. 7 females
were scored, and there is no apparent difference in score, although numbers are small. (One (male)
outlier at 36 years of age is again not shown for clarity.)
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Figure 5. 6  Continence score shown against age, with patients grouped by age of surgery. Continence
scores of those operated on at greater than 12 months of age are significantly lower than those operated
on at between 7 and 12 months of age. (P ~0.01) Those operated on at < 7 months of age are midway
between the two other groups. Those operated on later (>12 months) were on average 10 months
younger at follow up than those in the earlier operation group (7 - 12 months). In addition, some of the
children operated on late are known to have had surgery delayed for reasons related to co-existing
disease. The age at which definitive surgery was performed is therefore unlikely to be an independent
risk factor for later incontinence.
Age versus continence score, with patients 
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Figure 5. 7 Continence score and length of aganglionosis.  Short segment disease is not necessarily
associated with better continence, but follow up is short in that small group. One TCA patient is
incontinent at ten years.
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Figures 5.2 - 5.7 (Previous page) Continence score against age broken down by groups. Figure
5.4 compares continence score with age at which the child walked unsupported, a measure of
general development.
Children with major co-existent disease had on average shorter follow up than those without,
suggesting recent improvement in outlook for these children but complicating the interpretation of
continence differences between groups. Average continence scores in those with two other major
problems (Cardiac, renal, duodenal atresia, epilepsy, spina bifida) were significantly less than in those
with no other problems. (Average score 3.4 vs 6.0: P ~0.01), but follow up in the more seriously
affected group averaged only 63 months as against 119 months for those with no other problems.
While there was an overall trend to improving continence with age, parents were also slightly
more likely to complain of constipation in their children at older ages, although this is not significant, it
is consistent with previous reports of a normal trend to decreasing stool frequency with age. (Weaver
1984)
Constipation incidence by age group
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Figure 5. 8  Number of children reported as suffering from constipation divided into five year
age groups.
Frequency of stooling showed a downward trend with age from an average of 3.3/day in the
first five years of life to an average of 1.4/day in those older than ten years. No families of patients
over 10 years reported very loose or watery stools, whereas this was common in children under 10
years.
A significant difference in continence was noted between those who learned to walk
unassisted at less than 30 months of age, and those who learned to walk later. (See Fig. 5.4.) None of
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the late walkers had achieved a continence score of more than 8 at the time of follow up. Although
children with CHD had significantly delayed onset of walking (31 months against 25 months: P < 0.05
), the age of walking correlated with continence in both CHD and non CHD groups when analysed
separately. Nine children for whom we had continence scores walked at 20 months or younger, with an
average continence score of 9.3, similarly nine children walked at more than thirty months of age with
an average continence score of 3.7 at follow up.
Similarly 36 children were grouped by birth weight, and long-term outcomes compared. The
average continence score in those with a birth weight ≤2.8kg was 3.4, while the average continence
score in those with birth weights > 2.8kg was 6.5. (P ~ 0.01) No children with BW ≤ 2.8 kg had social
continence. The frequency of associated CHD was similar in the two groups.
There was no significant difference in continence scores between those who had Soave (13),
or Duhamel’s operation (24). Mean follow up ages were 78 and 83 months respectively. There was a
small, but not significant difference between those who had primary repair and those who had staged
repairs. Although this did not reach significance, mean ages at follow up for primary repair patients
were 22 months less than for staged repair, representing the more recent popularity of this plan of
management in this country. (It will be interesting to revisit this in five years.)
 Although the continence score varied between groups who had early and late operation, the
significance of this is unclear. (Figure 5.6.)Those operated on at greater than 12 months of age have
significantly lower scores than those operated on between 7 and 12 months of age. (P ~0.01) Those
operated on before 7 months of age have scores midway between the two other groups. Those operated
on later (>12 months) were on average 10 months younger at follow up than those in the earlier
operation group (7 - 12 months). The children operated on late had surgery delayed either because of
delayed diagnosis, for reasons related to co-existing disease, or because of a policy of staged
management, or a combination of these. This group included five diagnosed at more than three months
of age, eight with major heart defects, one who had a myelomeningocoele, and two who also had
duodenal atresia. The age at which definitive surgery was performed is therefore unlikely to be an
independent risk factor for later incontinence.
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Continence scores were grouped by length of aganglionosis and plotted against age. Two
children with aganglionosis proximal to the splenic flexure, four children with aganglionosis below the
peritoneal reflection, and 31 with recto-sigmoid disease above the peritoneal reflection were scored.
None of the six children with non-recto-sigmoid disease achieved satisfactory continence. Three
children with transition zones above the sigmoid, and below the splenic flexure were scored. Two of
these children had scores of ten or above, suggesting similar continence to children with recto-sigmoid
disease.
Odds ratios were calculated for the association of selected features with a score of ten or
above (See Fig 5.9.) Significant risks were seen for the age of walking and the presence of more than
one other associated major malformation. Non-recto-sigmoid disease and advanced maternal age were
possibly associated with incontinence, and birth weight, sex, and the presence of CHD alone were not
significantly related to the development of incontinence. The age at which the patient was followed up
is clearly highly significant.
5.4 Discussion:
5.4.1 General.
Treatment of DS/HSCR is controversial, with some advocating an immediate long term
stoma. (Quinn 1994) This paper aims to give an overall impression of outcome, and then define factors
which may be used as criteria to guide initial management, and identify those likely to have a poor
outcome. These may benefit from adjunctive treatment, or from an early stoma.
This large long term follow up study of a relatively rare combination of conditions showed
that in spite of poor outcomes and higher mortality (Quinn 1994, Rescorla 1992) relative to the general
population of HSCR patients, satisfactory results can be achieved in many DS/HSCR patients. Family
satisfaction is not directly related to existing measures of continence. Children with major co-existent
disease had on average shorter follow up than those without, suggesting recent improvement in outlook
for these children but complicating the interpretation of continence differences between groups. In
addition, we have demonstrated a steady improvement in mortality over four decades, and a steady
improvement in continence with increasing age.
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The degree of developmental delay and the presence of certain associated anomalies correlate
with a poorer outcome as judged by continence scores. Short segment disease may also be associated
with severe late problems of obstruction and incontinence in some cases.
Mortality:
The ability to collect all cases from a geographically defined area has been useful in
providing numbers and avoiding ascertainment bias. We have attempted to collect representative
samples from outside the defined area also, but as some of these patients represent referrals of
individual surgeon’s case loads and referrals from the Down syndrome association, deaths may be
under-represented from these areas. In particular, early neonatal deaths, and those who were diagnosed
at post mortem may be missed. Those cases that have been collected are comparable to our
geographically based cases in clinical presentation. The steadily improving mortality rate, and the
higher proportion of children with few associated defects in the older age groups gives ample evidence
of improving standards of care for these children, but also complicates interpretation of follow up data.
Methodology:
Even in large referral centres children with DS/HSCR present rarely, 1 - 2 per year at our
institution. Accumulating a meaningful follow up series is therefore a task best attempted on a
regional, national or international level. This series collects cases from the East Coast of Australia and
elsewhere over an extended period, but even so, some potential outcome differences between groups
only just approach statistical significance. An example is the difference in continence scores between
those operated on early versus those operated on late. There was a small, but not significant difference
between those who had primary repair and those who had staged repairs. Mean ages for primary repair
patients were 22 months less than for staged repair, representing the more recent popularity of this plan
of management in this country, and suggesting that longer follow up may show some benefit from
primary repair in these children. Controlling for length of aganglionosis and presence or absence of
cardiac disease did not alter this result.
115
Changing surgical fashions make it difficult to obtain homogeneous sample groups. For
instance, one of the patients has recently had an ACE procedure, which has significantly altered his
continence score, and increasing numbers of children are undergoing primary resection as compared
with thirty years ago.
There was no significant difference in continence scores between those who had Soave (13),
or Duhamel’s operation (24). Mean follow up ages were 78 and 83 months respectively. There was a
small, but not significant difference between those who had primary repair and those who had staged
repairs. Although this did not reach significance, mean ages for primary repair patients were 22 months
less than for staged repair, representing the more recent popularity of this plan of management in this
country, and suggesting that longer follow up may show some benefit from primary repair in these
children. Controlling for length of aganglionosis and presence or absence of cardiac disease did not
alter this result.
Previous authors have pointed to the variance between physicians perceptions of outcome,
and patients perceptions (Shono 1994) In a large random study in the American mid west, Talley
pointed to the inconsistencies in the histories given by patients as to their bowel habit, and suggested
caution in interpreting self reported diarrhoea. (Talley 1994)  We have tried to overcome reporting
problems by using a standard continence score, and taking all our follow up data from a dedicated
interview. In those twenty-four patients who were contacted on more than one occasion, results have
been largely consistent over time.
Continence:
Puri and others in an eight year follow up noted only one of thirteen patients with normal
bowel function, and concluded that the outlook for these children was so poor that permanent
colostomy should be considered on presentation. (Quinn 1994)  By contrast Caniano and co-workers in
1992 felt that satisfactory continence was achieved in all but one of eight survivors of their series of
thirteen DS/HSCR patients. (Caniano 1992)  The need for at least one enema per week, night soiling
and constipation were felt to be consistent with a satisfactory outcome. Such small series should be
interpreted cautiously. Heij and co-workers have pointed out the importance of a detailed and specific
questionnaire in assessing the real incidence of problems at follow up. (Heij 1995)   
116
Although these children undoubtedly have poorer outcomes than other HSCR patients, in
careful follow up of a large series Shono and Hutson (Shono 1994)   showed only 50% continence for
an unselected group of Hirschsprung’s. In our series, we have shown that, although improvement is
slow, the majority of families are content, and that continence does improve with time as has been
noted for HSCR without DS (Shono 1994). Further, these children behave in a similar way to normal
children in that their stool frequency drops as they get older, although the rate of decrease is less than
for normal children. There is in addition, a higher rate of constipation episodes in older children, which
probably represents the normal tendency of the stool to thicken with age. (Weaver 1984, Tham 1996.)
5.4.2 Prediction of outcomes.
It would be useful to have a predictor of outcome for these children so that they could have
early appropriate surgical decisions made based on the likelihood of their achieving later continence.
Those judged unlikely to become continent should have a permanent stoma considered. We have
shown that the long-term outcome is influenced to some extent by factors that can be measured in
infancy. These factors are length of aganglionosis, multiple major anomalies, and delayed development
as measured by the age at which the child walked independently. Other factors which did not reach
significance were advanced maternal age, the presence of major CHD alone, and low birth weight.
(See Figure 5.9.)
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Figure 5. 9 Showing odds ratios for risk of incontinence (score below 10) from named risk
factors. Non standard length aganglionosis tended to be associated with poorer continence,
however clinical experience suggests long segment aganglionosis has a poor outlook. It is unclear
why advanced maternal age should be associated with poorer outcomes.
Only small numbers of DS/HSCR children had non-recto-sigmoid transitions. These children
had poorer continence at follow up, but none had very long follow up. The one TCA patient was
incontinent at the age of ten. Several patients with very short segments also had poor continence. All
those with continence scores over 10 had standard recto-sigmoid aganglionosis. My clinical impression
is that for long segment disease, the outcomes are worse, especially for those with transitions above the
splenic flexure. How children with low rectal transitions will do in the long term is at present
unknown.
Arbitrary scores have been assigned to the presence of multiple anomalies, age of walking,
and length of aganglionosis. (See Table 5.2.) The score obtained was then divided by the total possible
for the data available, and a percentage obtained. It can be seen that no patient with a score of less than
60% has obtained social continence. (See Fig. 5.10) It should be noted however, that a good score does
not imply a good outcome. Scatter of the data points is partly explained by widely differing ages at
follow up and absence of some data points. It would be desirable to have a developmental assessment
early in infancy to allow calculation of this score in time to influence surgical decision making,
whereas we have relied on a retrospective assessment of development by asking about the age at which
the child walked.
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Criteria Score
Birth weight ≤ 2.8 kg 0
> 2.8 kg 2
Length aganglionosis Below peritoneal reflection 1
Recto-sigmoid 2
Above recto-sigmoid 0
Age of walking unsupported ≤ 20 months 2
20 - 36 months 1
> 36 months 0
Number of associated major
malformations
0 2
1 1
>1 0
Table 5. 2  Suggested predictive score as discussed in the text.
Continence score (y axis) plotted against a predictive score 
oultined in the text.
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 Figure 5. 10  Plotting suggested predictive score against continence score (Holschneider). It will
be seen that no patients with a predictive score of less than 60% have achieved social continence.
χ2 = 14.2. (P < 0.001) The scatter in the continence scores is partly explained by widely differing
ages at follow up
Development of Continence Score for developmentally delayed children:
As the period of toilet training may last a substantial fraction of the life of a child with
DS/HSCR, the authors suggest that future assessment of continence in developmentally delayed
children with colonic and ano-rectal problems should take into account the number of constipation and
obstructive episodes, the number of years required to toilet train the child and the social isolation that
this imposes on child and family. While Holschneider’s score has been useful as a framework for
assessment of these children, it relies partly on subjective evidence of rectal sensation and
discrimination between fluid and solid faeces. This information in most cases can not be directly
obtained from the Down syndrome child, and must be inferred from his behaviour. The development of
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a new continence score for these children would therefore be timely as an instrument for judging long
term outcome and social cost of ano-rectal conditions in these children. A scoring system is proposed
in Appendix Table 5.3.
5.5 Summary:
This series has demonstrated a marked reduction in mortality in DS/HSCR children over a
period of nearly forty years. Overall mortality was 20%, but only 6% for those born since 1/1/1990.  It
has shown primary surgery to be safe and effective, but also that there is little or no disadvantage in
delaying surgery, and that this can be safely done if treatment of more major associated conditions
warrants it. Outcomes are better in those who are less developmentally delayed, as assessed by the age
of walking. It is suggested that formal developmental assessment should be used by the surgeon to
inform the choice of surgical management. In children with major associated defects it is justifiable to
treat with a stoma until the child’s developmental state is known. Even in children with no associated
anomalies, the path to continence is often a long and difficult one. For children with long segment
aganglionosis, and with very delayed development the parents should understand that it is very likely
that the child will never achieve completely normal continence, and that what continence he does
achieve may be delayed by up to ten years compared to the normal population. No children are
continent before five years of age. Faced with this choice some parents may choose to opt for a
permanent stoma.
Those children with recto-sigmoid aganglionosis, evidence of good developmental capacity,
and without major associated anomalies should be offered early definitive pull-through. While poor
tone in DS is correlated with poor intellectual development, unfortunately, an ideal intellectual
developmental criterion applicable to the neonatal period has yet to be defined.
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 Chap 6. Characterisation of microcephaly, mental retardation,
HSCR syndrome associated with 2q22 locus.
6.1 Background.
6.2 Materials and methods.
6.2.1 Microsatellites.
6.3 Results.
6.4 Discussion.
6.5 Gene screening.
6.6 Future work.
121
6.1 Background
Five patients were recognised as a discrete entity, and described by us (Mowat et al 1998).
One of these patients had a known interstitial deletion of chromosome 2, del (2)(q21q23). (See Fig.
6.2) Subsequently a sixth patient was referred and added to the group. This sixth patient, while having
the other features of the syndrome, was constipated, but with an apparently normal rectal biopsy.
Previously Lurie et al had published a description of a similar patient with a deletion in the same
region. This suggested that there was a likely HSCR associated gene in the 2q21 - q23 region. The
wide variety of features shared by these children suggested a contiguous gene deletion syndrome,
although a single gene effect was also possible. Because only one of our six patients had a
cytogenetically visible deletion, any contiguous deletion would need to be searched for using
molecular genetic methods.
6.2 Materials and methods
Four patients were identified from our state-wide HSCR database who had a characteristic
facial appearance associated with HSCR, microcephaly and severe retardation. A further patient was
referred to us with severe retardation, constipation, and the characteristic appearance. This patient was
felt to belong to the same syndrome in spite of a normal rectal biopsy, and was included in the
syndrome description. (Mowat 1998) We hypothesised a contiguous gene deletion syndrome in these
children and searched for this using the method of searching for loss of heterozygosity in highly
polymorphic microsatellite markers. This was followed by screening of genomic DNA for mutations in
GDNF, GFRα1, and RET, as described in chapter 10.
Figure 6-1 Typical patient: “striking blue eyes, sparse, widely
separated eyebrows, mildly down-slanting palpebral fissures, broad
nasal bridge, bulbous nasal tip, prominent columella, triangular jaw,
prognathism, open-mouthed facial expression, low-set posteriorly
rotated ears with uplifted lobes,....” (from Mowat 1998)
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6.2.1 Microsatellites:
Thirteen highly polymorphic microsatellite markers were chosen from the Genethon human
genetic linkage map. (Dib 1996) These markers, spanning a distance of 45 cM on the long arm of
chromosome 2, were typed for five families described. The fragment was amplified for the patient and
both parents. A genotype was assigned to both parents using arbitrary labels. The genotype of the child
was then assessed. If two bands were present, the child was considered heterozygous. If a single band,
the child was considered homo-, or hemi-zygous. Allele sizes were then checked against the parental
genotype.
Marker details are given in Table 6.1. The heterozygosity given in the table is the percentage
of the population heterozygous for each marker. Full details of markers are given in Appendix 4, page
215.
P32 radiolabelled PCR was performed using the primers given in Appendix 4 on an MJR thermocycler,
50ng DNA,  Mg2+  concentrations from 0.75mM to 2.5mM, Taq polymerase with a commercial
reaction buffer and a “Touchdown” type PCR program, as described in the appendix.
Table 6.1. Microsatellite marker details.
Marker Heterozygosity Location
D2S2215 87 2q21
D2S112 71
D2S114 84
D2S127 86
D2S122 88
D2S151 80
D2S2301 73
D2S356 47 2q22
D2S2241 77
D2S2299 79
D2S2370 77
D2S333 76 2q24.3
D2S326 85
5µl of PCR product was mixed with 1 µl of formamide buffer, denatured for 4 minutes at 950, and
loaded on an 8% denaturing polyacrylamide gel. (“Sequagel”)
Samples were run for an appropriate length of time, before the gels were dismounted, transferred to
filter paper, dried, and exposed to X-ray film (Kodak “Biomax”) to create an autoradiograph. These
autoradiographs were then read for genotype data, as described above.
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6.3 Results:
The results of microsatellite mapping in five families are shown in Table 6.2. If the patient
was heterozygous for a marker, he was assumed to have two copies of chromosome 2 at that point. If
the parents shared an allele of a particular marker, and that allele was the single one expressed, the
marker was regarded as uninformative, in the absence of other haplotype information. Clearly, the
greater the number of alleles at each locus, and the larger the heterozygosity, the greater the chance of
finding that marker to be informative.  If both markers from one parent were missing in the child there
was considered to be loss of heterozygosity. Markers which were technically unreadable have been left
blank.
The observed heterozygosity of alleles observed in this series of markers broadly agrees with
the predicted average heterozygosity quoted in Dib et al: 72.22% observed, against 77.69% predicted.
Patient 721 was ascertained and investigation started after the others, and markers telomeric to the
deletion boundary of patient 207 were not investigated, as deletions in this region would not overlap
with that in patient 207.
 Patient 207 was known to have an interstitial deletion between 2q21 and 2q23. The boundaries of this
deletion were set between D2S2215 and D2S151, a minimum distance of 9, and a maximum of 18 cM.
Figure. 6-2 Karyotype of patient
207. Pairs of normal and deleted
chromosomes on right. Diagram on
left.
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Table 6.2. Interestingly patient 21 was uninformative from D2S114 to D2S2301, although the
family was outbred. The significance of this finding is uncertain.
Marker Patient 21 Patient 207 Patient 303 Patient 627 Patient 721 Location
D2S2215 Het Het Het Het Het 2q21
D2S112 Het Un Het Het Het
D2S114 Un Loss Het Het Het
D2S127 Un Loss Het Het Het
D2S122 Loss Het Het
D2S151 Un Het Het Het Het
D2S2301 Un Het Un Un
D2S356 Het Un Het Het 2q22
D2S2241 Het Het Het Het Het
D2S2299 Un Un Het Het
D2S2370 Het Het Un Het
D2S333 Un Un Het Un 2q24.3
D2S326 Un Het Het Het
Abbreviations: Het: Heterozygous; Un: Uninformative; Loss: Loss of heterozygosity;
Blank space: no result.
Figure 6-3. Picture at left shows genotype of patient 207 (on left),
father (in middle), mother (on right). Patient 207 has lost his
father’s copy of a segment of chromosome 2. It will be seen that
the father is homozygous for the marker, and that that marker
has not been transmitted.
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6.4 Discussion.
We have shown no evidence of microdeletion in patients 303, 627, and 721. The deletion
boundaries have been defined in terms of microsatellite markers for patient 207. Patient 21 is
interesting in demonstrating a single allele at each marker spanning the entire region of deletion of
patient 207. The markers were chosen primarily for heterozygosity. Multiplying (1- the
heterozygosities) of each uninformative marker in patient 21 we obtain the probability of obtaining the
observed stretch of homo(hemi)zygous alleles by chance. p = 0.0012. This result could be explained by
consanguineous mating, but there is no history of this, and the flanking markers are consistent with the
overt paternity. Technical error is possible, but none of the other samples analysed at the same time
show such a result, and there was no suggestion of the three alleles that might have appeared if there
had been cross contamination of parental samples. Uniparental disomy would have given the same
result as a simple microdeletion. The explanation for this result is at present unknown, but it is likely
that patient 21 is deleted for one or more of the markers for which he carries a single allele, and which,
moreover, correspond exactly with the known deletion in patient 207.
In summary, although the experiment shows no definite evidence for common microdeletions
in this syndrome at the scale of search used, there is one definite and one possible patient with a
microdeletion out of five that have been screened. The boundaries of the region of interest were more
closely defined.
6.5 Gene screening.
Because HSCR is polygenic, we looked at three genes in this group of patients with clinical
evidence of a chromosome 2 locus. None of these genes are on chromosome 2.
6.5.1 GDNF
No SSCP variants were found in GDNF in this group of patients.
6.5.2 GFRa1
Patient 303 had the longest segment aganglionosis in the five with a transition zone near the
splenic flexure. He was also the only patient to carry an exon 2 polymorphism in GFRa1 recognised by
the author while working at the Mulligan lab in 1997. This sequence variant has since been published
by that laboratory (Myers 1999) and is known to have a frequency in the general population of
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between 0.02 (Angrist 1998) and 0.04 (Myers). In our sample of 113 unrelated patients who were
screened for sequence variants in GFRα1, 9 carried this variant (freq. = 0.02) In our sample of 9 with
this variant two had long segment disease extending substantially into the small bowel. The other 7 had
standard length phenotype. It is uncertain what effect this polymorphism has, but it may act as a
modifier for severity of phenotype, in certain circumstances. (See Chapter 9.)
6.5.3 RET
Homozygous RET exon 11 polymorphism in patient 627.
Exons 3, 10, 11, 15, and 16 of RET were screened using primers given in the appendix, and
previously published. (See chapter 9 and appendix.) SSCP was performed on PCR products, run on
PAGE under at least two conditions. Two sequence variants were found in patient 627. The first was a
homozygous RET polymorphism in exon 11. The polymorphism is a ggT to AgT causing glycine 691
to change to serine. Ceccherini et al gives the frequency of the common allele as 0.79 (restriction site
present) (Ceccherini 1994)  This polymorphism removes a Ban I restriction site. Accordingly,
representative PCR products were treated with this enzyme, and the polymorphism was confirmed.
(Figs 9.4.3 a and b in Chapter 9 show the SSCP gel appearance, restriction enzyme digest and
sequence data for RET exon 11.)
Because of the distinct SSCP banding pattern in patient 627 (associated with homozygosity)
the sequence was further confirmed by direct sequencing in forward and reverse directions. In this
patient sequencing confirms the Ban I digest and SSCP in showing a homo- (possibly hemi-) zygous
sequence at this site.
Homozygous RET exon 15  polymorphism in patient 627.
Interestingly a second sequence variant was found in exon 15. The SSCP appearance is shown
in Fig. 9.4.3c in Chapter 9. The exon was sequenced in both directions confirming a c to g change.
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(The wild type sequence: nttcctacgt, mutant sequence: nttcgtacgt). (See Fig. 6.2 for sequencer output.)
This polymorphism (S904S) is silent.
Figure 6-4 Forward (on left) and
reverse (on right) sequence
printouts for RET exon 15
polymorphism (S904S) in
patient 627. Only a single peak is
shown at the position of the
polymorphism, corresponding to
a single allele.
These two polymorphisms were seen together in seven out of eight cases, but in only this case did both
show a single allele. It is possible that patient 627 has a microdeletion in RET that is not
cytogenetically visible, making him hemi-, rather than homozygous for this haplotype. Further work on
the parental genotypes would be needed to investigate this possibility. Both these polymorphisms are
under-represented in HSCR, not only in our population (see Chapter 9.), but in a Spanish population,
suggesting that they may be protective against HSCR. (Borrego. 1999) It is therefore doubtful whether
homozygosity for these two sequence variants as such contributes to the HSCR of patient 627.
6.6 Future work
6.6.1 Further refinement of interval
Using these boundaries as starting points, Patel, Murday and others (CV Patel 2000) at St
George’s Hospital Medical School in London searched a panel of two further syndromic patients as a
B Med Sci thesis. They found a loss of allele in one at D2S2236, and non-informative markers from
D2S2277 to D2S141. In the other there was felt to be a loss of allele at D2S321. Paternity was
confirmed in the second case. These results ought to be regarded with suspicion however, although the
potential deletion boundaries may overlap each other, they do not overlap our own patient’s deletion,
and they lie distal to the now known SIP1 locus.
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6.6.2 SIP1
Using our markers as boundaries, and on the basis of a translocation patient with the same
syndromic features, Wakamatsu  et al (Wakamatsu 2001) and Cacheux et al (Cacheux 2001) searched
for candidate genes. The gene for SIP1v (SMAD Interacting Protein 1) was regarded as a good
candidate.  This gene lies between D2S122 and D2S151.
Mutations were found in this gene in four out of five syndromic patients who were screened
by Wakamatsu. All five patients had HSCR, and characteristic facial features as we described in
Mowat et al. One had a translocation breakpoint involving a 5Mb deletion between D2S129 and
D2S151, two had nonsense mutations, and one had a 4 base pair deletion. (Wakamatsu. 2001)
Mutations were found in three of those screened by Cacheux.
It may still be that, even in the translocation patients, as well as disruption of the gene at the
breakpoint, there is loss of genetic material, loss of genetic material between our markers in the
apparently undeleted patients, downstream effects due to loss of regulatory areas in the translocation
patients, or loss of material at the breakpoint.
The most likely explanation however is that SIP1 mutations cause effects in a number of
neural crest related genes, and that no other gene effects are require to produce a form of the syndrome.
The high frequency of karyotype abnormalities in the syndrome suggests that there are at least some
contiguous genes involved. The similarities of this to ECE1 mutations have been noted. The neural
crest is again the likely target structure in SIP1 mutations.
6.6.3 SIP1 in non syndromic HSCR
To clarify the role of SIP1, screening of non syndromic HSCR will be required. It may still be
that the features seen in some of the sufferers of this syndrome are related to a contiguous gene
deletion.
                                                          
v Or “SMADIP1”
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6.6.4 Demographics of “SIP1” Hirschsprung’s.
We are now aware of 16 patients who clearly have this condition. Of the seven known
personally to the author, only one has aganglionosis beyond the sigmoid colon. Of those summarised in
our paper (Mowat 1998) eight have both the typical facial features, and HSCR. Two more are reported
by Patel in her BSc report cited above, and one is known to the author from his clinical practice in
Nottingham. Five more are reported by Wakamatsu. Sadly, not all these reports include full clinical
detail. There seems to be a tendency to short segment aganglionosis in this group of patients, as well as
a sex ratio less skewed than that usually seen in short segment disease. (4/11 with known sex are
female.) Brooks et al have already suggested that the sex ratio in syndromic HSCR is closer to 1 than
in simple HSCR. While this observation does not hold for DS/HSCR, it may be true for “Mowat”
syndrome HSCR.
Our five patients arose in a HSCR population approaching 300. These patients therefore seem
to make up 1 - 2% of the HSCR population. Wakamatsu et al report a similar incidence. Multicentre
collection of data will be necessary to address the question of whether these patients do behave in a
similar way to other HSCR.
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Chap 7. Congenital Central Hypoventilation Syndrome and
Hirschsprung’s Disease.
7.1 Introduction
7.2 Materials and methods.
7.3 Case presentations
7.4 Review of published cases.
7.5 Discussion: Features of the syndrome.
7.5.1 Sex ratio and length of aganglionosis.
7.5.2 Patterns of Hypoventilation.
7.5.3 Associated features.
7.5.4 Incidence.
7.5.5 Genetics
7.6 Recommendations for treatment.
7.7 Summary
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7.1 Introduction.:
OC was first reported in association with HSCR by Haddad in 1978. (Haddad 1978) A
number of cases of the association have been reported since, and these are reviewed later in this
chapter. OC results in hypoventilation, most pronounced during sleep, with relative insensitivity to
hypercarbia, and a lesser insensitivity to hypoxia, in the absence of other abnormalities of the cardio-
respiratory system. OC is also known as Congenital Central Hypoventilation Syndrome. The name
Ondine’s curse derives from a figure from Germanic mythology.vi  Ondine’s curse properly refers only
to the condition  where hypoventilation is restricted to the sleeping state.  Both OC and HSCR are
uncommon, and their co-occurrence suggests a common aetiology, probably involving a fault of neural
crest development.
The largest single series (five cases) of the Congenital central hypoventilation syndrome,
Hirschsprung’s disease Association (“Haddad syndrome”) is here reported. These children have
presented to the Children’s Hospitals of NSW and the ACT since 1975, and are added to the forty one
already reported in the English literature. These children present a challenging spectrum of problems,
and represent a subgroup of more severely affected HSCR.
7.2 Materials & Methods:
Cases were ascertained by retrospective review of HSCR admissions to Children’s hospitals
in NSW and the Australian Capital Territory over the twenty one year period from 1st January 1975 to
31st December 1998. During this period there were 380 admissions to the three teaching hospitals with
a diagnosis of HSCR. Five patients who were noted to have the concomitant diagnosis of OC were
then reviewed separately. Two OC/HSCR children are known to have died at the time of writing. The
families of surviving children were contacted for follow up interview, and collection of blood for
genetic studies.
A review of the literature was also performed. Forty one previously reported cases of the
association are summarised in Table 1. An additional 10 patients mentioned in the literature, without
supporting detail (Weese-Mayer 1993, Flageole 1995.), are not included in the analysis.
                                                          
vi Ondine (or Undine) was a water nymph who married a mortal knight. When the knight was
unfaithful, she responded with a curse: that the erring knight would have to volountarily control all his
vital functions, condemning him to a life without sleep, lest he forget to breathe. The name is very apt!
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7.3 Case presentations:
Case descriptions of the five Ondine/HSCR patients follow:
Case 1:
This male infant was born to non-consanguineous Turkish parents at term, and was
noted to be hypoventilating in the first hour of life. He was referred to a neonatal ICU for ventilatory
support and further assessment. At 36 hours he came to surgical notice with failure to pass meconium,
and abdominal distension. Oral feeds were not tolerated. A Barium enema suggested HSCR with a
sigmoid transition zone. Rectal suction biopsy confirmed aganglionosis associated with numerous
small nerve twigs. No dysmorphic features were noted. Repeated attempts to extubate the patient were
unsuccessful. Although he would spontaneously breath for up to several hours while awake, he
developed periods of apnoea and cyanosis while asleep. Transcutaneous oxygen monitoring confirmed
desaturation to 20% at these times, down from 60 - 70% at other times.
Sleep polygraphy performed at 10 days of age showed hypoventilation most marked in quiet
sleep. There was no detectable response to elevated inspired CO2 levels. Hypoxia  caused some
arousal, but only slight ventilatory response. There was a lack of normal heart rate variability for age,
and brain stem auditory evoked responses were also abnormal.
Gas exchange and CXR were normal. A CT brain scan was said to be normal, as was a head
ultrasound. There was no evidence of underlying metabolic disease. Catecholamines were not
examined.
The child was sustained on TPN, and remained ventilator dependent. After discussion with
the parents, treatment was withdrawn on day 19 of life, and the child died on day 20. No post mortem
was allowed.
Case 2:   
This female infant was born to Caucasian parents at term. Pregnancy was
complicated by gestational diabetes from 6 months, and her mother smoking 5 cigarettes / day  during
the pregnancy. Antenatal ultrasound at 4 months was normal.  At birth she was noted to be floppy,
lethargic and cyanosed in air. Bilateral fixed and dilated pupils were noted, and in addition she had a
right ptosis. She was transferred to the Sydney Children’s Hospital for respiratory management.
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Passage of meconium was delayed, and on the 3rd day vomiting, abdominal distension and
dehydration were noted. Abdominal radiograph  showed dilated loops of bowel. Contrast enema
showed a meconium plug, but no transition zone was seen. Rectal suction biopsy confirmed the
diagnosis of HSCR, and was followed by colectomy and ileostomy at the age of two weeks. Karyotype
is normal female, 46 XX to 450 band resolution.
 A sleep study performed at 22 days demonstrated features consistent with OC. There was a
reduction in the amount of REM sleep, and a decrease in chest excursion and respiratory frequency on
passing from wakefulness to sleep. There was a markedly decreased response to asphyxia and
hypercarbia in quiet sleep. No arousal occurred in spite of end tidal CO2 rising up to 100mmHg, and Sa
O2   falling to less than 70%. Examining cardiovascular responses, it was found that spontaneous
variation in heart rate, response of heart rate and blood pressure to tilting, and cold pressor test were all
normal. There was no evidence of gastro-oesophageal reflux.
A Duhamel recto-colectomy was performed at the age of 5 months. The transition zone was
13 cm into the ileum. At review aged 4 years, she was on nocturnal home ventilation via a tracheotomy
and making good progress with toilet training. One year later she is grossly developmentally normal,
and attending pre-school. Grand mal fits were treated with Tegretol, but have not recurred since the
fourth birthday.
In the family history it is of interest to note that on the maternal side there are two cases of
thyroid disease, and two of Crohn’s disease. Mother suffered from epilepsy in childhood. Her father
has a marked grey patch in the hair of the right parietal region, present since youth.
 
Case 3:
This female infant was born to Caucasian parents after an uncomplicated pregnancy.
Antenatal ultrasound was normal. Apgars were: 21, 55 .The child was intubated from day 1. Attempts at
extubation on days 1 and 4 were unsuccessful. Periods of good spontaneous respiratory effort occurred
while awake, lasting from 15 - 45 minutes every 2 - 3 hours. These episodes were followed by apnoeic
episodes when the baby became hypoxic and hypercarbic. Chest X-ray was normal. Sleep polygraphy
was not performed.
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Abdominal distension was noted from day 3, with bilious naso-gastric aspirates from day 4,
and no passage of meconium for at least 5 days. Contrast enema on day 7 was consistent with TCA.
Rectal suction biopsy confirmed the diagnosis of HSCR. No ganglion cells were seen, and nerve trunks
were not increased.
The baby was felt to show proximal weakness, as well as a paucity of facial movement, and
absent swallowing. Cardiotocograph had been flat before birth, and after birth diminished beat to beat
variation in heart rate was noticed. The pupils were fixed and dilated, but the eye movements were
otherwise normal. Facial features were felt to be slightly unusual, with hypertelorism, an underslung
jaw, a tented upper lip, and a small mid facies.
Abdominal ultrasound showed masses  medial and inferior to both kidneys. Head CT
demonstrated an increased subarachnoid space, and attenuation in periventricular white matter. MRI
suggested delayed myelination, a small IVH, and communicating hydrocephalus.
In view of the multiple problems, ventilation was withdrawn at 10 days of age, and the patient
died on the same day. Post mortem was refused.
Case 4:
This male infant was induced post-term, the second child of three born to non-consanguineous
Melanesian parents. The first and third children are healthy. At ten minutes he was noted to be
cyanosed, and was given oxygen. At three hours he was transferred to a neonatal unit, intubated and
ventilated. Forty eight hours later a bowel obstruction was diagnosed, and a diagnosis of HSCR made.
Subsequently, a tracheotomy and colostomy were performed. After seven months of in-hospital care,
he was transferred to Australia for further assessment and treatment.
On admission, he was noted in addition to have: a left amblyopia, with squint and unequal
pupils; right ptosis, with a right Marcus-Gunn jaw winking sign (ptosis associated with exaggerated
reflex elevation of upper lid on jaw movement); deafness, probably due to bilateral otitis media; mild
developmental delay; episodes of bradycardia which were asymptomatic; and gastro-oesophageal
reflux with dyscoordinate swallowing and aspiration. As a result of aspiration episodes he had
recurrent pneumonia, and was ventilator dependent for 20 hours per day at the time of arrival in
Australia.
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After treatment of his respiratory infection he was able to be ventilator free for 10 hours
during the day. Sleep study, however demonstrated the classical picture of OC, with rapid desaturation
within 90 seconds of the onset of sleep.  There was virtually no respiratory effort during sleep.
Catecholamines were examined, and were found to be near normal range. (VMA 6.8 [NR<5], HVA 6.3
[NR <6], all others normal.) Abdominal ultrasound and CT scan were normal, as was thoracic CT scan.
MRI of brain was normal. In particular the medulla was normal.
At 10 months of age fundoplication and gastrostomy were performed. Four weeks later
Duhamel recto-sigmoidectomy was performed. The transition zone was demonstrated to be in the
proximal sigmoid at operation. His transverse colostomy was closed three weeks post-operatively, and
9 days later he was transferred back to the referring institution for home ventilation. Twelve  months
after discharge he is living at home in the Pacific Islands. He is gaining weight on nocturnal
ventilation, although recurrent respiratory infections are a problem, and there is said to be evidence of
pulmonary hypertension. He is passing three stools per day, with no episodes of enterocolitis.
Case 5:
This female infant was born  at term to Caucasian parents after an uneventful pregnancy.
There was a strong maternal family history of goitre, but nil else of note. Emergency caesarean was
performed for foetal distress. Apgars were 21, 55. Abdominal distension became evident, and HSCR
was diagnosed on day 3, followed by formation of a sigmoid colostomy on day 4. She was transferred
for further assessment to a tertiary centre on day 7 of life. A sleep study confirmed central
hypoventilation most marked during sleep, and maximal during quiet sleep, necessitating ventilatory
support. During REM sleep, however, fluctuation in end tidal CO2 and desaturation were minimal, and
spontaneous correction occurred. There was a rapid rise in end tidal PCO2 from 30 - 36mmHg, (and
normal PO2) during wakefulness up to PCO2 50mmHg in quiet sleep, when IMV was re-instituted.
This rise in PCO2  in deep sleep was associated with oxygen desaturation. While desaturation down to
85% occurred during active sleep, spontaneous correction occurred. Waking respiratory parameters
were normal during the course of the study. No abnormality was detected on CT brain scan.
Autonomic testing did not suggest any dysautonomia, and brain stem auditory evoked potentials were
consistent with normal hearing. Karyotype is 46 XX at the 500 band stage of resolution.
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Subsequent management included a tracheotomy, and Swenson recto-sigmoidectomy,
performed at the age of nine months.
At the age of three years she was clean by day and night with two hard stools per day and
little need for laxatives. Her general health is said to be good with home ventilation. Repeat sleep study
at the age of three years showed no change in the pattern of her ventilation. At the age of five she is
doing well, gaining weight, and due to have a repeat sleep study, with a view to transferring to
nocturnal mask ventilation, from tracheostomy ventilation. She is said to have no trouble with
constipation or incontinence, and is on no laxatives.
Summary:
Clinical details of these five patients are summarised in Table 7.1. All had biopsy proven
HSCR, and evidence of congenital central hypoventilation on ICU monitoring or by formal sleep
studies. There are two males and three females. Treatment was withdrawn from two, and there are
three survivors at the time of follow up by the author. These children are now satisfactorily managed
on home ventilation.
Three children had sigmoid aganglionosis and two had total colonic aganglionosis. In three
patients this was confirmed on histology, and in two patients (one from each group) in whom the
parents refused post mortem it was inferred from barium studies and rectal biopsy. Although Ba enema
is known to give a misleading level in as many as 30% of cases (Smith 1991) , the presence of
numerous nerve twigs in the rectal suction biopsy suggests a level
of aganglionosis less than TCA. Two of our cases had gastro-
oesophageal reflux, one had dyscoordinate swallowing on Ba
swallow, and one had a complete absence of swallowing reflexes.
Information is inconclusive for the fifth case.
Figure 7. 1 Patient 4, showing strabismus, ptosis and
tracheotomy.
137
ID
1
2
3
4
5
Sex
M
F
F
M
F
L
ength agang.
?sigm
oid
TC
A
?TC
A
sigm
oid
sigm
oid
G
estation
39
39
35
>40
40
B
W
3.38
3.44
2.76
3.5
3.085
A
ssociated
A
bnorm
al brain
stem
 auditory
evoked
responses.
D
ilated pupils
R
ight ptosis
G
O
 reflux
C
onvulsions
A
utonom
ic dysfunction
Fixed dilated pupils
A
bnorm
al facies
A
bsent sw
allow
ing
Possible bilat. neuroblastom
a.
Left am
blyopia
R
ight ptosis
C
om
plex oculom
otor disturbance.
G
O
 reflux &
 dysco-ordinate
sw
allow
ing.
G
O
 reflux
X
anthom
a on scalp.
A
live?
N
o
Y
es
N
o
Y
es
Y
es
A
ge of pres. of H
SC
R
D
ay 2
D
ay 3
D
ay 3
D
ay 2
D
ay 3
V
entilation pattern
H
ypoventilation/
apnoea, m
ost
m
arked in quiet
sleep.
Severe sleep apnoea
Periods of spont. breathing w
hen
aw
ake.
O
nly short periods spont. vent
aw
ake or asleep.
U
p to 10 hours off ventilator
w
hile aw
ake.
Sleep apnoea, m
ost severe in
quiet sleep.
Fam
. H
ist.
G
oitre
Pigm
entary changes
Strong m
aternal Fam
. history of
goitre.
T
able 7-1 Sum
m
ary of clinical details of five N
SW
 O
C
/H
SC
R
 patients.
7.4
R
eview
 of published cases. (T
able 7.2 - over page.).
T
able 7.2 Sum
m
ary details of collected patients from
 the literature.
138
Author
Sex
G
est.
age
H
SC
R
diag.
Age
vent.
Length affected
Eye/ear/neurologic
autonom
ic
N
euroblastom
a/O
ther.
Fam
H
ist
O
utcom
e
Ref.
H
addad
f
37 w
k
7d.
H
ours
D
C
 +
?
N
o
sib
D
ied 2 m
o.
20
H
addad
f
37 w
k
5d
3 hrs
TC
A
H
ypotonia; fits; G
O
R
a)
N
o
sib
D
ied 5 m
o.
20
H
addad
f
term
10d. +
M
inutes
ileal
H
ypotonia; fits
G
anglioneuroblastom
a
(b)
no
D
ied 2 m
o.
20
B
ow
er
m
term
3d
D
ay 2
Sigm
oid or less
Episodes diaphoresis
N
euroblastom
a
?
D
ied 9 m
o.
21
Stern
m
term
3d.
day 1
ileal
N
o
N
o
N
o
D
ied 15 m
o.
22
G
uillem
inault
m
term
4d.
4d.
TC
A
H
ypotonia
N
o
?
D
ied  24 d.
23
G
uillem
inault
m
term
2d
2d.
TC
A
Fits
N
o
N
o
A
live at 24 m
o.
23
Petterson
m
?
?
?
TC
A
?
N
o
?
D
ied 4 w
k.
24
O
’D
ell
m
term
21d.
birth
ileal
?
N
o
?
A
live 5 m
o.
25
Poceta
f
term
14d.
First hr.
PJ (h)
O
cular; B
A
ER
 H
ypotonia; fits
?
D
ied 40d.
26
Poceta
m
term
2d.
B
irth
TC
A
H
ypotonia; fits
?
D
ied 30 m
o.
26
Sato
m
?
?
?
Trans. colon
N
o
N
o
?
A
live 8 m
o.
27
R
oshkow
m
term
?
?
M
J
N
o
N
o
N
o
D
ied 3 m
o.
28
R
oshkow
m
34 w
k.
ileal
N
o
N
o
still sibs
A
live at 13 m
o.
28
R
oshkow
m
term
PJ
N
o
N
o
?
D
ied 15 d
28
W
eese-M
ayer
?
?
?
?
TC
A
?
?
?
?
?
29
W
eese-M
ayer
?
?
?
?
TC
A
?
?
?
?
?
29
Levard
f
?
Trans. colon
ganglioneuroblastom
a
30
Levard
m
?
TC
A
ganglioneuroblastom
a
30
H
am
ilton
f
term
7d.
6hr
rectum
Esotropia
H
alf sib
A
live 54 m
o.
17
H
am
ilton
m
term
4d.
B
irth
rectum
N
o
H
alf sib
A
live 30 m
o.
17
M
inutillo
f
39 w
k
3d.
8 hr.
Ileal
O
cular
Facial dysm
orphism
N
o
D
ied 19 d.
13
G
aisie
m
term
5d.
B
irth
?
N
euroblastom
a
?
D
ied 7 m
o.
31
Fodstad
f
term
3 m
o.
20 m
o.
rectum
N
o
N
o
N
o
A
live
32
Fodstad
f
?
1 m
o.
B
irth
R
S
H
ypotonia, fits
N
o
N
o
A
live
32
Fodstad
m
36w
k
3 d.
D
ay 1
duodenum
N
o
N
o
N
o
D
ied 1 m
o.
32
M
ukhopadhyay
f
35w
k
D
ays
B
irth
?
A
-V
 m
alform
ation
(i) H
ypotonia; fits
N
o
?
A
live at 36 m
o.
33
El-H
alaby
f
term
13d
few
 hrs.
ileal +22cm
s
O
cular; M
ild hypotonia, fits
N
o
N
o
A
live at 57 m
o.
15
El-H
alaby
f
term
16d.
11h.
R
-S junction
O
cular; M
ild hypotonia
N
o
A
live at 17 m
o.
15
El-H
alaby
f
term
20d.
4h.
SF
O
cular
A
SD
N
o
A
live at 7 m
o.
15
V
erloes
f
38 w
k
?
15hrs.
Trans. colon
Fits (g)
Facial dysm
orphism
N
o
A
live 2yr
12
V
erloes
m
term
4d.
4d.
TC
A
G
O
R
N
o
N
o
D
ied 5.5yr
12
Stovroff
f
term
1d.
B
irth
ileum
O
cular
N
euroblastom
a
?
D
ied 2 m
o.
34
N
akahara
m
37 w
k
19d.
2hrs
Trans.
N
o
?
A
live at 13 m
o.
35
C
om
m
are
m
term
?
B
irth
?
B
A
ER
; m
otility
(c)
11
C
om
m
are
f
term
?
B
irth
?
B
A
ER
  M
ultiple
(d)
N
euroblastom
a
11
C
om
m
are
m
term
D
ays
4days
?
B
A
ER
  M
ultiple
(e)
11
C
om
m
are
f
term
?
18hrs
?
O
cular;  m
otility
(f)
11
C
roaker
f
term
2d.
B
irth
rectum
H
eart rate; G
O
R
N
o
A
live at 47 m
o.
C
roaker
f
term
2d.
12 hrs
TC
A
O
cular ; convulsions; G
O
R
N
o
A
live at 61 m
o.
C
roaker
m
term
36hrs
3 hrs
sigm
oid
O
cular, heart rate; G
O
R
N
o
A
live at 19 m
o.
C
roaker
f
35 w
k
2d.
B
irth
TC
A
?
O
cular, heart rate; absent sw
allow
M
ultiple. Perirenal m
asses. (j)
N
o
D
ied 10 days.
C
roaker
m
term
36hrs
30 m
in.
Sigm
oid?
B
A
ER
, heart rate; Fits
N
o
D
ied 19 days.
139
(a.) Also had abnormal oesophageal motility, and GO reflux on barium swallow, and lack of heart rate
variability.
(b.) Also had idiopathic septal hypertrophy and subaortic stenosis.
(c.) Oesophageal dyskinesia, and achalasia.
(d.) Ocular abnormalities; heart rate changes; mega-oesophagus; excessive perspiration.
(e.) Cardiovascular instability; oesophageal dyskinesia and GOR
(f.) Oesophageal dyskinesia and GOR
(g.) Also had recurrent hypoglycaemic episodes.
(h.) Abnormalities of myenteric plexus even in proximal jejunum; abnormal peristalsis noted
throughout gut.
(i) A-V malformation involving both lobes of cerebellum, raises the question whether this child has
true primary OC.
(j) Including dysmorphic facies.
Abbreviations: DC:descending colon; TCA: total colonic aganglionosis; PJ: proximal jejunum; BAER:
(abnormal) brain stem auditory evoked response; GOR: gastro-oesophageal reflux; ASD: atrial septal
defect.
Table 7-2 (Previous page.) Details of cases collected from literature, and including our own cases.
Summary: (For those whose details are known.)
Sex: 51% Male
Gestation: 89% term
Length: 59.5% TCA or longer
Mortality: 51.3% alive at time of reporting
Neural crest tumour: 7 (+ 1 possible) reported.  7/43 = 16.3%
In our Australian series there was no definitive evidence of neural crest tumour, although one
case had undiagnosed retroperitoneal masses at the time of death. Features of autonomic dysfunction
are common in other reports, and have been noted in the table. Abnormal facies was noted in one of
our cases. The two surviving females have both had karyotype examination, which is normal female to
the 450 , and 500 band stage of resolution respectively. The surviving male is overseas, and therefore
unavailable for study at the time of writing.
7.5 Discussion: Features of the syndrome.
Congenital central hypoventilation syndrome, results in a decrease in the depth, rather than
the rate of breathing, most severe during quiet sleep, and less marked in REM sleep. There is however,
a spectrum of severity, so that the more severely affected hypoventilate both sleeping and waking, and
rate may also be affected. Insensitivity to hypercapnia is the most constant finding, with a variable
response to hypoxaemia. (Weese-Mayer 1992)
It is of interest that there has been a recent report suggesting that up to 30% of patients with
HSCR may have some form of dysautonomia. (Staiano 1999.)
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If this observation is true, then OC/HSCR, may well represent the severe end of the spectrum for
autonomic manifestations as well as for length of aganglionosis.
7.5.1 Sex ratio and length of aganglionosis:
Of the total 46 cases in the literature (including our own 5 cases), 21 were female, and the sex
of three is unknown.  This 1:1sex ratio compares to the usual 4:1 sex ratio in HSCR, and is supported
by previous observations that the sex ratio in overall HSCR becomes more nearly 1:1 as the length of
aganglionosis increases (Sieber 1986). Nonetheless, the sex ratio for TCA patients with OC/HSCR is
the same as for TCA patients in our non-OC group (1.5:1). A female preponderance at short segment
length leaves the sexes equal overall in OC/HSCR. In the group of patients with transition zones up to
and including the splenic flexure, the M:F ratio = 4:7. Previous authors have noted an increased male
preponderance in short segment aganglionosis. There is a male preponderance for those with TCA with
or without small bowel involvement. (M:F = 12:8) This difference in ratio between short and long
segment depends on the most severely affected being exclusively male, but  is not significant by χ2.vii
The length of aganglionosis is definitely known for 34 of the 46 cases, with another 6
doubtful, and 6 unknown. There was no definite evidence that females were affected more or less
severely than males, however equal numbers of males and females (eight each) had aganglionosis
affecting the total colon or ileum. The four most severely affected, with aganglionosis extending into
mid small bowel or more proximally, were all boys. Counting three whose sex is unknown, 24 out of
40 where there is some information about the length of aganglionosis (60%) have aganglionosis
probably (3) or certainly (21) affecting at least the whole colon.
Of those with less than TCA, five of sixteen had long segment HSCR with aganglionosis to
the splenic flexure or beyond. Only eight had aganglionosis of sigmoid length or less, a striking
reversal of the usual length distribution in HSCR. (See Figure 7.2.) Although the length distribution
remains bimodal, the major peak of the distribution in OC/HSCR is at the level of the ileo-caecal
                                                          
vii Assuming the proportions of the sex ratios remain the same, to prove the reversal of sex ratios
shown here is non-random, we would need to collect a series ten times larger to achieve a p < 0.05 by
χ2. The observation that in short segment HSCR associated with OC girls outnumber boys, while boys
are exclusively affected at the very longest lengths of aganglionosis is a fascinating reversal of the
usual progression of sex ratio with length of aganglionosis. If female sex is protective (as it seems to
be), are some (most) males with Haddad syndrome stillborn to give the equal sex ratio?
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valve, and there is a gradual tapering of the distribution into the proximal bowel. The difference of the
distribution in OC/HSCR compared with both DS/HSCR, and non-syndromic HSCR, suggests a
different aetiological mechanism for OC/HSCR. The bimodal distribution might suggest that migrating
ganglion cells have to cross potential barriers at the level of ileo-caecal valve, and recto-sigmoid
junction which become impassable in the disease state. The University of Liverpool research group
have demonstrated that expression of endothelin 3 is organised in time and space, being most intense at
the caecum, with a gradient proximally and distally. (Leibl 1999, Woodward 2000) This circumstantial
evidence suggests that a localised fault in the expression of this ligand for EDNRB is responsible for
the peak incidence of transition zones at the ileo-caecal level in OC/HSCR. This might explain the co-
occurrence of pigmentary anomalies in a number of TCA patients. Moreover, Leibl quotes Shirasawa
as pointing out that lesions of the enx Hox gene cause abnormalities of the ENS also centred on the
caecum (hypoplasia of the ENS proximal, hyperplasia distal to the caecum.), suggesting that there may
be other localised mechanisms that might cause the same migration barrier at this level.
Cass suggests that alternatively the bimodal distribution might suggest that the bowel is
populated by a small number of discrete clones and their progeny. If one clone is missing sigmoid
aganglionosis is the result, if several, then TCA is the result. (Cass 1994)
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Figure 7-2  Distribution of length of aganglionosis in Haddad syndrome, comparing lengths of
aganglionosis between collected OC/HSCR, and the Sydney 30 year experience of HSCR alone,
or with Down syndrome. (See Appendix 3, page 214, for data.)
7.5.2 Patterns of Hypoventilation:
While there is little data on normal respiratory values in infancy (Silvestri 1996), of the
patients with OC alone at our institution, two patients on home ventilation both presented late, one at
12 months, and one at 6 years (Dr C.Seton, personal communication.). A third patient (who has since
died) presented at the age of three years. In clear contrast to this, 90% of the cases in this collected
series of OC/HSCR were ventilated on day 1 of life. In fact the median age for commencement of
ventilation in the 25 patients for whom the data is given, was 3 hours. Khalifa et al in 1988 asserted
that the majority of primary central hypoventilation occurs in adult life, and that OC may represent a
more severe form of this disease. (Khalifa 1988) Weese-Mayer noted that there was an excess of SIDS
in relatives of patients with OC. (Weese-Mayer 1993) If  SIDS is part of the same disease spectrum as
OC, then clearly OC/HSCR represents the opposite extreme, as it is also at the more severe end of the
HSCR spectrum.
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7.5.3 Associated features:
Eyes:
Overall 10 of 46 (21.7%) of the group reviewed here were noted to have abnormalities of the
pupils, extra-ocular muscles, or eyelids, either unilateral or bilateral. By contrast, in a series of 32
patients reviewed by Weese-Mayer with OC (with or without HSCR), 60% were said to have
ophthalmic abnormalities.(Weese-Mayer 1992)  Three of five of the patients newly reported here have
ophthalmic abnormalities, consistent with Weese-Mayer’s report, which suggests that the low
incidence in the collected series probably represents under reporting, rather than a true difference in
incidence.
Patient 4 was noted to have a Marcus-Gunn jaw winking sign. Meire et al. reported a patient
with Waardenburg syndrome, a variety of ophthalmic abnormalities and HSCR, but with no mention of
OC in 1987. (Meire, 1987) Staiano et al (Staiano, 1999) have reported a variety of autonomic
disturbances (including pupillary and other ocular disturbances) in HSCR patients, without OC.
Kusafuka and Puri in their review of 1997 (quoting Durbec) point out that in RET deficient mice, the
superior cervical ganglion is reproducibly absent. (Kusafuka 1997) This effect of RET abnormality
may be, at least in part, responsible for the ptosis.
Swallowing:
Four of five of our patients have an abnormality of swallowing or of oesophageal motility.
This suggests a generalised abnormality of GI motility. This tendency is confirmed in the broader
series, where overall 10 of 46 had evidence of oesophageal dysmotility, with or without documented
reflux.
Hearing:
Five of the forty six patients had abnormal brain stem auditory evoked responses. It is not
possible to say what percentage of OC/HSCR children have a sensorineural hearing deficit, as it is
unclear how often this is tested for. It is of interest however, that sensorineural deafness forms part of
the Shah-Waardenburg syndrome, now known to be related to a defect in the Endothelin signalling
pathway. (Hofstra 1996) Two of three children with near total intestinal aganglionosis, but without
OC, who were tested with brain stem auditory evoked responses (BSAER) showed abnormalities
consistent with inner ear dysfunction. (Shimotake 1994)  These results suggest that hearing loss is
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likely to be found more often than previously reported, if it is routinely looked for in very long
segment aganglionosis.
Neuroblastoma:
There have been several previous reports of the association of OC and HSCR with
neuroblastoma, and neuroblastoma with either of the other conditions alone. (Chatten 1967, Hope
1965, Hunt 1978.)
Of the 46 cases reviewed here, there are seven (15.2%) with neuroblastoma or
ganglioneuroma. The patient with peri-renal masses on ultrasound would make an eighth, or 17.4% of
the total group, who have sympathetic chain tumours. These tumours tend to be multiple and bilateral
when present. There is no evidence that they are more common in the children with longer segment
disease in this series.  Three further patients with Haddad syndrome are reported to have had raised
catecholamines on at least one occasion, but without other evidence of neuroblastoma. (Patient 4, and
in Commare 1993.) Unfortunately, falling post mortem rates make it hard to be accurate in estimating
the real incidence of neuroblastoma and related tumours in these children. Neuroblastoma should
however be looked for in all children with the Haddad syndrome. This significant association suggests
that adrenal tissue from these children is worthy of further study.
Miscellaneous:
A variety of other conditions reported in association with this syndrome are listed in Table
7.2. Three patients were reported to show facial dysmorphism, but so far there is no characteristic
facial feature that will identify these children. Hypotonia, and/or fitting has also been commonly
reported (in 13 of 46 patients). Although this may be secondary to hypoxia, it is also possible that it is
a primary phenomenon. One of our patients who required anti-epileptic treatment for several years, has
a mother who also has a history of seizure disorder, pointing to the possibility of a (possibly
associated) inherited tendency.
There is a history of piebaldism in the family of patient 2. (Her father has a lifelong grey
patch.) A mutation in endothelin 3 has been reported by Bolk (Bolk 1996) in an OC patient. Mutations
in this gene are known to be rarely associated with HSCR and piebaldism. Hofstra has reported a
mutation in endothelin converting enzyme 1 (ECE 1) in a child who had multiple congenital anomalies,
including autonomic dysfunction and HSCR (Hofstra 1999). ECE 1 is responsible for the processing of
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endothelin precursors to their active forms. Lastly, homozygous endothelin 1 knockout mice are
apnoeic at birth. Unfortunately Kurihara does not tell us if these rodents were aganglionic as well.
(Kurihara 1994)
The clinical observation of piebaldism in one of our families, as well as the further genetic
evidence cited here argues for a link between endothelin pathway genes and OC in at least some cases.
The altered sex ratios and severity of aganglionosis however suggest that there is at least one other
factor, genetic or environmental, at work in these children, consistent with earlier epidemiological
studies.
7.5.4 Incidence.
The five cases here reported have arisen from a retrospective review of HSCR presenting to
NSW and ACT teaching hospitals over 21 years. Total HSCR presentations during that time in NSW
and the ACT were 341. On this basis, OC/HSCR has an incidence of 1.5% of  HSCR. Uncomplicated
OC presents to our sleep unit at a rate of much less than one per year. In fact there are only two
patients currently on long term home ventilation in the study area for pure OC, without HSCR. A third
patient has recently died. (Dr C Seton , & Dr M Rosier, Personal comm.) Currently there are three
living OC /HSCR patients from this series. HSCR/ OC therefore forms a maximum of 50 % of our OC
population. In a survey of 32 OC patients in 1992, Weese-Mayer found  five patients (16%) with
associated HSCR. (Weese-Mayer 1992) The same author in a subsequent paper makes the statement
that there are fewer than 100 published cases of OC (Weese-Mayer DE, Silvestri JM, Kenny AS et al
“Characterisation of CCHS” presented at Second International Hirschsprung disease meeting,
Cleveland, Ohio, October 1995). That the current review extends the number of cases of the OC
/HSCR association to 46 suggests that the risk of HSCR to OC patients may in fact be higher than
16%, although it is possible that OC/HSCR may be relatively over-reported, compared to OC alone.
El-Halaby and Coran in reviewing their patients note that three of seven  (43%) OC patients on home
ventilation had co-existent HSCR (el-Halaby 1994), a figure that broadly agrees with our own figure of
50%.
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7.5.5 Genetics:
In only three of our patients was a family history recorded, with none having a positive family
history for HSCR or OC. Family history is unknown for 19 of the previous 41 cases, but 4/19 children
represent two sibships, suggesting that the familial risk (2/17 families) is similar to the recurrence risk
for total colonic HSCR (approximately 10%). Of our three families for which we do have a family
history, tantalisingly, two have a history of thyroid disease, and one has a history of pigmentary
anomalies. These features may both be linked to separate specific HSCR related genes. (Hofstra 1996,
van Heyningen 1994)
 Both HSCR and OC separately have been reported to have a familial occurrence. Complex
segregation analysis suggests that the inheritance of OC is the same with or without HSCR, although
this is based on only one positive sibship out of 50 OC probands. (Weese-Mayer 1993)
Recent work has shown that the penetrance of mutations in the HSCR associated genes RET
and the endothelin B receptor (ENDRB) in HSCR is affected by sex (Puffenberger 1994, Edery 1994).
The equal sex incidence in OC/HSCR, and the low rate of detection of mutations in RET, GDNF and
endothelin pathway genes suggests that an additional genetic mechanism may be at work in this
condition. Marazita et al (Marazita 2001) suggest that OC is inherited as a “co-dominant Mendelian
trait”, with other family members showing a tendency to exhibit less severe traits of autonomic
neuropathy. The very high incidence of associated autonomic anomalies in OC/HSCR supports this
possibility by suggesting that the underlying anomaly may exert its influence at an earlier stage of
development than RET or ENDRB mutations, or, over a longer segment of neural crest.
A number of possibilities are already known that may act as second loci for this condition.
1.) Kerstjens-Frederickse described a case of an interstitial deletion in chromosome band 22q11.2 with
HSCR and paroxysmal hypoventilation.
2.) Bolk et al reported a linkage of HSCR with a locus on chromosome 9 near the Riley-Day locus,
which interacts with RET mutations. (Bolk 2000) The Riley Day (familial dysautonomia) gene would
be an excellent candidate as a HSCR modifier, and this locus may indeed be the Riley Day gene itself.
3.) MASH-1 is a transcription factor involved in the regulation of expression of a number of other
proteins, including RET. MASH-1 knockout rodents have been created which show central
hypoventilation in heterozygotes. (Dauger 1999)   
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4.) Rnx is a homeobox gene expressed in medulla oblongata. Shirasawa et al have shown that
deficiency of rnx results in central hypoventilation in mice, resulting in universal early lethality.
(Shirasawa 2000) It is unclear whether this gene has any effect on the bowel however.
It is of interest that Haddad syndrome has been transmitted as an apparently autosomal
dominant characteristic to two half sisters with a common father. (Hamilton 1989)  Defects in the
known HSCR related genes have only rarely been published in OC /HSCR, however. Bolk failed to
show any mutations in screening the RET proto-oncogene in OC patients, (Bolk 1996A) although
Sakai et al have shown a point mutation in exon 12 of RET (Thr 706 Ala) in a girl with OC/HSCR
(Sakai 1998) and only one case report of a point mutation in the endothelin 3 gene in a case of pure OC
has been published. (Bolk 1996B)  Involvement of the endothelin signalling pathway may account for
the frequent observation of abnormal brain stem auditory evoked potentials in these children, as
mutations in endothelin 3 and the endothelin B receptor (ENDRB) are known to be associated with
sensorineural deafness and HSCR. Interestingly, a point mutation in this gene in the Mennonite
kindred is associated with a shorter segment form of HSCR, deafness and pigmentary anomalies,
unlike the long segment disease seen in OC/HSCR patients. (Puffenberger 1994) Hofstra et al have
reported a case of TCA associated with deafness and depigmentation in an inbred family carrying an
endothelin 3 mutation (Hofstra 1996, Edery 1996). Possibly the TCA in these cases is due to the
homozygosity of the mutations, but there is no mention of autonomic dysfunction. If the endothelin
pathway is involved in this condition, then it seems likely that there are also modifier(s). In summary:
RET, GDNF, endothelin 3, and EDNRB mutations are at most rarely discovered in OC children, with
or without HSCR.
7.6 Recommendations for Treatment:
The combination of a condition requiring long term ventilation with long segment HSCR, and
its attendant problems is a daunting one, however three out of five of our patients remain alive and in
good health at the time of most recent follow up. The two children who died in our series did so after a
considered withdrawal of treatment.
There have been 19 deaths of 41 in the series (in five, the outcome is not mentioned). Six of
those who died have been reported since 1990. They have an average survival of 19 months. Those
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reported before 1990 (13 cases) died at an average age of 5.9 months. It is not surprising that
improvements in TPN, and home ventilatory support should be reflected in improving survival.  In fact
improvements in survival in these children parallel improvements in survival in other children with
TCA over the last 20 years. Anecdotal reports (cited by Weese-Mayer at the International HSCR
meeting in Cleveland in 1995) suggest that the first survivors of  OC are now reaching adulthood, and
that they have the potential for a healthy and largely normal existence at least into their twenties.
Because of the well recognised link between TCA and OC it is suggested that all children
with TCA should undergo sleep monitoring after diagnosis, in order to rule out milder or less obvious
forms of OC. It is possible that routine monitoring of other HSCR patients would pick up subtle and
previously unrecognised ventilatory changes. In fact two of nineteen children with TCA treated in this
state since 1/1/1975 have clinical OC. Thus, OC must be regarded as a significant risk in children with
TCA. The author suggests that OC should be considered in short segment females also, especially in
the presence of pigmentary disturbances.
Similarly, clinicians who make the diagnosis of OC should be aware that HSCR is common in
these children, and a rectal suction biopsy should be mandatory. Finally because of the high incidence
of associated conditions, these children should be carefully assessed by their attending surgeon and
physician with particular care to exclude neural crest tumours, and sensorineural deafness.
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7.7 Summary:
I have presented five cases of the OC/HSCR association, and reviewed 41 other published
cases. OC /HSCR is a condition distinct from classical HSCR, with a distinctive spectrum of severity.
It occurs in 1% to 2% of all HSCR, and 10% of TCA. OC /HSCR contributes up to half the case load
of OC referred for home ventilation to respiratory units. People presenting to neonatal units with either
TCA or OC alone should be screened for the other condition. Of all the children reviewed,
approximately half are dead, half are female, and half have total colonic HSCR.
Children who present with TCA should undergo sleep monitoring, and consideration of a
rectal biopsy should be mandatory in children who present with OC.
There is a high risk of associated neuroblastoma, which may occur in nearly 20% of
OC/HSCR cases. This should be looked for whenever the OC/HSCR combination is seen. Other less
severe, but clinically important associated problems are common, including sensorineural deafness,
ocular problems, and GI motility disturbances.
 Management is difficult, and a multi-disciplinary approach in a well supported referral centre
is ideal. Although we can afford to be guardedly optimistic in prognosis, even at the start of the third
millennium some families will opt to withdraw treatment, and this wish should be respected.
Clearly OC/HSCR forms part of a spectrum of HSCR with a range of autonomic disturbances.
Are these disturbances present in other HSCR patients in a less severe phenotype? Aspects of this
question are addressed in the next chapter.
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Chap 8. Autonomic monitoring of HSCR patients.
8.1 Ondine’s Grumble, not Ondine’s Curse?: Pulse oximetry and pulse
variability in Hirschsprung’s Disease.
8.1.1 Hypothesis and introduction.
8.1.2 Materials and methods.
8.1.3 Results. 1.) Desaturation.
2.) Pulse variability.
3.) Response to hypoxia.
8.1.4 Discussion
8.1.5 Conclusion.
8.1.6 Further work and long term follow up.
8.2 Electrogastrogram studies.
8.2.1 Background.
8.2.2 Materials and methods.
8.2.3 Results.
8.2.4 Discussion.
8.2.5 Follow up proposals.
8.3 Clinical examples.
8.3.1 Discussion of cases.
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8.1.1 Hypothesis:
That HSCR is a disease which involves not only the enteric nervous system, but also the general
autonomic nervous system
.
Introduction:
OC is characterised by lack of central respiratory drive, most marked at night. Haddad
described three cases of OC and HSCR occurring together in 1978 (Haddad 1978). The 50 further
cases reported and summarised by Croaker et al. up to 1997 (Croaker 1998) estimated that Haddad
syndrome made up 1 - 2% of all HSCR. That paper (incorporated here as chapter 7.) further noted that
in the published cases central hypoventilation was overwhelmingly of early onset and severe.
Similarly, the aganglionosis in these patients tended to be more severe than that of the HSCR
population at large. This suggested the possibility that less severe forms of hypoventilation might be
present in the less severely aganglionic population.
Automatic control of breathing is centred in the so called respiratory centre of pons and
medulla.(Ganong) GDNF is a neurotrophic factor which binds to RET, the major gene associated with
HSCR, (Bolk 1996A) GDNF is expressed widely in the nervous system, including the mesencephalon.
(Springer), and is known to be mutated in some cases of HSCR.(Angrist 1996, Salomon 1996)  This
strengthened the case for searching for more diffuse neurological manifestations in HSCR. Other
authors, notably Staiano et al. (Staiano, 1999) had already shown that there were autonomic
manifestations in HSCR outside the gut, but had not shown any abnormality in breathing control.
Meanwhile Cheng et al had shown sub-clinical sensorineural hearing deficits in a large percentage of
HSCR patients, (Cheng, 2001) further reinforcing the notion of a diffuse neuropathy.
Transcutaneous pulse saturation monitors have been available for a number of years as an
adjunct to the management of anaesthesia and ICU patients, and are increasingly being used in the
routine post op. monitoring of patients. A number of studies cite their use in the investigation of
breathing patterns and CNS disorders, for instance those of Neumann, and of Gries. (Neumann 1995,
Gries 1996) Polysomnography is also an established method of investigating disorders of breathing
during sleep. While it would be desirable to investigate our patient population with this method, the
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limited facilities available and the expense of this method have made it impractical for this type of
study.
This study was conceived to test the hypothesis that sub clinical central cardio-respiratory
control abnormalities are common in HSCR patients, even when OC is not present.
8.1.2 Materials and Methods:
Patients presenting with HSCR to Nottingham City Hospital and The Queens Medical Centre
(QMC) were asked to participate in the study. Data was recorded on the age, sex, length of
aganglionosis, associated features, especially cardio-respiratory disease, pre, or post operative state,
and if post op, the presence or absence of analgesics. Controls were selected from patients admitted to
the QMC paediatric surgery ward. Those with a history of cardio-respiratory or CNS illness were
excluded.
Pulse oximetry was performed in 35 cases using one Ohmeda transcutaneous monitor. The
Ohmeda 3700 is a portable bench instrument that provides low perfusion warnings and pulse
plethysmography (PPG) display. The reference oximeter was connected via a standard Ohmeda Flex
probe attached to toe or finger in larger children, or across the lateral side of the foot in small infants.
Recordings were performed with other machines in seven cases: a second Ohmeda in four HSCR
cases, a Quartz Q400 in one HSCR case, and an Oxford polygraph telemetry unit in two control cases.
A personal computer (PC) was used for recording, thus allowing large amounts of data to be
collected at a high resolution. Data obtained was transferred directly from the serial port at the rear of
the Ohmeda 3700. In default mode the oximeter outputs a data stream in character format every 2
seconds. The output is in the form of a six beat average. This produces a time referenced text file of
pulse and oxygen saturation (SpO2) Recording in this way also permits direct reading of the resultant
data file into a spreadsheet for interpretation. Raw data from the oximetry session was analysed using
Microsoft Excel.
Recording sessions were extended as long as possible, up to a full night, but less than one full
day in all cases. Unfortunately, overnight recordings were not obtainable in all HSCR patients.
Recordings under one hour were discarded. Data points that were identified as poor quality by the
software were also discarded.
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The resultant time series of pulse and saturation data was then analysed in three ways:
1.) A histogram of saturation against cumulative time was constructed. The time that subjects
spent at less than 95% saturation was then compared.
2.) The pulse data series was analysed by detrended fluctuation analysis to obtain its long term
fractal scaling exponent. This was done using the method described by Peng et al. (Peng 1995) , using
time windows ranging from 34 seconds to eight hours. A value of this long term scaling exponent close
to one is consistent with normal pulse variability, which has persistent long range correlations (“1/f
noise”). Higher values are consistent with more regular (abnormal) behaviour. The resulting
coefficients were compared between patients and controls, and amongst the HSCR patients. Short term
variability analysis could not be done owing to the nature of the data collected by the oximetry probe.
3.) Pulse was plotted against saturation, and an assessment was made of the response of the
subject to hypoxic episodes.
Subjects
There were overall 16 HSCR patients, and 26 controls who had a pulse oximetry studies. The
male to female ratio was approximately 4:1 in both groups.(See Table 1.) Results were analysed with
and without Patients KD and BO. They were then excluded from further analysis as patient KD
subsequently went onto nocturnal ventilation, and clearly had symptomatic Ondine’s curse. (This was
foreshadowed by difficulty in extubation post operatively.) Patient BO was also then excluded as he
had Tetralogy of Fallot, and was consequently severely and constantly hypoxic. Two symptomatic post
tracheo-oesophageal fistula patients were studied as positive controls, confirmed to have significant
periods of desaturation, and excluded from the control group on the basis of pre-existing symptomatic
thoracic disease.
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8.1.3 Results:
Initials Sex Length Age (months) Diagnosis Time below 95%
AM2 m 139 2 days post appx. 18.33%
KS m 163 2 days post appx. 13.83%
WH m 108 2 days post appx. 12.94%
ES m 111 3 days post appx. 1.18%
BC m 148 5 days post appx 36.35%
DH m 6 6 days post PSARP 17.30%
JT m 130 abdo. pain 0.38%
RT f 168 antibiotics - appx abscess 5.46%
LW† m 5 Awaiting RIH repair 50.91%
HS f 1 constipated 14.45%
LD m constipated 0.50%
DT m 154 constipation 0.58%
KG f 161 constipation 21.15%
JR m 59 constipation. dev.delay 6.58%
C3 m post hypospadias repair. 7.14%
EH m 2 FTT 24.29%
BK m 2 gastroschisis 13.11%
SP m 4 Awaiting RIH repair 34.46%
IB f 1 neonatal abdo. distension 16.66%
JC2* m 135 normal 0.30%
MC* f 109 normal 0.07%
JC m 135 post appx. 0.85%
BS m 2 post pyloromyotomy 15.73%
JY m 1 post pyloromyotomy 9.87%
AM m 2 rectal biopsy for
constipation
16.20%
TS m 2 pyloric stenosis 5.13%
JW m 27 rectal biopsy for
constipation
39.89%
ZC m 4 short bowel 11.72%
KP m 3 4 days post laparotomy. 27.35%
JC3 f 6 FTT 2.82%
AS m SS 2 HSCR 14.2%
LS m SS 1 HSCR 40.4%
BK2* m SS 105 HSCR 0.62%
CA m SS 0 HSCR 29.60%
CD m SS 1 HSCR 9.78%
CT m LS 48 HSCR, Dev. delay 1.34%
CW m LS 19 HSCR 19.30%
JB* m SS 10 HSCR 32.62%
KM m SS 3 HSCR 36.92%
LW2* m SS 2 HSCR 29.50%
LW3 f LS 50 HSCR 7.70%
RH* m LS 1 HSCR 4.42%
TS m SS 5 HSCR 31.55%
ZA f SS 2 HSCR 24.33%
BO** m SS 7 HSCR (and Fallot) 100%
SW* f SS 101 HSCR/DS 53.20%
KD** m LS 6 HSCR/OC 97%
AF m SS 39 HSCR/DS/OA-TOF 20%
†   : Outlying value. Motion artefact?
* : Different machine used.
**: Confounding conditions.
Table 8. 1 Desaturation times for HSCR and controls.
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Details of patients studied.
1.) Desaturation scores.
A clear decline in desaturation time was seen as the HSCR patients aged (Fig. 8.1). A similar
but less marked decline was also seen amongst the controls. There was no correlation between
desaturation time and length of aganglionosis.
The mean duration of  time spent under 95% saturation was clearly different between patients
and controls with all patients and controls included: p < 0.01. Patient KD had OC, and as such falls
outside the scope of this study. Patient BO had CHD, and similarly has a cardiac explanation for
chronic hypoxia. When patients KD and BO were excluded, a comparison between the 16 remaining
HSCR patients and 30 controls showed a significant difference, with HSCR patients having a mean
desaturation time of 21.2% and controls having a mean desaturation time of 14.2% (p = 0.034
Student’s “t” test, one tail.) There was no significant difference between modal saturations. A high
desaturation time in one outlying control patient (see Fig 8.2.)may represent motion artefact. If this
child is also excluded on that basis, then p ~ 0.01
When the study was further broken down, and nocturnal recordings (2100 hours to 0600
hours) on five patients under one year were compared with nocturnal recordings in five controls under
one year, a significant difference was again found. Controls spent 16.5% of their time under 95%
saturated, whereas HSCR patients spent 28.3% of their time under 95% saturated. (p < 0.01 on t test).
Mean ages of these groups were comparable, the five HSCR patients averaging 3.1 months, and the
five controls averaging 2.2 months. There was no overlap between the desaturations found in this small
group of patients. There were no complicating conditions in this small group of patients.
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Age vs. desaturation in HSCR patients
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Figure 8-1. Decline in desaturation with age in HSCR patients. Outlying data points are patients
with congenital cyanotic heart disease or OC (two at top left), or uncomplicated Down syndrome
(top right.)
Figure 8-2 Comparing HSCR and control total desaturation times (percent) below 95%
saturation. Outliers are marked. The control outlier is a five month old patient who has had a
hernia reduced and is awaiting operation. He was noted to be very active at the start of the
study, and his high value may represent motion artefact. The two HSCR group outliers suffer
from OC, and Tetralogy of Fallot respectively.
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2.) Long term correlation exponent.
Pulse series data were then extracted from the data files and transferred in a blinded way to
the department of electrical and electronic engineering at Nottingham for analysis. A long term
correlation exponent has been calculated for thirty four subjects. It was not possible to separate HSCR
patients from controls on the basis of this exponent. When the exponents were ranked however, they
approximately matched the length of aganglionosis in the HSCR patients, so that longer segment
HSCR patients had a more abnormal exponent. (See Table 2) There was one exception to this. This
was patient AF with short segment aganglionosis, but who has Down syndrome and has had previous
oesophageal surgery that may explain his abnormal result. (Kimura 1996) Four of twelve HSCR
patients had an abnormal correlation exponent, as did seven of twenty two controls. Two of these
seven “abnormal” controls had had recent general anaesthetics, four of the seven had severe chronic
constipation, and one had an old TOF.
Init. Scale exp. Diagnosis Length Init. Scale exp. Diagnosis
CA 0.6901 HSCR SS KG 0.7384 CSC
AS 0.7297 HSCR SS ES 0.819 5 days post appendicectomy
LS 0.8080 HSCR SS HS 0.8423 CSC
ZA 0.8584 HSCR SS BS 0.8994 Post pyloromyotomy
KM 0.8896 HSCR SS MS 0.908 Old OA/TOF
JB 0.9476 HSCR SS AM 0.9097 CSC
TS 1.0054 HSCR SS IB 0.9353 CSC
CD 1.0847 HSCR SS BC 0.9529 3 days post appendicectomy
CT 1.1402 HSCR LS BK 0.9574 Old gastroschisis
CW 1.1768 HSCR LS KP 0.9812 4days post appx
AF 1.3226 HSCR* SS JT 1.006 Abdo. pain
LW3 1.336 HSCR LS LW 1.0157 Hernia(pre-op)
JC 1.0313 Post appendicectomy
EH 1.0503 Failure to thrive
KS 1.086 2 days post appx. off narcotic > 24 hrs
JR 1.1132 CSC. dev.delay
DT 1.2178 CSC alone (Fam hist. of CSC.)
JW 1.2259 CSC
WH 1.2666 2 days post appx. On narcotic.
LB 1.3385 Old OA/TOF
JW 1.3674 CSC 7 hrs post GA
AM2 1.4093 2 days post appx. Same day narcotic
* This patient also had DS, and had an OA/TOF repaired previously. One HSCR patient(ZA) had had
a recent anaesthetic. SS: Short segment; LS: Long segment. CSC: Chronic severe constipation.
OA/TOF: Oesophageal atresia, tracheo-oesophageal fistula, appx: appendicectomy.
Table 8.2. Twelve HSCR patients had pulse series data that were suitable and available to be
analysed for variability, by means of calculating a long term scale exponent characterising the
fractal form of the pulse. Normal values are near 1.0. Altogether thirty four pulse series were
analysed. MS had pulse variability analysed, but was excluded from desaturation analysis as he
presented with cyanotic episodes from tracheomalacia.
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3.) Tachycardic response to hypoxia.
Pulse was plotted against saturation and a regression line and correlation coefficient
calculated. Acutely pulse is expected to rise as saturation falls, giving a negative slope on a plot of
pulse against saturation. Overall HSCR patients had a smaller response to hypoxia than controls, and
some HSCR patients showed a clear fall in pulse with hypoxia. Overall, 47% of 30 controls showed a
regression line with positive slope when pulse was plotted against saturation, while 75% of 12 HSCR
patients showed a positive slope. (NS)
Pulse vs Saturation. HSCR Pt NC
0
50
100
150
200
0 20 40 60 80 100
Saturation
Pu
ls
e
Figure 8-3 Scattergram of pulse vs. saturation in neonatal HSCR. No tachycardic response to
increasing hypoxia. Caution should be exercised in interpreting the lowest saturations in the
absence of corroborative ECG recording. There are nonetheless systematic differences between
HSCR and control patients.
8.1.4 Discussion:
HSCR is associated with hypoxia for various reasons, including both the central and
obstructive apnoeas associated with Down syndrome, and the chronic hypoxia associated with
congenital cyanotic heart disease, as well as the central hypoventilation of OC. Down syndrome is the
most common associated neurological condition associated with HSCR, comprising up to 10%
(Passarge 1967) of all HSCR patients. OC is much rarer, occurring in between 1% and 2% of all HSCR
patients.(Croaker, 1998)  Importantly, this syndrome is defined by its nocturnal central
hypoventilation. Numerous other autonomic control abnormalities have also been described in OC,
including abnormalities of heart rate control.(Haddad) In the collected cases that I reviewed in 1998,
central apnoea was of early onset, requiring ventilation soon after birth in most cases, while the
associated aganglionosis was also of a more severe spectrum than that of uncomplicated HSCR
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patients. This suggested the idea that shorter segment HSCR might be associated with less severe
hypoventilation disorders. viii
There are also molecular genetic reasons for suspecting a link between respiratory control
disorder, and HSCR. In fact, in rare cases mutations in HSCR associated genes have been found in
cases of OC without HSCR. Sakai et al described a mutation in exon 12 of RET in OC/HSCR in 1998
(Sakai 1998)  Bolk et al. described a case of a mutation in the RET gene in an OC case in 1996 (Bolk
1996B ) . Burton et al in 1997 demonstrated CO2 insensitivity in heterozygous RET knockout
mice.(Burton 1997)
Bolk et al further demonstrated a frameshift mutation in endothelin 3 in an OC case in 1996.
(Bolk 1996C) Mutations in endothelin pathway genes are associated with Shah-Waardenburg
syndrome, which combines pigmentary anomalies, deafness, and aganglionosis. Two of the patients in
the study in fact have all white pigmentation and long segment aganglionosis reminiscent of the
phenotype in a naturally occurring horse model which has a defect in the endothelin B receptor. (Yang
1998) One of these patients subsequently went on to nocturnal home ventilation. (See Section 8.3)
While overnight polysomnography is the method of choice for investigating central
apnoea/hypopnoea, beds in sleep units are rare, required for therapeutic studies, and are expensive.
Duchna et al (Duchna 1995) facing the same problem of resources, have established that overnight
pulse oximetry is a sensitive method for detecting those with sleep apnoea who ought to go on to
polysomnography. The present study has also taken the form of overnight pulse oximetry, which is
cheap and available, but potentially prone to movement artefact. (Barratt 2001) Barratt et al in that
paper also established the equivalence of data produced by the Ohmeda equipment, and an ambulatory
unit used on several patients and controls in the current study.
The method used in this study has shown a clear decline in desaturation times with ageing, a
clear increase in desaturation in symptomatic positive control patients, and a difference between the
                                                          
viii An initial hypothesis that an inherent autonomic abnormality in HSCR might be reflected in
abnormal apgar scores was not born out. 119 non-syndromic HSCR patients from NSW were no more
likely to have an apgar less than 7 at one minute than were babies born in NSW in 1994. (Day 1997)
(See Chap. 3.)
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study and control groups. Dauger et al likewise showed deficiencies in CO2 sensitivity in MASH-1
knockout mice, which were present in juvenile mice, but not in adult mice. (Dauger 1999) The
similarity between MASH-1 knockout mice and HSCR children in improvement in desaturation with
age is of great interest. The mechanisms by which ventilatory control becomes more normal in the face
of an inherited abnormality in neural crest derived cells deserves further study. Importantly, the
hypoventilation of OC does not predictably improve with age, suggesting either that MASH-1 is not
important in human OC, or that the mouse knockout is simply not a good model for human OC.
Ten control patients were between 12 hours and 6 days post GA. These patients had an
identical amount of desaturation to those controls who had had no GA, although two of the highest
desaturation times in the control group were post GA. It is possible that including these patients in the
control group has decreased the difference between HSCR and control groups.
The results actually obtained are broadly consistent with those obtained by Gries et al (Gries
1996). Their group of 350 healthy subjects ranging in age from one month to eighty five years spent on
average 10% of the time at or below 94.7%. Care was taken to exclude motion artefact in this group.
The control group in the present study, which was much younger, and who represented a sample from
a surgical ward, spent on average 14.18% below 95% saturated. Some, but not all motion artefact was
removed by the recording software. A strong trend to less desaturation with increasing age was seen in
the HSCR patients. This trend was less marked in the controls , who were a much more heterogeneous
group. While many of the controls were 1 to 6 days post operative, all were felt to be stable, and
without respiratory sequelae. The control group as a whole was also significantly older than the HSCR
group, but differences in saturation remained when comparing younger and older separately. Allowing
for these differences in populations, it is felt that the saturation differences between HSCR and control
groups are significant.
This difference is much more marked when nocturnal recordings only are compared.
Likewise, Neumann et al (Neumann 1995), while failing to show any difference between patients with
severe diabetic autonomic neuropathy and controls during daytime pulse oximetry recordings, showed
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a significant difference in overnight recordings. There are not sufficient long segment HSCR patients
in this group to detect any trend to greater severity of hypoventilation with increasing length of
aganglionosis.
A number of workers including Peng and others have shown that the normal healthy human
heart rate varies continuously with long range fractal correlations (Peng, 2000). This variability is
altered in a number of conditions, including autonomic neuropathy, heart failure, and after
oesophagectomy. (Neumann 1995, Kimura 1996, Peng 2000). We have investigated this aspect of
cardiac behaviour by calculating the long range fractal scaling exponent of the heart rate according to
the method described by Peng (Peng, 1995). While we think that in order to get the long-range fractal
scaling exponent this method is applicable to the time averaged data supplied by the Ohmeda machine,
more sophisticated analysis involving the short-range exponent or spectral representation is not
possible, as R-R intervals are not recorded by this equipment. The results in Table 8.2. suggest an
association between longer segment disease, and more regular heart rate. The only short segment
patient with an abnormal long range correlation coefficient had in fact had previous oesophageal
surgery for an oesophageal atresia/ tracheo-oesophageal fistula. An abnormal coefficient in this patient
would fit with previous reports of heart rate control abnormalities post oesophageal surgery. (Kimura
1996) HSCR patients were overall more likely than controls to have an abnormal correlation exponent,
40% vs. 33% (NS.). There appeared to be no correlation between long term fractal scaling exponent
and the time spent desaturated.
An abnormal long term fractal scaling exponent was also found in seven of the controls.
Several of these had had general anaesthetics within the previous two days, four had severe chronic
constipation, and one had had a TOF. While the meaning of these results is not clear, it is possible that
they represent drug related effects in three, autonomic neuropathy as the basis for constipation in four,
and surgery related vagal nerve damage in one, as has been previously reported. (Kimura 1996)
Repeating the study with normal school children, would be desirable to avoid possibly “abnormal”
controls. The exponent did not vary with age in the controls, but showed a slight tendency to increase
with age in the HSCR group. (Correlation coefficient ~0.8. Data not shown.)
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To confirm the accuracy of the fractal scaling exponent calculated over very long time
windows, the calculation was performed again using shorter windows (100 - 1000 beats, and 100 -
3500 beats) to avoid finite length effects. The results of analysis on all three scales are very similar,
leading to the same conclusions.
Finally, the scatter plots of pulse against saturation again showed a tendency towards less
tachycardia with desaturation in HSCR patients, consistent with an autonomic control abnormality in
some patients.
8.1.5 Conclusion:
The available data support the hypothesis that HSCR patients are prone to a defect in central
control of breathing, which is more noticeable during sleep, even when OC is not evident. Some (but
not all) may also have abnormalities of heart rate control of the type already described in other
autonomic neuropathies. This may be more common in those with long segment disease. Formal
polysomnography will add detail to our understanding of these phenomena.
Hirschsprung’s disease patients warrant very long term follow up studies to assess the effect
of these abnormalities in middle and old age.
8.1.6 Further work and long term follow up.
The link between HSCR and GDNF signalling pathways which may be involved in the
phenomena discussed here, and the recurrent hypoxia that may be suffered by some HSCR patients
suggest the form of the long term follow up. We expect that HSCR children, especially those with long
segment disease, will start to show a higher incidence of Parkinson’s disease and other
neurodegenarative disorders in old age. This may be related directly to lack of GDNF/RET signalling,
or indirectly due to the effects of mild chronic hypoxia if it is confirmed that these children have
increased sleep apnoea.
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A very long term follow up of a cohort recruited for a heart study in Hawaii thirty years ago
(1971 - 1974) were incidentally questioned about bowel habit at the initial assessment. At follow up
over 24 years it was shown that a constipated bowel habit at the initial (asymptomatic) interview was
highly significantly correlated with the development of Parkinson’s disease at follow up. (Abbott
2001) HSCR ought to be even more strongly associated with Parkinson’s due to the known high
frequency of abnormalities in the GDNF/RET system, and the dependence of midbrain neurones on
GDNF. (Indeed, when GDNF was characterised it was felt to hold hope of a treatment for Parkinson’s
disease.)
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8.2 Electrogastrogram (EGG) studies in Hirschsprung’s disease.
8.2. Hypothesis
That HSCR patients are not only spastically contracted in their aganglionic segments, but have a
diffuse abnormality of the enteric nervous system, leading to measurable changes in gastric electrical
and physical activity.
8.2.1 Background
As noted in the previous section, there is evidence of a diffuse subtle abnormality in the
autonomic nervous system of at least a subset of HSCR patients (Meire 1987, Croaker 1998, Croaker
2001, Tam 2000, Staiano 1999). Staiano et al have published work demonstrating widespread
abnormality in the autonomic systems of HSCR patients. In addition, Aslam & Spicer in Bristol have
demonstrated that even the “normal” bowel in HSCR patients has an altered rate of secretion of mucin,
for reasons that are unknown. (Aslam 1997)
Catto-Smith and Hutson (Catto-Smith 1995) have noted that there is a high rate of less than
satisfactory outcome in HSCR at long term follow up. 53% of their patients suffered from significant
soiling at follow up, while a further 27% had less severe soiling. While soiling in Catto-Smith’s study
was more common after dilatation, it does leave open the question of whether dilatation is a result of,
rather than a cause of, pre-existing ano-rectal and colonic dysfunction.
 My own impression of follow up of HSCR patients in NSW suggested that there was a high
incidence of gastro-oesophageal reflux in these patients, although this was not one of the specific aims
of the study, and information was not collected systematically. (unpublished data) Collectively, the
available clinical and scientific information supports the idea that there is a diffuse abnormality of the
gut outside the aganglionic zone in HSCR. Work published in May 2000 showed abnormalities of
Gastro-intestinal transit  in 12 of 21 HSCR patients studied. (Miele 2000)  While the present study was
in preparation, in July 2000 work was presented at the annual meeting of the British Association of
Paediatric Surgeons (BAPS) which demonstrated abnormalities of the EGG in 6 of 7 HSCR patients
who were studied. (Johnson 2000)
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Nagahama et al (Quoted by Cass in Holschneider’s textbook.) noted abnormalities in the three
dimensional structure of the ganglionic bowel even in the duodenum of the spotting lethal (sl) rat. The
spotting lethal rat shows a total colonic (and sometimes shorter) aganglionosis. Cass asks whether the
diffuse subtle abnormalities in this animal’s ganglionated gut imply diminished function. (Cass) If the
histological abnormalities described by Nagahama are also present in humans, they may provide an
explanation for the findings in the current study. We address a question of function in the “normal” gut
in this chapter.
This study aims to add to the data defining the broader implications for the long term outlook
of the child who is born with HSCR. It will be of particular interest to know if abnormal gastric
electrical activity predicts enterocolitis, GOR, or other symptomatic problems.
EGG
EGG has been used as an experimental tool for most of the 20th century, the first reference to
it being by Alvarez in 1922. (Alvarez 1922) The chief barrier to its widespread adoption has been the
lack of appropriate signal processing electronics to filter the faint gastric electrical signal from the
electrical noise generated by the gut, heart, respiratory movements, and body wall movement. (Chen
1993)
Work in dogs has shown that the transcutaneous EGG does miss some electrical spike and
other localised gastric electrical activity, however it is able to pick up the underlying gastric rhythm,
which is normally close to 3 cycles per minute (cpm) It is also able to show changes in overall gastric
activity related to eating. The EGG has been shown to have an amplitude proportional to the intensity
of the gastric electrical activity. “Power” on the EGG output depends on the square of the amplitude of
the trace.(ix. See footnote 2  pages over.) Normally the “power” in the normal frequency range (2.0 - 4.0 cpm)
increases two-fold after a meal. (Verhagen 1999) It is essential that the raw EGG is carefully scanned
and interpreted for the presence of artefacts, most of which are due to motion. Motion artefacts will be
interpreted as increased power in the low frequency range after application of the fast Fourier
transform to the raw data. Similarly, non sinusoidal waveforms of the EGG may produce harmonics
which are exact multiples of a fundamental frequency, and which are evident as increased power in the
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high frequency range (Verhafen 1999). As movement artefacts are the most common source of
spurious frequency peaks, EGG studies are generally more satisfactory in older, more co-operative
subjects in our experience.
In practice, the EGG consists of the placement of three recording electrodes over the patients’
upper abdomen from the antrum proximally. (Although placement may be assisted by use of an
ultrasound probe to localise the gastric bubble, we have found that placing the ground electrode at the
level of the transpyloric plane, 5 - 10 cm to the right of the midline, the first recording electrode at the
same plane in the midline, and the second recording electrode 5cm from the first on a line angled at 45o
to the transpyloric plane gives reliable recordings. (see Fig 8.4) This method has been established in
previous work carried out at the Queen’s Medical centre, and is described both in the literature (Abell
1988), and in the Synectics users’ manual. (Synectics Medical, Digitrapper EGG Users’ Manual 1997).
The electrical signal collected from these electrodes was then recorded over a minimum of 30 minutes
pre and thirty minutes post prandially. Pre and post prandial power and frequency of the gastric
electrical activity was noted.
Figure 8.4 Showing
"Digitrapper" box and
location of electrodes.
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8.2.2 Materials and Methods
EGG was performed using a Synectics Medical Digitrapper and associated software. Studies
were performed by sampling at 4Hz, and a moving average of 1 sample. At the end of the study, data
was uploaded to a PC for analysis by Fast Fourier Transform using proprietary Synectics
ElectroGastroGram software.
Twenty controls, and ten HSCR patients were originally studied. Controls were recruited from
general surgical ward patients, from staff, and from children of staff. Four of these were discarded due
to technical faults with the recording [non compliance(1), detached lead(s)(1), faulty cable (2)]. Details
of the groups is in Table 8.3 The raw data of the remaining 26 was then scanned for quality. Finally
twelve of these have been analysed after discarding recordings with obvious flaws, as shown for
example in Fig 8.5a. (page 171.) If the trace was affected by noise to such an extent that meaningful
data was judged unobtainable, even with editing, then it was discarded. (Fig 8.5a -d  over two pages,
shows good and poor quality recordings, both in raw signal, and in output after Fourier analysis.) The
conclusions are unchanged by rejecting over half the raw studies, but statistical power is lost. (Table.
8.4 shows all subjects.) Subjects are not matched for age and sex. Dominant frequencies identified for
the pre and post prandial periods identified by the software were compared between the two groups.
The “power” of the dominant frequency was defined as the square of the amplitude in that frequency
band, and automatically calculated by the software. (Synectics technical manual)ix The ratio of pre and
post prandial dominant frequency power has also been calculated and compared for the twelve best
quality studies, which are summarised in Table 8.4.
Table 8.3 Patient details.
N Male Female Age range
(months)
Av age
HSCR 10 9 1 0.3 - 120 51 months
Controls 16 5 11 0.75 - 252 95 months
                                                          
ix More generally, Power is expressed in decibels, so that P(db) = 10log10(A2), where A is the
amplitude of a sinusoidal signal.
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8.2.3 Results
Age (months) Sex Diagnosis PDF post PDP pre PDP post PDP(post/pre) Patient
120 M Normal 2.81 168.29 243.47 1.446728861 Control
132 M Normal 2.11 355.51 387.99 1.091361706 Control
0.75 F Constipated 2.11 499.53 595.63 1.192380838 Control
108 F Normal 2.58 417.35 186.39 0.44660357 Control
108 F Normal 3.28 412.7 52.78 0.127889508 Control
96 F Normal 2.58 369.66 885.71 2.396012552 Control
144 M Post appendicitis 3.28 190.41 1431.45 7.517724909 Control
108 F DS/SS 3.05 1994.71 2584.66 1.295757278 HSCR
36 M TCA 8.2 643.67 296.07 0.459971725 HSCR
0.3 M SS (pre-op) 8.91 502.89 348.43 0.692855296 HSCR
0.5 M SS 1.41 1147.83 443.45 0.386337698 HSCR
108 M TCA 3.52 169.95 365.27 2.1492792 HSCR
Abbreviations: PDF: Period dominant frequency; PDP: Period dominant power - pre-, and post-
prandial; DS/SS: Down syndrome, short segment HSCR; TCA: total colonic HSCR.
Table 8.4 Pre- and post-prandial period dominant power and frequency in 12 studies reported
here.
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Fig. 8.5a (above) EGG signal obscured by noise.
Fig 8.5c (above). Fairly clean EGG signal from normal
control.
Fig. 8.5d (right) Resultant Fourier analysis of trace in
Fig. 8.5c. Steady peak frequency with few or no gaps or
outliers. Period dominant frequency here is 3.05cpm.
Fig 8.5b (above) Resultant analysis of trace in 7.2.2a.
Spurious and irregular 0.23 cpm peak.
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 Gastric pacemaker frequency:
Average post prandial PDF in HSCR was 5.018. Average post prandial PDF in controls was
2.678571. The high post prandial PDF in HSCR children was largely due to two children who
exhibited clear and sustained tachygastria.x Two tailed “t” test for this difference in average PDF
showed a “p” value of 0.091516. Pre prandial PDF’s are not compared, as preprandial PDF values in
the younger children all show suspiciously low frequencies, suggestive of agitation associated with
hunger. Both HSCR and controls showed a slight tendency to an increased PDF with increased age.
(More marked in HSCR.) This may reflect less low frequency motion artefact in older children. There
was no difference between the sexes in pre-prandial PDF in controls; no difference between small
numbers of constipated and non constipated HSCR patients in pre-prandial or post-prandial PDF; and
no difference between symptomatically refluxing and non refluxing HSCR patients in pre-prandial or
post-prandial PDF.
Power response to a meal:
Power response to a test meal was evaluated in 12 subjects with the best quality recordings. (7
controls and 5 HSCR patients.) While the controls had a mean pre/post prandial dominant frequency
power ratio of 2.03, the HSCR patients had a mean ratio of 0.99, with only one patient getting over 2,
and three patients having ratios below 1. The numbers are too small to approach significance on “t”
test, but are highly suggestive.  See Table 8.4
8.2.4 Discussion.
Detailed analysis of this cohort is difficult because of differences in age and sex of the HSCR
and control groups. Increased movement artefact in the younger HSCR group, especially pre-
prandially, may well contribute to a lower post /pre-prandial power ratio in the HSCR group than in
control subjects. We await more studies of older HSCR patients to clarify this point. In spite of this,
some clear points can be made.
                                                          
x As at 4/2/02 we have conducted EGG on 40 children. Four of fourteen HSCR children have shown
tachygastria, which is present in none of the controls. Only one of these children has TCA. There is
now a suspicion that children with tachygastria demonstrate more evidence of functional obstruction at
follow up than others. This is still being evaluated.
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Two of the HSCR patients showed clear tachygastrias. One of these was a TCA patient, but
the other had recto-sigmoid length aganglionosis. (See Fig 8. 6 - next page, for graphic display of
tachygastria) The TCA patient had been previously operated on, but the short segment patient was
operated on a week after the EGG study. We can therefore conclude that tachygastria is not necessarily
a response to colectomy, nor is it a spurious signal picked up from a Hirschsprung’s colon. Unlike the
preliminary report presented at BAPS in 2000 (Johnson 2000), the tachygastria was not seen only in
TCA patients.
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Figure 8-6. Top: Normal pre- and post-prandial study of DS/HSCR (short segment) patient with
history of gastro-oesophageal reflux. Dominant frequency: 3.05cpm.
   Bottom: tachygastria (8.91 cpm) both pre- and post-prandially in a one month old with
short segment aganglionosis.
It is suggested that tachygastria may be a marker of a subtle bowel wide abnormality. This
abnormality is also marked by the blunted response to a meal shown by the HSCR patients. As both the
children with tachygastriaxi have had HAEC at one time, and continue to suffer abdominal distension,
it is possible that this may predict ineffective enteric clearing contributing to HAEC. It is known that
                                                          
xi Two new cases with tachygastria are recently diagnosed, one has suffered at least one episode of
HAEC while on washouts, and there is no follow up data on the other as yet.
173
tachygastria is associated with mechanical inactivity of the stomach. (Verhagen 1999) It is interesting
to speculate that gastric arrythmias are associated with abnormalities of rhythm and mechanical activity
elsewhere in the gut, thus contributing to stasis and HAEC.
One tachygastric patient had presented with HAEC prior to his EGG, but was well at the time
of study. He had previously had a colectomy for TCA. The other tachygastric (CD) had also presented
obstructed and enterocolitic in the new-born period. He was washed out, and the EGG study was
carried out subsequently when he was stable and awaiting pull through. The tachygastria is unlikely
therefore to represent a response either to colectomy or acutely to enteritis, as both patients had settled
at time of study. Subsequently he has suffered further episodes of distension. Of those with normal
dominant frequencies, only one of the three is known to have a history of HAEC, while two of two
with tachygastria have had at least one bout of HAEC.
It will be interesting to see if EGG develops as a useful predictor of HAEC with greater
numbers of subjects.  It may be useful to study children during an acute episode to establish whether
there is any change during acute episodes of HAEC.
Interestingly one patient, SW, a seven year old Down syndrome girl with a long history of
symptomatic reflux, and treated short segment HSCR, who was expected to have an abnormal gastric
rhythm on the basis of the author’s initial hypothesis linking abnormal gastric rhythm and reflux, in
fact had a completely normal gastric rhythm. (Fig 8.6 top recording)
A lower than normal average power response to a test meal was noted in the HSCR group.
While this may in part be artefactual, it is hard to believe that this is the case in all patients. Ratios
below 1 are unusual in healthy individuals, and may represent an abnormal gastric response to feeding.
(Mantides 1997)
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8.2.5 Proposal:
The author regards the data presented in this chapter as preliminary. Further studies are going
on at present to get better statistical evidence, to get better quality data, and to match HSCR and
control groups better. In addition, to validate this study, and to gather evidence that slow intestinal and
gastric transit may contribute to the development of HAEC, the author proposes a follow up study
combining EGG with a means of measuring gastric emptying, and with two dimensional whole-mount
studies of normal ganglionated stomata. Functional studies will take the form of impedance electrical
tomography (IET) in the first instance. This is a non-invasive method of measuring emptying of the
stomach following administration of a test meal. In the longer term, hydrogen breath testing which
gives a measure of transit time to the colon, may be more useful. Clearly it would be of interest to
compare the three dimensional structure of the ganglionated bowel (as was done in the ls rat) with the
EGG and IET result. The non-invasive modalities are also likely to have a place in the investigation of
children with constipation, particularly as adjuncts in the decision to do rectal biopsy or not. And in
those without HSCR, they may help in assessing prognosis, as there is evidence that chronic severe
constipation may be linked to autonomic neuropathy in some patients. (Raethjen 1997)
IET
IET is a technique for estimating gastric (or other hollow organ) capacity by measuring the
electrical resistance between pairs of electrodes placed circumferentially around the body at the level
of the organ to be studied. It does not measure gut electrical activity per se, but may aid interpretation
of the EGG. In particular it may allow us to discriminate between gastric electrical activity associated
with gastric emptying, and gastric activity associated with antral mixing.  (Nour 1995, Ravelli 1994,
Lamont 1988)
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8.3) Clinical examples.
Patient CW and patient KD both presented with TCA confirmed at histology, and a
hypopigmented phenotype reminiscent of the lethal white foal. (See Fig. 8.7) CW in particular has
deep blue eyes, and all white hair with a few pigmented hairs at the crown only. This all white
phenotype, with a few pigmented hairs between the ears and at the base of the tail has been reported to
the author by Paint Horse breeders in the lwf. (unpublished data.) This strain of horse is known to
carry a mutation in exon 1 of the endothelin B receptor. (Yang 1998)  Animals heterozygous for this
mutation characteristically display the overo spotting pattern (See appendix 8 for picture.), while
animals homozygous for the mutation display an all white coat (sometimes with the exceptions noted
above), and a total colonic aganglionosis. The heterozygous minimal pigmentation phenotype is to
have colour limited to the top of the head, the so called “medicine hat” overo, shown in Fig. 8.7.
Both CW and KD had saturation monitoring performed, but only CW has been studied with
an EGG. These two hypopigmented children are interesting, because KD suffered from Ondine’s
Curse, with nocturnal hypoventilation requiring artificial ventilation. (He has since died.) CW did not
suffer from OC, but his heart rate variability was unusual, with a long term scaling exponent just
higher than normal (1.1768 ). In addition, CW spent nearly 20% of a sleep study at less than 95%
saturated. While this is less than the average desaturation time for HSCR patients, it is more
desaturated than the average of 14.6% for controls. In addition CW demonstrated sustained
tachygastria on EGG, and clinically demonstrated long term functional obstruction, in spite of evidence
of a technically adequate surgical result. He has recently had a permanent ileostomy fashioned.
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8.3.1 Discussion of cases.
The similarity of pigmentary phenotype to the lethal white foal suggests an endothelin B
receptor mutation in these children. The long segment aganglionosis and the similarity to the
homozygous horse model suggest that these two children may in fact be homozygous for an EDNRB
mutation. The pattern of depigmentation allied with the long segment aganglionosis suggest that both
enteric neuroblasts and melanoblasts in these children complete their migration at an early stage. It is
possible that white hair with pigmentation at crown only is a marker for long segment or TCA. This
hair colour pattern should be carefully looked for in children with signs of neonatal bowel obstruction.
SOX 10 mutations have also been described in association with long segment aganglionosis
and Waardenburg syndrome, but the author is unaware of a description of the all white hair colour with
pigmentation at the crown. Meire et al (Meire 1987) in 1987 described a child with (presumably short
segment) aganglionosis, Waardenburg syndrome, and Marcus-Gunn ptosis, demonstrating a prior
observation of a connection between HSCR, pigmentary anomalies, and autonomic dysfunction.
These two patients with a phenotype reminiscent of WS (Hearing not formally tested, but no
clinical evidence of hearing loss.), long segment aganglionosis, and evidence of autonomic dysfunction
of varying severity provide suggestive evidence of a further link between autonomic disturbance and
Figure 8-7 Top of head of CW, (top
left) showing all white hair, with a few
pigmented hairs at the crown barely
visible. (The yellowish colour is an
artefact of photography. The hair is
white.) Compare this with the pictures
of lethal white foal, (bottom left) and
“medicine hat” overo horse (right)
Brief details of overo horses are given
in appendix 8.
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the endothelin pathway/SOX10 genes. SOX 10 has been shown to contribute to the modulation of the
expression of RET. (Lang, 2000) RET deficient rodents have been shown to have altered CO2
sensitivity, (Burton 1997) suggesting that mutations in either gene might contribute to a tendency to
hypoventilation. Unfortunately for this hypothesis however,  RET/GDNF mutations have rarely been
shown in Ondine’s Curse, either alone or in combination with HSCR.  (Sakai 1998, Amiel 1998) Bolk
et al found only polymorphisms in their survey of RET in OC.(Bolk 1996B) A Case of mutation in
SOX 10 has been described with HSCR and demyelination in both central and peripheral nervous
systems. (Inoue 1999) Such demyelination might have a variety of effects, but central hypoventilation
is not commented on in Inoue’s case. (The author in fact is unaware of any systematic search for
SOX10 mutations in OC.) Work done in the Chakravarti lab has also shown a mutation in endothelin 3
(Bolk 1996C) in Ondine’s Curse. Mutations in either SOX10, endothelin 3, or endothelin B receptor
have been associated with HSCR/ Waardenburg syndrome. While these genes make suggestive
candidate genes for central hypoventilation and other autonomic disturbance, it is of interest that
mutations have only rarely been found in Ondine’s Curse.  Two other genes rnx (Shirasawa 2000), and
MASH-1 (Dauger 1999) have been implicated in abnormalities of respiratory control in the rodent, but
again, mutations in these genes are not reported in human HSCR. As noted above, the CO2
insensitivity in MASH-1 knockout mice was greatest in young animals, and not detected in adults.
Interestingly desaturation in our children also declined with age.
It is likely that genes, or regulatory regions yet to be discovered are involved in this condition,
and in the autonomic effects described. The pigmentary anomalies noted here suggest that (some of)
the genes are likely to be related to SOX10 or the endothelin pathway genes. MASH-1 is involved in
regulation of RET expression. It also is a good candidate gene.
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Chap 9. Results of mutation screening in GDNF and related genes
in Hirschsprung’s disease.
9.1 Hypothesis:
9.2 Background and introduction.
9.3 Materials and methods
9.4 Results
9.4.1 GDNF screening.
9.4.2 Partial GFRα1 screening.
9.4.3 Partial RET screening.
9.5 Conclusions.
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9.1.) Hypotheses:
1.) That GDNF mutations will be responsible for a percentage of HSCR.
2.) That GFRα1 mutations will also be responsible for a percentage of HSCR.
3.) That RET polymorphisms as well as RET mutations will contribute to HSCR 
susceptibility.
9.2.) Introduction:
Hirschsprung disease (HSCR), is a serious condition leading to neonatal bowel obstruction or
chronic severe constipation. It is known to have a significant genetic component, and to be inherited in
a complex fashion, with both incompletely penetrant autosomal dominant and recessive forms
observed. In 85% of cases there is no family history of the disease. Histologically, HSCR is
characterised by a lack of ganglion cells extending proximally from the anus for a variable distance. It
occurs in approximately 1 in 4,000 live births, and affects boys four times as frequently as girls. Eighty
percent of HSCR cases involve no more than the recto-sigmoid region of the colon, in ten percent more
than the sigmoid, but less than the whole colon is involved, and in ten percent of cases at least the
whole colon is involved [Total colonic aganglionosis (TCA)], with possible small bowel involvement..
In these long segment cases the sex ratio is closer to equality. (Bodian 1949, Bodian 1963, Passarge
1967, Badner 1990) An association between mutations of the RET proto-oncogene and HSCR was
discovered at the end of 1993 (Luo 1993). Between 3-7% of sporadic and 40-50% of familial HSCR
patients have mutations in this gene (Svensson 1998, Seri 1997). Attié et al. found a penetrance for
RET mutations of 72% in males, and 51% in females, in a sample of 80 patients (Attie 1995). The low
penetrance of RET mutations, along with the low frequency of mutations in RET, and the evidence of
rare involvement of other genes (ECE1, [Hofstra 1999] EDN3 [Bidaud], EDNRB [Puffenberger 1994],
SOX10 [Pingault 19998] SIP1[Wakamatsu 2001] , and NTN [Doray], and loci [Bolk 200, Graivier
1966, Mowat 1998, ] have all supported the idea of HSCR as a polygenic disease. The underlying
genetic mechanism of the majority of HSCR remains to be determined however, as mutations in all
these genes taken together, account for no more than half of overall HSCR.
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RET, the most frequently mutated gene in HSCR, encodes a receptor tyrosine kinase normally
required for development of kidney, peripheral and central nerves.  It is particularly critical for
development of the enteric nervous system (Schuchardt 1994). RET is activated through interaction
with both a circulating ligand and a cell surface bound co-receptor (Treanor 1996).  The ligands  are
members of the glial cell-line derived neurotrophic factor (GDNF) family.  GDNF-knockout
experiments in mice have shown that homozygous animals have aganglionic guts (Sanchez 1996),
similar to the phenotype seen in RET-null animals (Schuchardt 1994). Interestingly, a recent study by
Shen et al. (Shen 2002), has shown that an HSCR-like phenotype occurs with variable penetrance and
expressivity in 20% of heterozygous animals also.  In humans, several studies have screened for
mutations of GDNF but found very low frequencies. A number of the previous studies of GDNF
mutations have concentrated on selected cases, (Amiel 1998, Kerstjens-Frederikse 1999, Munnes 2000,
Inoue 2000, Borrego 1998, Shimotake 2001.) for instance that of Inoue, who screened only the most
severe cases of HSCR. These cases are neither representative of the HSCR population as a whole, nor
of the population incidence of sequence variants. While potentially giving useful information about the
details of function of the gene,  they are unable to tell us about the possibility of rare polymorphisms
contributing to disease phenotype.
Other broader, population based studies of GDNF (Martucciello 1998, Gath 2001, Hofstra
2000, Ivanchuk 1996, Salomon 1996, Angrist 1996, Sakai 2000) still have limited numbers for the
study of rare gene effects, where large numbers are needed to see significant differences in frequencies
of alleles between studied and control populations. These studies are summarised in Table 2.3 of
chapter 2, as well as GDNF mutation studies in related conditions. (Amiel 1998, Knowles 2000,
Svensson 1999, Woodward 1997, Marsh 1997)
It was therefore postulated that mutations in RET, in the RET ligand GDNF, and in the co-
receptor GFRα1 might also be found in HSCR patients, or that rare polymorphisms in these genes
might be distributed in a non-random way in HSCR. In order to test this hypothesis, we have screened
a large population-based panel of  HSCR patients for mutations in GDNF, most of GFRα1, and five
exons of RET.
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9.3.) Materials and Methods:
Data was obtained on all individuals presenting to a paediatric unit in New South Wales
during a 20 year period (1975-1995). Families were then contacted for follow up information, and
asked to contribute blood for DNA extraction. DNA from 113 unrelated patients from this 20 year
cohort forms the core of our sample set. Material was ascertained both prospectively on admission, and
retrospectively by contact with patients and families identified through a search of the medical records.
15% of the genetically studied patients suffered from TCA, in comparison with 6% of those with TCA
in the medical record. 22% had a positive family history, compared with 10% in the medical records.
23% suffered from mental retardation (Down syndrome in 13%), compared with 16% in the medical
record. The sex ratio of HSCR patients was similar in both those who gave blood, and those who did
not.
DNA was extracted from these specimens using standard protocols. (Sambrook, 1989) PCR
was carried out under the conditions specified in each section, and in Appendix 5, page 216.
DNA from the two coding exons of GDNF were amplified by polymerase chain reaction
(PCR) in three fragments. Primers used in PCR were: GDX1F/ GDNR5 for exon 1; GDNF6/GDNR3
and GDNF2/ GDNR4 for the two fragments of exon 2. A 55oC annealing temperature was used for
GDX1F and GDNR5, while a Touchdown program was used for GDNF6/GDNR3. Details of primer
sequence and PCR conditions are given in the appendix. Primers are those published by Ivanchuk et al
(Ivanchuk 1996)
Initial screening was performed using single stranded conformational polymorphism (SSCP)
analysis . PCRs for SSCP analyses were prepared in 10 µl reactions, as described in the appendix,
except that only 100 µM dNTPs was used and 0.5 µCi of [α-32P]dCTP was added.  Reactions were
denatured at 95oC for 5-10 min and electrophoresed.  A minimum of two conditions were: 6 W
overnight at 15oC on both 8% acrylamide gel and  6% acrylamide with 5% glycerol in 0.5 X TBE
buffer.  SSCP variants detected by this method were confirmed by direct sequencing in forward and
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reverse directions of gel purified PCR products. Sequence data for comparisons was obtained from
Genbank, (http://gdbwww.gdb.org/) Accession numbers L19062, and L19063 for GDNF.
9.4.) Results:
9.4.1) GDNF screening results.
PCR products corresponding to each of the GDNF exons were obtained from 113 unrelated
individuals. A clear band shift on SSCP was obtained in an exon 2 amplicon from one individual
which was then sequenced in forward and reverse directions (Fig. 9.1a and b.).  We identified  a C to
T transition in codon 93, leading to a non conservative change from arginine to tryptophan (“R93W”)
at this position.   We further investigated this variant in the proband’s affected son as well as an
unaffected half brother of the proband. (Fig 9.2a [page 185] shows the family.)  We found the R93W
variant in both the affected father and son, but not in the unaffected half brother. No other sequence
changes were confirmed in any of these individuals.
The proband had long segment aganglionosis with a transition zone in the transverse colon.
Interestingly, he is also monoplegic in the upper limb since birth, and is of limited educational
attainment, but has no clear syndromic abnormality. The son had a  more severely affected gut, with a
transition zone in the mid small bowel. He had no other associated features noted. The son also carried
a sequence variant in exon 3 of the RET co-receptor, GDNF family receptor alpha 1 (GFRα-1), a
protein involved in the interaction of GDNF and RET. This was a tyrosine to asparagine change at
codon 85 (Y85N) inherited from his healthy mother. (D Croaker, unpublished data.)
Fig. 9.1a Showing C/A heterozygosity in GDNF exon 2 of patient 469 (forward on left [position 97],
reverse on right). This pattern was seen in both 469 and 469.1, but in no other sequence data reviewed.
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Fig. 9.1b Showing SSCP band shift (at left) in patient 469.
+
469 469.2
+
469.1
469.3
Figure 9.2a Family 469. The proband (469) has a transverse colon transition zone. His son, 469.1, has
total colonic aganglionosis with a mid-small bowel transition zone. 469.1 inherits a GDNF sequence
variant (R93W) from his father, and a GFRα 1 exon 3 polymorphism (Y85N) from his unaffected
mother. 469.3 did not inherit the GDNF sequence variant, and is unaffected.
184
Fig 9.2b. Showing Y85N transmission in family 469, and in “SIP1” patients for comparison. The
Y85N polymorphism is present in those samples with an extra horizontal band. 469.1 has very long
segment disease, and 303 has the highest transition zone of the “SIP1” patients. 469.2 is unaffected.
Discussion:
GDNF was identified as the RET ligand in 1996 (Durbec 1996). It interacts with RET via a
membrane bound glycosyl-phosphatidylinositol linked protein known as GFRα-1 (Treanor 1996). As
such, GDNF represents an obvious candidate gene for HSCR, as mutations in RET itself have been
shown to be an important contributor to the pathogenesis of HSCR. If that were not enough however,
Gdnf -/- mice have been created which show, inter alia, an aganglionic phenotype.  (Sanchez 1996,
Moore 1996, Pichel 1996) Gdnf heterozygotes have a variable phenotype, with 20% having a
condition very similar to human HSCR (Shen 2002)
With this in mind, several investigators have published results of gene screening for mutations
in GDNF in HSCR, in Ondine’s curse, and in neural crest related tumours. (Table 2.3.) The surprising
thing about these series has been the low incidence of GDNF mutations found. Subsequently
         469.1  469   469.2   469.3   21        627     303
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Martucciello and others have shown a low expression of GDNF in aganglionic gut. (Martuciello 1998,
Zhan 1999, Ohshiro 1998) The current study was undertaken to contribute more data to the
understanding of a rare disease locus for HSCR.
The publication of this group of patients brings to 749 the number of patients screened for
GDNF mutations in HSCR. In these patients eleven probands (1.5%) have been described with seven
different sequence variants. Only one of these was a de novo mutation (Ivanchuk 1996) The published
sequence variants in GDNF occur throughout the protein. Only one published sequence variant occurs
in exon 1 (Ivanchuk, 1996), which encodes  the discarded part of the immature 211 amino acid protein.
One other mutation is 25 base pairs upstream of the start of translation. (Sakai 2000) The variant found
in our group occurs close to the boundary of the two coding exons, but does not obviously create or
destroy a splice site. It lies 16 amino acids from the site of final cleavage to form the mature 134 amino
acid peptide, but it is unclear whether this would disrupt protein cleavage.
At least four of the reported patients with GDNF sequence variants have long segment
disease, three have short segment disease, and the extent of disease is unknown in four. The HSCR
population as a whole however suffers from total colonic aganglionosis (TCA) in only 10%, and long
segment disease (including TCA) in 20%. There is therefore a bias to long segment disease in patients
with GDNF sequence variants. This is more common than expected  on the basis of chance, (p < 0.005
by chitest, assuming that long segment disease affects 20% of the overall studied sample, as in the
overall HSCR population.) It is unclear to what extent this result reflects ascertainment biases in the
screened populations. TCA is twice as common in those who were screened in our group, compared to
the population incidence (14% vs 8%). It is possible that such inherent biases were present in other
groups as well. The high incidence of long segment disease in GDNF sequence variant carriers
probably represents a mixture of ascertainment bias and physiological effect.
In addition to the higher incidence of long segment disease in our genetically studied group,
there was a higher incidence in the screened group, of children with associated conditions such as
Down syndrome. Salomon et al.(Salomon 1996) reported a child with a GDNF variant in exon 2, who
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also had Down syndrome. It is possible that the effects of these variants may be affected by other
genetic factors, so the composition of the studied groups is important. None of the Down syndrome
children studied showed evidence of sequence variants in GDNF. These ascertainment biases
presumably represent the greater contact that the more severely affected children have with the treating
institutions, and consequent greater ease of collecting material. There was however, an attempt to
obtain material from all patients within a geographical area served by the NSW paediatric surgical
units with this study.
Svensson et al. (Svensson 1998) (and personal communication) have also screened a
population based group for mutations in RET and GDNF. As in the present study, the frequency of
GDNF mutations was found to be low (no mutations in GDNF were found).
The R93W sequence variant, described above, has been described on at least five occasions
(including the present) in patients with abnormalities of presumed neural crest origin, 3 of them HSCR
(Salomon 1996, Angrist 1996) , one phaeochromocytoma (Woodward 1997), and one patient
with Ondine’s Curse (Amiel 1998). It was not found in 790 control chromosomes. Two of the five
cases of R93W occur in families with multiple cases of HSCR (Salomon 1996, current study).  In the
proband we describe, it is associated with a palsy of the upper limb, apparently present since birth. In
the case described by Angrist et al.(Angrist 1996), the HSCR was sporadic and short segment and was
associated with malrotation . In that case the sequence variant was inherited from the heterozygous and
unaffected father. This child also had a RET mutation. In the family reported by Salomon et al., R93W
occurred in multiple members of a multi-case HSCR family. The GDNF variant occurred in both
affected and unaffected family members.  The disease clearly segregated with a RET mutation in this
family, however the GDNF R93W variant was thought to correlate with more severe disease
phenotype in the presence of the RET mutation in that family. Angrist et al did not see this change in
98 control individuals (196 chromosomes) nor in 105 other patients (210 chromosomes), and it was not
seen in 180 control chromosomes by Salomon et al. In both these two R93W carrying families the
HSCR phenotype was associated with RET mutations.
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Table 2.3. (on page 27) summarises the available data on GDNF screening in HSCR and
related conditions. Overall, 946 individuals who have been screened for HSCR, Ondine’s curse, or
Multiple Endocrine  Neoplasia type 2-related tumours are included. In addition 395 controls (790
alleles) have been screened for GDNF mutations. As already noted by Salomon et al, there is a
significant difference between the incidence of GDNF sequence variants in HSCR and controls (p
<0.05). The R93W variant is responsible for nearly half the identified variants, and the difference in
incidence of R93W between affected and controls approaches significance at p ~ 0.12 by χ2 . In the
Ondine’s curse patient, R93W was inherited from an apparently healthy mother. It was also present in
both tumour and germline tissue in one patient with sporadic phaeochromocytoma.
R143R has been reported twice, once in association with a RET mutation, and D150N has
been reported twice, once in association with Down syndrome.
RET mutations are known to cause HSCR by a loss of function mechanism (Iwashita 1996),
although not all mutations are equally potent in this regard. The ideas of Passarge, Bodian and others of
complex inheritance are supported by several recent papers such as that of Bolk et al (Bolk 2000)
showing the effect of a second locus on the phenotype of RET mutations. A number of papers
(Puffenberger 1994, Griseri 2000, Sancandi 2000, Borrego 2000) demonstrate non-random differences
in polymorphic allele frequency between the HSCR and normal populations. Presumably, these
variants act to increase (or decrease) HSCR susceptibility, but are not sufficient on their own to cause
disease. GDNF variants are clear candidates to complement RET variants and mutations, contributing
to the complex inheritance observed. Studies, to date, offer some support for a role for GDNF in
HSCR, but the low frequency of sequence variants suggests that it is not a major factor in modifying
the phenotype of HSCR in most cases. R93W may be a rare susceptibility allele, present in the normal
population, but predisposing to HSCR by modifying the penetrance of mutations  in RET or other
genes. The R93W variant in HSCR in particular seems to be associated with long segment disease (at
least 6 of 8 affected individuals in three families reported) and multi-case families.
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While homozygous GDNF knockout mice have not only total intestinal aganglionosis (TIA),
but also lack kidneys, (Sanchez 1996, Moore 1996, Pichel 1996.) the described patients were mostly
long segment but not TIA, and none were reported as having recognised renal problems, much less
renal agenesis. The GDNF -/- mice described by Sanchez et al were born at a ratio slightly (not
significantly) less than the expected Mendelian ratio. Clearly GDNF is not absolutely required for
development to term in mice, however it is possible that significant loss of function in GDNF in
humans is embryonic lethal. This hypothesis is not easily testable, but might explain the apparent low
rate of GDNF mutations in human HSCR.
The GFRα-1 polymorphism in the second generation of our family is T253A in exon 3,
resulting in an amino acid change Y85N. It is inherited from a healthy mother. It is present at equal
frequency in 10 of 113 unrelated individuals in our patient population, and in previously published
control groups. (Angrist 1998, Myers 1999) Myers et al and Angrist et al have studied the role of
GFRα1 in HSCR, and concluded that it is of little importance in the pathogenesis of the condition, on
the basis that no mutations were found in over 350 patients in the combined series, and that there were
no obvious differences in polymorphism frequency between HSCR and controls in either series alone.
The association of Y85N here with a very long segment disease may be random, but as this is a non-
conservative amino acid change, in a residue conserved in human, rat, mouse, and chicken, (Angrist
1998) it may conceivably act as a modifier for disease phenotype in the presence of other alterations in
GDNF and/or RET. The importance of GFRα-1 polymorphisms for HSCR phenotype await further
study.
This paper highlights not only the rarity of mutations in GDNF in HSCR (less than 2%), but
also the limitations of single gene screening in polygenic disease. No single genetic test is ever likely
to be useful in screening HSCR families, but more subtle investigation of GDNF may reveal further
involvement of this gene.
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Pilot studies of GFRα1 and RET.
9.4.2 GFRα1 screening using SSCP.
Eight GFRα1 fragments were amplified from the total eleven exons of this gene, using
sequence and gene structure data as it became available in 1996 - 1997. These fragments cover most of
the coding sequence of the GFRα1 gene. Exon 1, over half of exon 2, and three quarters of exon 11 are
untranslated. These exons have not been screened. Exon 5 is a small exon, consisting of 15 base pairs,
and its existence was not appreciated by us or our collaborators at the time of this work. It also has not
been screened. Angrist et al (1998) give a definitive account of the genomic structure of GFRα1. Table
9.1 shows a summary of our work on this gene. Band shifts were found consistent with the published
polymorphisms in this gene, and at approximately the same frequencies. (Angrist 1998, Myers 1999.)
Primers Exon Results
22DC - 8 proximal exon 3 no definite shifts in 113 products
RAF7 - HRAR2 distal exon 3 9 shifts in 113 products.
RAF20 - RAR18 exon 4 no definite shifts in 106 products
RAF11 - RAR19 exon 6 2 frequent alleles (f~0.45 & 0.55)
RAF24 - RAR23 exon 8 no shifts in 115 products
GRA16R - IRF1 exon 9 4 shifts of 90 products
RAF10 - RAR13 exon 10 3 shifts of 116 products.
17 - 9DC proximal exon 11 1 shift, 3 possible of 114 products.
Table 9.1. Primers and SSCP results for  GFRα1 screening.
9.4.2.1 Discussion
9.4.2.1.1 Y85N
The polymorphism Y85N in exon 3 was noted at a frequency ~0.04 of studied chromosomes.
(9 unrelated heterozygous patients out of 113.) The sequence was confirmed in six, the other three
showed an identical migration pattern under several different conditions, and are assumed to be
identical. No restriction site is altered by this polymorphism to allow easy screening.
The presence of the Y85N in the very long segment patient described earlier in this chapter,
the presence of the same polymorphism in the longest segment case of the children with the SIP1
mutation phenotype, described in chapter 5, and my impression that long segment cases were over
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represented in the initial cases discovered while working at the Mulligan lab in November 1997 led me
to hypothesise that GFRα1 is a modifier of disease severity, if not a causal agent in itself. In particular,
Bolk (2000)  and others, and Angrist and others, (Angrist 1998) have shown no linkage of HSCR to
the GFRα1 locus at 10q25 in multi-case families.
Several tests were proposed to test this hypothesis:
1.) Is the incidence of the polymorphism the same as in control populations?
2.) Is the incidence of long segment disease the same as in the population with the common
allele?
3.) Is the allele transmitted with the disease in those multi-case families in which it occurs,
and is there any evidence that it modifies length in those families?
9.4.2.1.2 Is the incidence of the polymorphism the same as in control populations?
The incidence of this polymorphism in our sample is 9/113 (8.7%) unrelated probands, as
determined by SSCP migration pattern, and sequencing of the first six individuals. This compares with
2% in the series of Myers et al, and 4% in the controls screened by Myers et al. Although the
frequency difference between our patients and the Myers controls is just significant, when the
combined series are analysed, the incidence of the Y85N polymorphism is nearly identical in HSCR
and controls. The incidence of Y85N is 3.2% of patients, and 2.3% of controls in the series of Angrist.
(Angrist. 1998) Taking all three series together, there is no significant difference between the incidence
of Y85N in cases (475) and controls (305).
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9.4.2.1.3 Is the incidence of long segment disease the same as in the population with the common
allele?
Two out of nine unrelated probands carrying the allele have long segment disease. This is the
same as the incidence of long segment disease in the sampled population. The details of the carriers of
the polymorphism are given in Table 9.2.
It is of interest that all probands with the Y85N polymorphism in GFRα1 are male. Compared
to the 3.9:1 sex ratio in the overall samples population, this difference in sex ratio is not significant.
The last patient in the table, patient 630 is the 55 year old grandmother of patient 55. While she has
had very severe constipation all her life, she lives in a country area, and has been managed with a
series of sphincterotomies and other procedures. A biopsy has recently been taken, but the apparently
negative result should be treated with caution, in the absence of a report by an expert paediatric
surgeon and paediatric pathologist. She is not counted in the calculation, as she is neither a proband,
nor is the diagnosis certain.
ID Details Sex Length
285 Downs, sporadic m rectal
303 “SIP1” phenotype,
sporadic
m desc. colon
317 m unknown
51 Downs, sporadic m rectal
55 (multicase?) m recto-sig jn
589 multicase m 20cm ileum
59 sporadic m sigmoid
613 sporadic m recto-sig jn
469.1 multicase m mid small bowel
630*  (multicase*) f rectal
* Diagnosis not confirmed - see text above. Grandmother of 55.
Table 9.2 Details of carriers of Y85N polymorphism in GFRα1 exon 3.
9.4.2.1.4 Is the allele transmitted with the disease in those multi-case families in which it occurs, and is
there any evidence that it modifies length in those families?
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The GFRα1 exon 3 fragment was amplified in families known to carry it, and the results of this
genotyping are shown below. (Figure 9.3) Five initial patients were sequenced to confirm the identity
of the SSCP variant. Subsequent identically migrating samples were assumed to have an identical
sequence.xii
417.15
417.3417.6
417.8
+
417.13
+
417.12 417.11
+
417.10
417.7
417.4
417.2417.1 417.5
417
+
417.14+
589
Fig. 9.3 Showing non-linkage of Y85N with HSCR in family 417, and no clear evidence of a
length modifying effect. Patient 589 carrying Y85N has TCA, and patient 417 with a splenic
flexure transition does not carry Y85N but 417.5, with TCA, also does not carry Y85N. (Y85N
carriers marked with a “+”. Family genotyping gel shown at bottom left.)
Family 417 has been extensively studied previously by
our collaborators in Cleveland, Ohio. (Bolk,  Pelet et al.
2000) It is a large multicase family known to segregate
the disease with the RET locus, although no causative
mutation has been found in this family after screening all 21 exons of RET. There may be changes in
adjacent regulatory regions accounting for the failure to find changes in exonic sequence. This family
also segregates a locus on 9q31 which is thought to be important for phenotypic expression of HSCR
in families with weakly acting RET mutations. The Y85N GFRα1 exon 3 polymorphism is seen in a
number of members of this family. It does not segregate with the disease, arising from separate
ancestors in separate branches of the family. It is present in one but not both TCA patients, and is
absent in patient 417 who has a splenic flexure transition zone. If it is a modifying factor in this family,
it is not the only one. It seems to have no effect on  its own, being present in both constipated and
completely unaffected members of the family.
                                                          
xii A second polymorphism has been reported in this exon, and may account for some of the
unsequenced bandshifted patients, but, as all shifts appeared identical, this is not expected.
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Family 469 has been discussed at length above. In this father-son family Y85N is associated with very
long segment in the son, but is not carried by the father, who has a transverse colon transition. The
R93W GDNF variant carried by both these individuals has previously been reported in association
with RET mutations. (Ivanchuk, Salomon, Angrist)
9.4.2.1.5Exon 6 polymorphism.
This amplicon showed the presence of two common alleles very clearly under all SSCP
conditions. Alleles were counted directly from the SSCP gels. Allele “A” has a frequency of 0.56, and
allele “B” a frequency of 0.44 of 266 chromosomes examined. There was no correlation between the
presence of either allele and being affected or having either long or short segment disease. This
distribution of alleles was very similar to those reported by Myers et al and Angrist et al. They also
found no correlation between the presence of one or other allele and the presence of disease. Figure 9.4
shows a gel appearance from which alleles were counted.
Figure 9.4 Appearance of common alleles of exon 6 polymorphism on SSCP gel.
9.4.2.1.6Exon 9 polymorphism.
Five SSCP shifts were seen in 90 products. (f = 0.07) This is the same frequency as that
reported by Myers et al, and very similar to that reported by Angrist et al. for the T366A
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polymorphism.xiii  The polymorphism was confirmed on one directional sequencing in two individuals,
and was quite clear. Normal sequence was confirmed on two subjects without band shifts.
One individual with a shift on SSCP did not show the T366A variant, but appeared
heterozygous for a T to g change in intron 9, 11 bases 5’ from the beginning of exon 9. This does not
create an alternate splice site, and the importance of it is doubtful. It has not been confirmed by bi-
directional sequencing. It is of interest that it occurred in a member of a multicase family with FMTC,
Hirschsprung’s and a known RET exon 10 mutation (cys620arg).
In our series the same shift was seen in a mother and daughter from a multicase family, one
affected, and one unaffected presumed mutation carrier. This family was previously reported by Lipson
and Harvey. (Lipson and Harvey) Assuming that SSCP is a sensitive test for this polymorphism, and
taking the published data together with our own data on this exon, there is a difference approaching
significance between the frequency of the alleles in HSCR and in controls. The rare allele is under-
represented in HSCR. As at least one of the shifts does not represent the same sequence variant,
T366A is even more under-represented in HSCR. Table 10.2.2 shows observed and expected
frequencies along with a χ2 value, assuming all shifts are T366A.
HSCR Control Expected (control) χ2 value
ACT 840 537 549.3351
GCT 64 63 50.66489
0.070123
Table 9.4 Comparison of T366A alleles in HSCR and controls.
9.4.2.1.7 Exon 10/Intron 10. (Primers RAF10/RAR13)
Three shifts were seen in 116 products. The shifts themselves were dramatic, consistent with
heterozygosity for a small insertion or deletion. Angrist et al report just such a deletion at a similar
frequency just upstream from this fragment. One of the patients with this SSCP polymorphism is
known to be a compound heterozygote for mutations in Mullerian inhibitory substance (MIS), a second
has Down syndrome and HSCR, and the third is a member of a multicase family suffering from both
HSCR and FMTC, and known to carry the cys620arg mutation in RET. No clear sequence alteration
                                                          
xiii Reported as T361A in Myers et al counting for the alternative splice without the 15 base pair exon
5.
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was shown in these patients on bi-directional sequencing however. The significance of this SSCP
pattern remains unresolved, but perhaps is artefactual.
9.4.2.1.8 Proximal exon 11. (Primers RAF17/RAR9DC)
One definite shift, and three possible shifts were seen in this exon out of 114 PCR products.
These shifts were not characterised. Polymorphisms in exon 11 are not reported in either Angrist et al,
or Myers et al.
9.4.2.2 Conclusions:
Our preliminary survey of GFRα1 shows that, contrary to expectation, but in line with other reports,
mutations in this gene are rarely if ever important in HSCR, although mutations can not be ruled out in
all our cases. Polymorphisms however, are common and may contribute to HSCR susceptibility.
The Y85N. polymorphism in GFR α1 probably does not have a strong effect on the HSCR
phenotype, but can not yet be ruled out completely as a modifier for length of aganglionosis,
particularly in certain subgroups of the condition, such as SIP1, and RET mutation carriers. It is often,
but not always seen in combination with T366A. The skewed gender expression is interesting, but the
number of probands is not large enough to allow us to say with confidence that the polymorphism
protects females against HSCR.
N184N in exon 6 does not appear to be associated with either risk for HSCR, nor with greater
severity of aganglionosis. Data to hand suggests that T366A in exon 9 is less common in HSCR, at a
level approaching significance. Larger numbers and rigorous screening with an appropriate restriction
enzyme (Fnu4HI) may settle this question.
Some SSCP shifts remain uncharacterised due to problems obtaining sequence data.
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9.4.3 RET screening.
Although some have reported that up to 50% of cases of long segment and familial cases of
HSCR will have RET mutations, population based screening has given different results. Svensson et al
found only five mutations in a population based group of 69 patients, with seven from multicase
families. (Svensson) As our study was also population based, large numbers of mutations were not
expected. It was thought however that altered frequencies of RET polymorphisms might be found in
HSCR as compared with control groups.
The exons chosen were 10, 11 and 16, as they constitute three of the five exons associated
with MEN2, a disease that rarely co-segregates with HSCR. In particular exon 11 contains the site of
mutations most commonly involved in MEN2a, and exon 16 contains the site of a highly specific
mutation associated with MEN2b. Although this is a rare association, from a clinical viewpoint, it is a
highly important one. (Mulligan, 1994A Eng. 1996, Sijmons) In addition exon 11 contains a frequent
polymorphism that would serve as a control for the sensitivity of SSCP, and whose distribution is of
interest in itself. Exon 15 was screened as there have been a number of reports of mutations in this
exon, including several in children with total intestinal aganglionosis. (Shimotake 1997, Inoue. 2000)
It also harbours a common polymorphism. (Ceccherini. 1994) Exon 3 was studied as one of our
patients was already known to have an exon 3 mutation that might serve as a positive control for this
exon. Together these fragments include part of the cadherin like domain (exon 3), the cysteine rich
domain (exons 10 and 11), and the tyrosine kinase domain (exons 15 and 16).
Limited screening of RET was performed on a panel of at least 48 individuals, including
seven unaffected individuals, and DNA from two animal models as markers and positive controls.
Exons 3, 10, 11, 15, and 16 of RET were screened using primers given in the appendix, and
previously published. (Edery 1994, Mulligan 1993, Attie 1995, Hofstra 1994) SSCP was performed on
PCR products, and run on PAGE under at least two conditions. The sequence variants found are
summarised below, and discussed in more detail in succeeding paragraphs. Two separate homozygous
sequence variants were found in patient 627. This patient has been described in chapter 6.
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Primers Exon Results
RET3F - RET3R exon 3 No definite variants in 54 products.
RET10F - RET10R exon 10 No new variants in 78 products. (One known mutation.)
RET11F - RET11R exon 11 Eight definite shifts in 44 products. (G691S)
RET15F - RET15R exon 15 Seven shifts in 53 products. (S904S) + 1 mutation
RET16F - RET16R exon 16 Two shifts in 58 products. (Uncharacterised.)
Table 9.5. Primers and SSCP results for  RET screening.
9.4.3.1 Exon 3.
54 samples were amplified for this fragment, of these 46 were HSCR patients. There were two
positive controls from animal models of HSCR. (horse, and rat) to act as markers on the gel, and to
verify a minimum sensitivity of the technique. No definite band shifts were detected in any human
samples. One patient (Patient 74) showed a subtle difference in SSCP appearance and was sequenced
in both directions.  The Val 125 polymorphism reported by Ceccherini et al was ruled out. ACA to
AAA  (T106K) could not be excluded on sequencing in both directions, but is not clear.
Horse DNA amplified well, and showed a clear band shift. Rat DNA did not amplify using these
primers. DNA from a family known to have an exon 3 mutation and previously published also did not
amplify.
9.4.3.2 Exon 10.
78 samples were amplified. 71 of these were HSCR patients, and there were 7 controls.
Included was DNA from two members of a family having multiple cases of both HSCR and FMTC.
(Published as Family 023 in Marsh DJ et al 1994.) This family is known to carry a cys620arg mutation
in exon 10, associated with FMTC. Patient 625 is a member of this family suffering from HSCR and
FMTC. Using him as a positive control we were able to demonstrate a band shift in his sample on
SSCP, but no shifts in other samples. As cys620arg is not carried by all HSCR affecteds in this family,
we were hoping to pick up additional mutations in GDNF or GFRα1 in this family, but were unable to
do so.
9.4.3.3 Exon 11.
This is the site of a frequent polymorphism, previously reported (Ceccherini et al). The
frequency of the RET polymorphism in exon 11 was estimated from our panel. The polymorphism is a
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change from ggT to AgT causing glycine 691 to change to serine (G691S). Ceccherini et al gives the
frequency of the common allele as 0.79 (restriction site present) This polymorphism removes a
restriction site with the enzyme BanI (Promega Corporation).
Ban I recognises the sequence:
 5’..g^g(T/C)(A/g)CC...3’
3’...CC(A/g)(T/C)g^g...5’  (cutting at the “^”). The enzyme is used with the supplied
buffer containing 50mM TrisHCl (pH 8.2) and 5mM MgCl2.
PCR products were incubated with this enzyme and the appropriate buffer and the
polymorphism was confirmed in selected cases. The remaining SSCP variants were then counted and
compared by chi squared test with the numbers quoted by Ceccherini. One apparently homozygous
individual was also directly sequenced, directly verifying the SSCP and restriction digest data. (Fig.
9.5b SSCP gel appearance, Fig 9.5a Restriction enzyme digest. Fig 9.5b Sequence.)
Figure 9.5a Ban I digests of representative RET exon 11 G691S polymorphism samples. Homozygous
rare allele on left (cut site absent: -/-), heterozygote next right (W/-), homozygote common allele (cut
site present W/W), heterozygote (control) on right. (Samples in groups of three. Digested fragment on
left, fragment without enzyme in middle, without enzyme or reaction buffer, right.)
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Figure 9.5b Forward (on left), and reverse (on right) sequence of homozygous G691S in patient
627. Wild type sequence is 5’..TTCCGGTGCC>>3’. Picture on right is SSCP gel. Lane 1 (on
left): homozygous wild type, lane 2: Pt 627 (G691S/ G691S), lanes 3, 5, and 6: wild type, and lane
4, heterozygous.
Distinct from the findings of Ceccherini et al in control chromosomes, we have found the
SSCP pattern of the  Ban I negative polymorphism in 8 out of 74 (0.11) HSCR chromosomes amplified
for this fragment. Polymorphism identity was confirmed by a combination of sequencing or enzyme
digestion or both in 6 individuals. One individual was homozygous for this change. (Patient 627)
There is no evidence that the individuals carrying this variant are atypical of the overall screened
group. Two have long segment disease, (one total intestinal aganglionosis), two have a positive family
history, and two have had definite, and one “possible” enterocolitis. Six are boys, and one a girl.
Ceccherini et al found the Ban I negative polymorphism in 0.21 of 53 control individuals.
There is a significant difference by chi squared at p < 0.01. The under-representation of this
polymorphism in the HSCR population amplifies recent findings of polymorphisms in RET
contributing to susceptibility in HSCR. It raises the possibility that G691S is protective against HSCR.
Recent findings of altered frequencies of polymorphisms in exons  3, 11, 14 and 18 support this idea.
(Puffenberger 1994, Griseri P 2000, Sancandi M 2000, Borrego S. 2000) Of these, only A45A in exon
3, and the exon 18 polymorphism are over-represented, and may contribute to increased HSCR risk.
The mechanism by which these polymorphisms alter risk is unknown. It would be interesting to know
whether there are reciprocal distributions of polymorphism frequency in MEN2 patients.
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9.4.3.4 Exon 15. 
There are several reports of exon 15 mutations in patients with total intestinal aganglionosis
(TIA). As we have DNA from two patients with TIA, (Patients 693, and 812) exon 15 was screened.
Out of 54 samples amplified, eight showed a shifted pattern. This included seven shifts in 48 HSCR
patients. There was one shift in a normal control. One TIA patient showed a shift. (Patient 693.)
Sequence data was obtained on five of seven SSCP shifted fragments in the HSCR patients, and on the
non-shifted TIA patient (Patient 812). This confirmed the presence of the neutral polymorphism
(S904S) C to g at base pair 20,674. Patient 627 was homozygous for this polymorphism, and has been
previously discussed.
Ceccherini reports a frequency of this neutral serine 904 polymorphism of 0.21 of 96 control
alleles. This polymorphism had earlier been reported by Mulligan et al in 1993. The frequency of this
allele in our sample appears to be only 0.09. (S904S: 10; wild type:96) This difference approaches
significance at p = 0.11 by χ2 test.
Clear bi-directional sequencing was obtained for most of the exon 15 fragment for patient
812. The change A20,681T was seen, predicted to change lysine to glutamic acid five codons before
the end of exon 15 (K907E) in the tyrosine kinase domain of RET. (See Figure 9.6) This has been
reported once before, by Hofstra et al. (Hofstra 2000) The other exon 15 variant, S904S, was not seen
in patient 812.
Figure 9.6 Forward (on left) and reverse (on right)
sequence of exon 15 sequence variant, K907E, reported here for only the second time. Position 133 on
forward, position 36 on reverse. Heterozygous A to g change.
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Fig. 9.7 SSCP gel of RET exon 15, showing patient 627 on left of picture, with a shift
representing homozygous S904S.
Interestingly, in every case in which S904S occurred, it was accompanied by G691S in exon
11. In only one case was G691S present unaccompanied by S904S. This coincidence is noted by
Borrego (Borrego 2000A), who has also noted that this haplotype confers an odds ratio of 0.52 for
HSCR risk. The one patient where these polymorphisms do not occur together may have undergone a
recombination event to separate them.
9.4.3.5 Exon 16
58 separate individuals were screened using SSCP under at least two conditions. 47 of these
were HSCR patients. Two were patients with phaeochromocytoma (one multiple), and the remainder
were controls and unaffected relatives. Two distinct and separate  SSCP shifts were seen in exon 16,
each was present under two conditions. Patient 27 is a short segment patient from a multicase family.
Patient 803 is a sporadic case, with very short segment disease, involving only the rectum below the
peritoneal reflection.
Bi-directional sequencing was carried out on these patients, but no unequivocal sequence
variant could be detected. Sequence data for the ends of the fragment was low quality however, and a
sequence change in those positions is not excluded. No common polymorphisms are reported in exon
16 to guide the search for the variant in this fragment. In particular there was clearly no change in
codon 918 associated with MEN2b. (Hofstra 1994, Eng 1996)
A summary of all sequence variants discovered is given in the table in Appendix 6, (page 227).
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9.5 Conclusions.
1.) No conclusions about mutation frequency are drawn from this limited study of RET. The lack of
band shifts that are not attributable to recognisable polymorphisms however support the observation of
Svensson et al that the rate of RET mutations in unselected populations is not high.
2.) The exon 15 mutation (K907E) seen in patient 812 has been reported only once previously in a
short segment patient as a “presumably causal” mutation (Hofstra 2000). It may in fact be a rare
polymorphism that acts as a susceptibility allele. The finding is however consistent with the tendency
of the tyrosine kinase domains of RET to harbour slightly more sequence variants than the rest of the
gene in HSCR patients.
3.) Polymorphisms in RET, such as that in exon 11, and possibly both those in exon 15, are not
randomly distributed, and the mechanism(s) by which these polymorphisms affect HSCR risk deserves
further study. In particular, the two polymorphisms in RET exon 11 and RET exon 15 are strongly
associated in our sample, and this haplotype is under-represented in our HSCR patients compared to
published control series.
4.) K907E in patient 812 would have been missed on SSCP evidence alone. SSCP may not detect all
sequence variants in RET or GDNF. This may partly explain the low rate of mutation detection in both
GDNF and RET in our hands, and in published series. On the other hand, polymorphisms that were
detected, tended to be seen consistently over a number of SSCP conditions.
5.) Mutations in GFRα1 and GDNF are rare, while there is evidence that polymorphisms in both these
genes (R93W in GDNF, T366A in GFRα1, and possibly Y85N in GFRα1) contribute to HSCR
susceptibility.
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Chapter 10. Discussion and Follow on studies.
10.1 Discussion.
10.2 Follow on studies.
10.2.1 Laboratory and late follow up autonomic studies.
10.2.2 Further molecular genetic studies.
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10.1 Discussion
The incidence and other demographic features of HSCR in NSW during the study period were
found to be consistent with previous studies. The multitude of associated conditions, and the frequent
family history of HSCR support the concept of HSCR as a polygenic condition. A number of patients
from this group were genetically studied as described in chapters 6 and 9, and several subgroups were
clinically assessed in more detail as described in chapters 4, 5, 6 and 7.
The observed sex ratio at the very longest segment aganglionosis is consistent with the
hypothesis that these cases are mainly if not entirely due to mutations in RET with a penetrance equal
to that given by Puffenburger and Attié. (50% in women, 70% in men) In fact Attié notes an increasing
male predominance with increasing length in multicase families with known RET mutations. Our own
observation of one mutation (or very rare polymorphism) in one of two TIA patients studied supports
the idea that tyrosine kinase domain mutations are slightly more common in these patients. Taken
together these data support the idea that short segment HSCR is rarely due to RET gene effects, while
long segment disease is commonly due to RET mutations, and that female sex acts to reduce the
phenotypic severity of these mutations. Some other gene(s) which is much more strongly sex modified
must be responsible for the majority of short segment cases.
Our  observation of the decreased frequency of the G691S/ S904S haplotype in HSCR
supports the idea that even where RET is not mutated, specific haplotypes in this gene contribute to
susceptibility (or resistance) to HSCR in a weak way, consistent with the polygenic model of the
disease.
Our observation of R93W in GDNF adds weight to the idea that this polymorphism is
similarly a susceptibility allele of weak effect in GDNF. In retrospect, the low incidence of GDNF
mutations is not surprising given the incidence of renal abnormalities in both homo and heterozygous
knockout mice, and considering that these findings are rare in humans. While there seems to be a
tendency to long segment aganglionosis and male sex in affected  carriers of this polymorphism,
numbers are not yet great enough to be confident about sex modifying effects on GDNF.
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Similarly we have observed a polymorphism in exon 9 of GFRα1 (T366A) which is under-
represented in HSCR compared to published controls. Screening of larger numbers of individuals for
variants in this gene is needed to obtain statistical power.
Our observation of a group of microcephalic, mentally retarded HSCR children, and
subsequent definition of an interval for a possible HSCR gene locus on chromosome 2 has contributed
to the identification of the SIP1(or SMADIP1) gene, now known to be mutated in some cases of
HSCR. Our own observation of a more even sex ratio in these cases suggests that this gene does not
explain the majority of short segment cases, and the lack of previously reported linkage to this locus
supports the idea that it is not commonly involved. SMADIP1 mutations are likely to be only rarely
responsible for HSCR, while we do not know what contribution SMADIP1 polymorphisms may make.
The observed sex ratios suggest their effect will be small.
Our observations of abnormalities in both gastric electrical rhythms, and in heart rate
variability and rates of oxygen desaturation during sleep strongly support the idea of HSCR as a
diffuse autonomic neuropathy. While RET mutations may theoretically contribute to CO2 insensitivity,
the rarity of RET mutations in OC suggests that there are other undiscovered genes which contribute to
OC, and probably also to HSCR. In particular, the equal sex ratio found in OC/HSCR is not that seen
in long segment HSCR with RET mutations. Several possible candidate genes for autonomic
dysfunction are discussed in chapter 8.
The observation of an increased time spent desaturated in HSCR patients in particular
suggests that HSCR patients are going to be at high risk of diseases related to chronic ischaemia as
they progress through middle age. We ought also to be aware that they may be at risk of Parkinson’s
disease, and that prior to the current era, large numbers of long segment HSCR patients did not survive
to old age. Very long term follow up of these patients will certainly be rewarding if it can be achieved.
A report of a multicase family with central hypoventilation, Parkinsonism, and apathy show that the
connection between neurocristopathy and Parkinsonism is more than theoretical. (Perry 1990)
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Why some patients and not others suffer from gastric dysrhythmias is unknown. The
observation of Cass that there is abnormal three dimensional architecture of the gut of the lethal
spotting rat even in the normally ganglionated bowel may offer a clue: Perhaps the architecture is
related to the rhythm, and perhaps mutations in only some genes cause the alteration in architecture?
The observation of HAEC associated with our small number of tachygastric patients suggests that
EGG may become a useful part of the early clinical assessment of HSCR patients, but so far no one has
found a link between particular mutations and risk of HAEC.
The clinical features of DS/HSCR were described. These children clearly have an increased
susceptibility (50 times) to HSCR, presumably from a susceptibility locus on chromosome 21. Several
candidate genes are described in chapter 4. These children have a higher frequency of duodenal atresia
than either other HSCR or other DS children, and vastly more than the general population. The sex
distribution of cardiac disease is also skewed beyond what would be expected in the HSCR population.
It is suggested that these are pleomorphic effects of a chromosome 21 HSCR susceptibility locus. Such
a locus is likely to be important not only in DS children, but also in the general HSCR population, and
identifying it may contribute to our understanding of the pathogenesis of HSCR.
In addition, DS/HSCR suffer a high rate of HAEC. This may relate to the known
abnormalities of immunity in DS children, and is of great practical importance in the management of
these children.
The long term outcome of DS/HSCR children has been a matter for discussion for many years.
(Caniano 1990, Quinn 1994) In chapter 5 we demonstrate a number of features which can be used  in a
practical way to predict outcome in DS/HSCR children.
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10.2 Follow up studies.
10.2.1.1 Autonomic and neurological studies.
 The diversity of expression sites of GDNF, RET, and the GFRα family receptors, together
with OC/HSCR demographic information presented in chapter 7 suggested that HSCR patients would
likely express a diversity of neurological phenotypic abnormalities in addition to those already
recognised. To pursue this hypothesis the work presented in chapter 8 was undertaken. A recent
intriguing report of very long term follow up of individuals, linking constipation in early life to later
development of Parkinson’s disease suggests that this investigation is likely to continue to be fruitful.
(Abbott 2001)
The work regarding pulse variability described in chapter 8 is currently being confirmed and
expanded as part of a PhD project in the engineering department of the University of Nottingham.
(Echeverria et al, submitted to Physical Review E., February 2002.) With my colleagues in the
department of electrical and electronic engineering at Nottingham University we have collected ECG
data as well as pulse oximetry data. From the small number of cases studied so far we can see the
abnormalities in both long and short term heart rate control emerging clearly. Future work will aim to
build on this experience, and to attempt to correlate functional disturbances with outcome and HSCR
phenotype, as we have been doing with EGG studies. In all probability there are other sensory and
cranial nerve abnormalities to be found in HSCR. Some have already been described. (Cheng 2001,
Staiano 1999) A challenge for the future is to see if we can devise ways of using non invasive means to
select those chronically constipated children who will need a rectal biopsy. Knowles et al have already
reported neurological abnormalities in some constipated children. (Knowles 1999) Selecting these
autonomically abnormal children from the simple constipants, and both from those with HSCR, is a
task still in front of us.
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Finally, we may be able to then return to the molecular genetics, and assess the frequency of
particular polymorphisms in RET and associated genes, and attempt to correlate these with the
presence or absence of an autonomic neuropathy phenotype.
10.2.1.2 Late effects.
Very long term follow up of HSCR patients as they approach middle age is important as these
patients are likely to be at increased risk of neurodegenerative conditions, such as Parkinson’s disease,
and indirectly from the long term effects of low grade autonomic abnormalities.
10.2.2 Molecular genetic studies.
10.2.2.1 Neurturin
Neurturin is a small soluble protein related to GDNF, and also known to bind to RET. As such
it is also a candidate gene for HSCR. Preliminary work has started on screening exon 1 of this gene.
Two SSCP variants have been identified in 48 samples. Sequencing has not yet been performed. The
intron has been amplified with a view to sequencing and designing primers to complete screening of
exon 2. The paucity of published mutations in this gene suggests that mutation frequency will be low.
(Doray 1998)
10.2.2.2 Contribution of GFRα1
Further genotyping of GFRα1 may settle the importance of T366A as a susceptibility allele.
Currently we know from the work in this thesis that this allele is under-represented in HSCR at a
frequency approaching significance.
10.2.2.3 Chromosome 21.
 Investigation of candidate genes on chromosome 21 is likely to show non-random association
of specific haplotypes with HSCR. Prime candidates for investigation are S100b protein, and possibly
DSCAM, both of which are in the DS critical region, and are not excluded as candidates. Of the two
genes, S100b shows a more intuitively obvious mechanism of action in causing HSCR when expressed
in excess, and the author recommends this as a first target of investigation.
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It is also possible that changes in membrane lipids in SLOS and DS may contribute to the
aganglionic phenotype, by affecting RET signalling. This hypothesis is testable in principle by looking
at the tissue lipid composition of DS patients with and without HSCR. Altered frequencies of
transmembrane domain polymorphisms (for instance in RET) in DS/HSCR compared to other DS may
also support this idea.
10.2.2.4  Other candidate genes.
The IKBKAP gene at 9q31, now known to be associated with Riley-Day familial
dysautonomia (OMIM #223900) is a prime candidate for investigation, both because work with which
we were associated has established 9q31 as a HSCR modifying locus, and because a mutation in this
gene has a phenotype of autonomic neuropathy.
MASH-1 and rnx are both genes that show an autonomic derangement phenotype when
mutated in the rodent. While they are unlikely to be responsible for human HSCR in their own right, it
is possible that polymorphisms in these genes may contribute to the HSCR phenotype in those with
mutations in other genes of major effect (for instance RET.)
10.2.2.5 New techniques.
Finally, it is of interest that in spite of the large number of known HSCR genes, and the great
effort devoted to searching for HSCR causing mutations in these genes over the last ten years, there
still remains at least 50% of HSCR cases where no mutation is known. Some families, for instance our
own family 417, are known to have a linkage to RET, but have not had a mutation demonstrated. A
recent advance is the technique of MAPH, (Armour, 2000) which has been used in other inherited
disease to show medium sized intragenic deletions which affect whole exons. These are not always
detected by the methods of SSCP, DGGE, and sequence mismatch cleavage which have been the
mainstay of molecular genetic laboratories. It is possible that a further large group of HSCR patients
will have mutations of this sort in the already described genes.
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Appendices.
Appendix 1.) Statistics.
Calculations of statistical significance in simple proportions were made using the chi squared
test, run on Microsoft Excel. The input data were “Group 1” and “Group 2” (for observed), and
“Expected”, for the result expected in group 2 if there was no difference between the groups.
“Expected” was calculated according to the formula shown. The program delivers a p value directly
from Group2, and Expected.
Group 1 Group 2 Expected
A a b (a+b)(b+d)/(a+b+c+d)
B c d (c+d)(b+d)/(a+b+c+d)
Table Appendix 1.
Calculations of significance in comparing groups of continuous variables were made using
Student’s “t” test where it was expected that the values were normally distributed. Again, the physical
calculations were performed using Microsoft Excel software.
Some calculations of differences between small groups of continuous variables were made by
calculating the number of standard errors of the mean (SEM) between the means of the two groups. If
the two means were more than two SEM’s apart, it was considered that p < 0.05
Calculations of the percentile height or weight of children were performed using an Excel
macro (“SDS”) with standard height and weight data derived from a contemporary English survey.
“The British 1990 growth reference.” Revised September 1996. This disc, provided originally by the
Child Growth Foundation, was passed on to me by Dr Richard Hubbard of Nottingham City Hospital.
It contains files that summarise the British 1990 growth reference for height, weight, body mass index
(BMI, weight/height
2
) and head circumference, from infancy to adulthood. Using the files it is possible
to adjust measurements for age and sex, and to convert them to a standard deviation score (SDS or Z
score). The reverse process, from SDS to measurement, is also provided.
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Appendix 2.) Down syndrome demographic data.
DS
Reference
Group
Number All DS Number Non-DS
(Reference
Group.)
Number
Number 100% 40 100% 90 100% 340
      Male 82.5% 33 75.6% 68 80.6% 274
      Female 17.5% 7 24.4% 22 19.4% 66
Birth weight kg (Both
sexes)
3.14 39 3.049 76 3.400 293
      Male BW 3.19 32 3.112 57 3.47 235
      Female BW 2.94 7 2.856 19 3.20 58
Gestation (complete
weeks) (Both sexes)
38.11 40 38.1 78 39.3 301
      Male 38.0 33 38.1 60 39.4 242
      Female 38.6 7 38.3 18 39.1 59
Maternal age. (years) 31.29 38 30.94 70 27.28 234
Paternal age. (years) 35.33 30 34.29 56 30.17 206
Birth order. (Average)
(Range)
2.16 (1- 7) 37 2.44(1 - 7) 71 2.12 (1 - 8) 155
CHD 67.5% 27/40 48% 43/90 5% 17/340
DA/stenosis 10% 4/40 10% 9/90 0.6% 2/340
Fam. Hist. HSCR 0% 0 4.4% 4/90 13.2% 45/340
Percentage diagnosed
by 1 week.
50% 20/40 48.8%* 41/84** 52.7% 118/224
 Table appendix 2. Showing similarity between reference DS/HSCR group, and total DS/HSCR
group, as well as selected comparisons between DS and non-DS/HSCR patients. The population based
reference group  contains more CHD than the overall group. This may reflect more complete
ascertainment for children with this condition, alive and dead, in the population based group. The male
preponderance of this group would also explain the slight difference in sex ratios between the
reference and broader groups. IN other respects the groups are nearly identical.
*For comparison: 13/84 were diagnosed at more than 3 months of age.
** Information available for 84 of 90
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Appendix 3.) Distribution of length of aganglionosis: Percentages on which Figure 7.2 is
based.
Length CCHS/HSCR Down Syndrome/HSCR All HSCR (No CCHS,
No Down Syndrome.)
Rectal 7.5% 7.5 % 10.9 %
Sigmoid 17.5% 70.0 % 65.2 %
Left colon 5% 12.5 % 12.2 %
Rest of colon 10% 2.5 % 3.6 %
TCA (+ ileal) 47.5% 5.0 % 6.5%
Mid small bowel 5% 0% 1.5%
Prox small bowel 7.5% 0% 0%
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Appendix 4.) Chromosome 2 microsatellite marker details.
Marker Heterozygosity Primer 1 Primer 2 Size range Location
D2S2215 87 ac ctg gga ctc aga aaa gtt tg ctg tgc cta aaa gta tgc 139 - 161 2q21
D2S112 71 ga gtg gcg gtg aga agg
tat
ag cca ttg cta tct ttg agg 136 - 150
D2S114 84 tg ttt atg gtc tct cgt ccc ct tgg gtt cca act cag aag 214 - 236
D2S127 86 tt ctg atg taa tcg act tgc c cac cca aac caa cag ata 283 - 303
D2S122 88 ca gat taa ctt tct gcc aga
gag
ga gtg ccc tag atg gaa ggt 92 - 111
D2S151 80 aa cta aga cac aca acc
ccg
cc aat tca gtg gca tct atg 211 - 229
D2S2301 73 a acc cta tgt acc atg aga
gtg
at gaa atc agt gtt gcc ttg 108 - 135
D2S356 47 ct gga cca ggg act gac gg ctt atg cta agg gta gtg 184 - 190 2q22
D2S2241 77 c aca tac aca tgc aca cac cac ttt tgg ttg act taa aga 76 - 92
D2S2299 79 cc acg ttg ctg caa atg a tga aga tgc ctg ctt ccc 272 - 294
D2S2370 77 atgaaagatccctgacaaga tg agg ttg tgt ctc agt gtc 87 - 101
D2S333 76 a agc aca gta gtt cat tca
gta ttg
t tga ttt aac cat ttn acg atg 184 - 202 2q24.3
D2S326 85 a tcc tcc tgt ggc aag gg aga gcg att ttc ctg 156 - 174
214
Appendix 5.) Laboratory methods.
5.1 DNA extraction and storage
DNA was extracted from these specimens using standard protocols as described in Sambrook.i Later
specimens had DNA extracted from either blood or tissue using the Qiagen system according to
published instructions. DNA was stored in either alkaline TE buffer, or simply alkaline tris 0.1mM at -
20oC. (I switched to alkaline tris from TE after concerns that the EDTA in TE buffer may occasionally
interfere with PCR.)
:
5.2) PCR.
PCR’s for SSCP analyses were carried out using a sense and antisense primer pair in 10 mM Tris-HCl
pH 8.3, 50 mM KCl, 0.75 or 1.5 mM MgCl2 (depending on primers), 0.01% gelatin, 1 µM of each
primer, 100 µM each of dNTPs and 0.5 - 1.0 U Taq DNA Polymerase (Fisher Biotech) in 12 µl
reactions, and adding 0.5 µCi of [α-32P]dCTP.  Reactions were denatured at 95oC for 4 min and loaded
immediately from ice onto the electrophoresis gel. For most fragments a “Touchdown” type PCR
program was used incorporating 5 annealing cycles at 65oC, reducing to 50oC annealing over 15 cycles
with 15 cycles annealing at 50o C: 35 cycles in total. 40 seconds per step. This type of program has the
advantage that it gives a pure product with strong amplification for most fragments.
Typical Touchdown PCR program:
950 denaturing for 4 minutes.
950 (40 seconds)/650 (40 seconds)/720 (40 seconds), x 5 - 10 cycles
950 (40 seconds)/650 - 10/cycle (40 seconds)/720 (40 seconds), x 15 cycles
950 (40 seconds)/500 (40 seconds)/720 (40 seconds), x 15 cycles
720 for 7 minutes.
40 until required.
For some fragments (including GDNF) a straightforward program of: 4 minutes denaturing at 95o C,
followed by: 40 cycles of 1 min at 95o C, 1 min at 55 o C and 1 min at 72 o C, followed by a final
extension at 72_C for 10 min, was used, either where this had already been shown to be satisfactory, or
where touchdown did not give good results.
SSCP variants detected by this method were confirmed by direct sequencing in forward and reverse
directions of gel purified PCR products. Except for the GFRα1 exon 3 sequences which I performed
using the di-deoxy terminator method, all sequencing was performed commercially using a dye
terminator system, and printed out to give both a graphical and written sequence result.
5.3) SSCP.
Samples were run on polyacrylamide gel electrophoresis (PAGE) with a composition 37.5:1
acrylamide :bis-acrylamide, using upright apparatus. Two conditions were employed as a minimum.
These conditions are shown below. Some samples were better resolved at other conditions, and 10%
acrylamide, 2.5% glycerol, and 6% acrylamide, 5% glycerol were also used for some fragments. For
the GDNF fragments studied in Kingston, Ontario, shorter runs at higher power and 4oC were also
tried.
0.5 x TBE buffer
8% acrylamide, no glycerol, and 6% acrylamide, 2.5% glycerol. Polymerisation with 
1/100 10% ammonium persulphate and 1/1000 TEMED.
Room temperature.
1 - 3 Watts. (Up to about 450V.)
                                                          
i Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A laboratory manual, second edn.
Cold Spring Harbor, Cold Spring Harbor, New York
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5.4) Reference gene sequences and primers.
4.4.1) GDNF
Sequence data for comparisons was obtained from Genbank, (http://gdbwww.gdb.org/) accession
numbers L19062, and L19063.
/translation="MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMP
EDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGRRGQRGKN
RGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQAC
CRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI"
Polymorphism R93W in red.
Genbank No L19062 (Exon 1) Primers in bold italics. Primer names are in superscript.
1 atgaagttat gggatgtcgt g(GDX1F) gctgtctgc ctggtgctgc tccacaccgc gtccgccttc
61 ccgctgcccg ccggtaagag gcctcccgag gcgcccgccg aagaccgctc cctcggccgc
121 cgccgcgcgc ccttcgcgct gagcagtgac t(GDNR5)
Genbank No L19063 (Exon 2) Primers in bold italics.
1 caaatatgcc agaggattat cctgat(GDNF6) cagt tcgatgatgt catggatttt attcaagcca
61 ccattaaaag actgaaaagg tcaccagata aacaaatggc agtgcttcct agaagagagc
121 ggaatcggca ggctgcagct gccaacccag agaattccag aggaaaaggt cggagaggcc
181 agaggggc (GDNF2) aa aaaccggggt tgtgtcttaa ctgcaataca tttaaatgtc actgacttgg
241 gtctgggcta tgaaaccaag gaggaactga tttttaggta ctgcagcggc tcttgcgatg(GDNR3)
301 cagctgagac aacgtacgac aaaatattga aaaacttatc cagaaataga aggctggtga
361 gtgacaaagt agggcaggca tgttgcagac ccatcgcctt tgatgatgac ctgtcgtttt
421 tagatgataa cctggtttac catattctaa gaaagcattc cgctaaaagg tgtggatgta
481 tctg(GDNR4) a
4.4.1.1 GDNF primers and PCR conditions.
Exon 1: GDX1F: GAA GTT ATG GGA TGT CGT G
GDNR5: AGT CAC TGC TCA GCG CGA
PCR conditions: 40 cycles at 95/55/72 for 1 minute. [Mg2+] 0.75mM
PCR product is 149 bp long.
Exon 2: GDNF6:GCC AGA GGA TTA TCC TGA T
GDNR3: CAT CGC AAG AGC CGC TGC AG
PCR conditions: A “Touchdown” type program incorporating 5 annealing cycles at 65o, reducing to
50o annealing over 15 cycles with 15 cycles annealing at 50o : 35 cycles in total, at [Mg2+]=0.75mM.
PCR product is 292 bp long.
Exon 2b: GDNF2: TCG GAG  AGG CCA GAG GGG C
 GDNR4: CAG ATA CAT CCA CAC CTT TTA GCG
PCR conditions: 40 cycles at 95/55/72 for 1 minute. [Mg2+] 0.75mM
PCR product is 314 bp long
216
5.4.2 GFRα1
Sequence data for comparisons was obtained from Genbank, (http://gdbwww.gdb.org/) accession
number NM_005264.
Protein translation="MFLATLYFALPLLDLLLSAEVSGGDRLDCVKASDQCLKEQSCST
KYRTLRQCVAGKETNFSLASGLEAKDECRSAMEALKQKSLYNCRCKRGMKKEKNCLRI
YWSMYQSLQGNDLLEDSPYEPVNSRLSDIFRVVPFISDVFQQVEHIPKGNNCLDAAKA
CNLDDICKKYRSAYITPCTTSVSNDVCNRRKCHKALRQFFDKVPAKHSYGMLFCSCRD
IACTERRRQTIVPVCSYEEREKPNCLNLQDSCKTNYICRSRLADFFTNCQPESRSVSS
CLKENYADCLLAYSGLIGTVMTPNYIDSSSLSVAPWCDCSNSGNDLEECLKFLNFFKD
NTCLKNAIQAFGNGSDVTVWQPAFPVQTTTATTTTALRVKNKPLGPAGSENEIPTHVL
PPCANLQAQKLKSNVSGNTHLCISNGNYEKEGLGASSHITTKSMAAPPSCGLSPLLVL
VVTALSTLLSLTETS"
Complementary DNA Sequence (CDS):
        1 gaattccggc cagaagaaat ctggcctcgg aacacgccat tctccgcgcc gcttccaata
       61 accactaaca tccctaacga gcatccgagc cgagggctct gctcggaaat cgtcctggcc
      121 caactcggcc cttcgagctc tcgaagatta ccgcatctat tttttttttc ttttttttct
      181 tttcctagcg cagataaagt gagcccggaa agggaaggag ggggcgggga caccattgcc
      241 ctgaaagaat aaataagtaa ataaacaaac tggctcctcg ccgcagctgg acgcggtcgg
      301 ttgagtccag gttgggtcgg acctgaaccc ctaaaagcgg aaccgcctcc cgccctcgcc
      361 atcccggagc tgagtcgccg gcggcggtgg ctgctgccag acccggagtt tcctctttca
      421 ctggatggag ctgaactttg ggcggccaga gcagcacagc tgtccgggga tcgctgcacg
      481 ctgagctccc tcggcaagac ccagcggcgg ctcgggattt ttttgggggg gcggggacca
      541 gccccgcgcc ggcaccatgt tcctggcgac cctgtacttc gcgctgccgc tcttggactt
      601 gctcctgtcg gccgaagtga gcggcggaga ccgcctggat tgcgtgaaag ccagtgatca
      661 gtgcctgaag gagcagagct gcagcaccaa gtaccgcacg ctaaggcagt gcgtggcggg
      721 caaggagacc aacttcagcc tggcatccgg cctggaggcc aaggatgagt gccgcagcgc
      781 catggaggcc ctgaagcaga agtcgctcta caactgccgc tgcaagcggg gtatgaagaa
      841 ggagaagaac tgcctgcgca tttactggag catgtaccag agcctgcagg gaaatgatct
      901 gctggaggat tccccatatg aaccagttaa cagcagattg tcagatatat tccgggtggt
      961 cccattcata tcagatgttt ttcagcaagt ggagcacatt cccaaaggga acaactgcct
     1021 ggatgcagcg aaggcctgca acctcgacga catttgcaag aagtacaggt cggcgtacat
     1081 caccccgtgc accaccagcg tgtccaacga tgtctgcaac cgccgcaagt gccacaaggc
     1141 cctccggcag ttctttgaca aggtcccggc caagcacagc tacggaatgc tcttctgctc
     1201 ctgccgggac atcgcctgca cagagcggag gcgacagacc atcgtgcctg tgtgctccta
     1261 tgaagagagg gagaagccca actgtttgaa tttgcaggac tcctgcaaga cgaattacat
     1321 ctgcagatct cgccttgcgg atttttttac caactgccag ccagagtcaa ggtctgtcag
     1381 cagctgtcta aaggaaaact acgctgactg cctcctcgcc tactcggggc ttattggcac
     1441 agtcatgacc cccaactaca tagactccag tagcctcagt gtggccccat ggtgtgactg
     1501 cagcaacagt gggaacgacc tagaagagtg cttgaaattt ttgaatttct tcaaggacaa
     1561 tacatgtctt aaaaatgcaa ttcaagcctt tggcaatggc tccgatgtga ccgtgtggca
     1621 gccagccttc ccagtacaga ccaccactgc cactaccacc actgccctcc gggttaagaa
     1681 caagcccctg gggccagcag ggtctgagaa tgaaattccc actcatgttt tgccaccgtg
     1741 tgcaaattta caggcacaga agctgaaatc caatgtgtcg ggcaatacac acctctgtat
     1801 ttccaatggt aattatgaaa aagaaggtct cggtgcttcc agccacataa ccacaaaatc
     1861 aatggctgct cctccaagct gtggtctgag cccactgctg gtcctggtgg taaccgctct
     1921 gtccacccta ttatctttaa cagaaacatc atagctgcat taaaaaaata caatatggac
     1981 atgtaaaaag acaaaaacca agttatctgt ttcctgttct cttgtatagc tgaaattcca
     2041 gtttaggagc tcagttgaga aacagttcca ttcaactgga acattttttt ttttcctttt
     2101 aagaaagctt cttgtgatcc ttcggggctt ctgtgaaaaa cctgatgcag tgctccatcc
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     2161 aaactcagaa ggctttggga tatgctgtat tttaaaggga cagtttgtaa cttgggctgt
     2221 aaagcaaact ggggctgtgt tttcgatgat gatgatcatc atgatcatga tgattttaac
     2281 agttttactt ctggcctttc ctagctagag aaggagttaa tatttctaag gtaactccca
     2341 tatctccttt aatgacattg atttctaatg atataaattt cagcctacat tgatgccaag
     2401 cttttttgcc acaaagaaga ttcttaccaa gagtgggctt tgtggaaaca gctggtactg
     2461 atgttcacct ttatatatgt actagcattt tccacgctga tgtttatgta ctgtaaacag
     2521 ttctgcactc ttgtacaaaa gaaaaaacca cccggaattc
GFRα1 Sequence data, as available from the laboratory of Lois Mulligan, Queen’s University,
Kingston, Ontario, 1996 -97, and used for the design of primers in this thesis. (The sequence includes
some intronic sequence. The existence of the untranslated exon 1, and the 15 base pair exon 5 were not
appreciated by us or our collaborators at this time.) Gene structure after Angrist et al (1998), and
Myers et al (1999). Intronic sequence courtesy of LM Mulligan.
Primers underlined and labelled in sequence. Primers with the suffix “DC” were designed in Sydney.
Published polymorphisms in red. Details in footnotes. (Angrist et al 1998. Myers et al. 1999.)
Exon 2
GCGGCCGCGTCGAC^iiGTTGGGTCGGACCTGAACCCCTAAAAGCGGAACCGCCTCCCGCCC
TCGCCATCCCGGAGCTGAGTCGCCGGCGGCGGTGGCTGCTGCCAGACCCGGAGTTTCCTC
TTTCACTGGATGGAGCTGAACTTTGGGCGGCCAGAACAGCACAGCTGTCCGGGGATCGCT
GCACGCTGAGCTCCCTCGGCAAGACCCAGCGGCGGCTCGGGATTTTTTTGGGGGGGCGGG
GACCAGCCCCGCGCCGGCACCATGTTCCTGGCGACCCTGTACTTCGCGCTGCCGCTCTTGG
Part intron 2
GTAAGTCGAGGCCCGCCGCGGGCTTTCTTACCCTCTGAGTCTTTCCTAGGGTCGCTTGCAG
CAGCCCACCCCGCCCTCCGCACCAAAATTGGGGNNNNNNNNNNGGGCGGAAATGACTCC
GATGTCGAGAGTGACCGCTCCAGAGCAGGCGCCCCGAAGGCTGGTCAAGCATCCCTGACC
GCGCGCGCCCTCGCCCGGAGCAGCGGCCGGGGTCCCGCCCGCCTGCACTCAGGCTCCCTC
CCCTCTGCCCCGCAG
                                                          
ii Start of exon 2
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Exon 3
ACTTGCRAF22DCTCCTGTCGGCCGAAGTGAGCGGCGGAGACCGCCTGGATTGCGTGAAAGCC
AGTGATCAGTGCCTGAAGGAGCAGAGCTGCAGCACCAAGTACCGCACGCTAAGGCAGTG
CGTRAF7GGCGGGCAAGGAGACCAACRAR8TTCAGCCTGGCATCCGGCCTGGAGGCCAAGGAT
GAGTGCCGCAGCGCCATGGAGGCCCTGAAGCAGAAGTCGCTC(T/A)iiiACAACTGCCGCTGC
AAGCGGGGTATGAAGAAGGAGAAGAACTGCCTGCGCATTTACTGGAGCATGTACCAGAG
CCHRAR2TGCAGG
Intron 3
GTACGGTGACCTCCACCACCTTCCTCCAGCAGCGCTTNNNNNNCAGCAGCAAAAACCTGC
TTGAAATATATGTTTTTCTGATCTGAGCCCAATCTTTCTGTTGTTTTTRAF18AG
Exon 4
GAAATGATCTGCTGGAGGATTCCCCATATGAACCAGTTAACAGCAGATTGTCAGATATAT
TCCGGGT(G/T)ivGTCCCATTCATATCAG
Intron 4
GTAAGCAGATTTATACTTCCATGCTGATGCCTTTGTGTGCTTGAATTCGTTGGCTTGCATTC
TCTTTGGCTCTCAAAGAGCATATAAGTAGATAGTTGAATGGCACAGTGTTTCTGGGAAATT
AGAAATAGGATGATGATAATGAAGAGGRAR20CATAATGCCTAGAGATGANNNNNNNNNNT
GTGACCATGCCTGTCTTTCTCTGCATTTGCAG
Exon 6.
TGGAGCACATTCCCAAAGGGAACAACTGCCTGGATGCAGCGAAGGCCTGCAACCTCGAC
GACATTTGCRAF11AAGAAGTACAGGTCGGCGTACATCACCCCGTGCACCACCAGCGTGTCC
AA(C/Tv)GATGTCTGCAACCGCCGCAAGTGCCACAAGGCCCTCCGGCAGTTCTTTGACAAG
GTCCCGGCCAAGCACAGCTACGGAATGCTCTTCTGCTCCTGCCGGGACATCGCCTGCACA
                                                          
iii Y85N polymorphism.
iv V134V polymorphism.
v N184N polymorphism.
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GAGCGGAGGCGACAGACCATCGTGCCTGTGTGCTCCTATGRAR19AAGAGAGGGAGAAGCC
CAACTGTTTGAATTTGCAGGACTCCTGCAAGACGAATTACATCTGCAG
Part of intron 6.(Total size >20kb.)
GTAAGTGGGCACTGGCAGCTGGTGATTAATGAGGTGACAGGGAAAGTCTTGGCGGCTGCT
TCGGCTGCCAAGCTCCCTTTTCTGTGCTTCTACCAAGGTAGAGGAGGGAGGGGAGCCCAG
TCCATTTGAATGGATTGGCAAAAANNNNNNNNTCCACCCCCACCCTTTTTCCTATTGTAG
Exon 7
ATCTCGCCTTGCGGATTTTTTTACCAACTGCCAGCCAGAGTCAAGGTCTGTCAGCAGCTGT
CTAAAGGAAAACTACGCTGACTGCCTCCTCGCCTACTCGGGGCTTATTG
Part of intron 7
GTAAGATCCGAGAGAAGCAGGATGGGAGAAGNTGTGGTTTGCATATACCTGCGTTCTTTC
CATTGCGCCTTGCTGATGTCTGCAGAAGTGAAAATCTCACAGTAACCTCTGGGCTGGGGTT
TGGATGTTAAATCCTTGAGGACATGCCTGTTNNAAAAAAAAAAAAAAAAAAAAAAAAAA
AATTGGNATANTGNATCCTTAAAAGGCAAAGGCNGNAACCGGGNATTNCTAAGNATTGG
GNNNNNNNNNNTATGTGCTCAAGATAAATTGCCGAGAAAATGCACTGCTTACATAATTTC
CCACTCAGCAAATACAATGTCTGTAATTATCCACGGTGCATCCGCCGTCAGAGGAATATT
GGTTTCTTTTTAGGCCATGGAAAAGTATCATCATACAACAATARAF24
AAATGCCTTGTTTTTATTCTTTTAG
Exon 8
GCACAGTCATGACCCCCAACTACATAGACTCCAGTAGCCTCAGTGTGGCCCCATGGTGTG
ACTGCAGCAACAGTGGGAACGACCTAGAAGAGTGCTTGAAATTTTTGAATTTCTTCAAGG
ACAATACATGTCTTA
Part of intron 8
GTGAGRAR23NTTGTAAAAAATAAGAAACAAAGGANCAAACGCATTTTCTTCTCCGAGCTCC
AGCTGTACCTCTTGTACCTTGTGCCTGTACCTCTTGTACCTTGTGCCTGTACCTCTTGTACC
TTGTGCCTGCTTCCTCTCTCTGTCTGTCTTTCTCCCTTTCTGCTTAGTCACTGATGGTAAATC
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CAGCTCCTTTTGTGGGCCACCCCGTGTAATGCAGCAGGGAACCCAGCAAGTGATGAACTG
GGTGCTGCTAAGACTGTGAATCCAAAGGCCTGAGANNNNNNNNNNTGCTATAATCAGAA
TTTCTAGTGTGCCTCTCTGIRF1GCTGTGTATATCCTGTCTGTTACGTTTGCTGCTTGACTTTG
AAATTGGATTTCCTCCTGTTTTACTGCAG
Exon 9
AAAATGCAATTCAAGCCTTTGGCAATGGCTCCGATGTGACCGTGTGGCAGCCA(G/Tvi)CCT
TCCCAGTACAGACCACCACTGCC(A/g)CTviiACCACCACTGCCCTCCGGGTTAAGAACAAGC
CCCTGGGGCCAGCAGGGTCTGAGAATGAAATTCCCACTCATGTTTTGCCGRA16R
ACCGTGTGCAAATTTACAG
Part of intron 9
GTGAGAACTGCGTCCAGATTCCTTGCTGGGGCTCCCTTCCTGGTGGGGGGGTGAAACACG
GGNNNNNNNNTTTT^viiiTTTCTTGTCCCTCTCCAG
Exon 10
GCACAGAAGCTGAAATCRAF10CAATGTGTCGGGCAATACACACCTCTGTATTTCCAAT
Intron 10
GTAAGTATGTTTCTTTTGGAGGCTTCGTGCATTTATAGARAR13AACATAGCCTTTGGGCCCC
TGGGCGAGGGTATCATATAAAGCATTCAAAGACAAGAAGGTATCCAGTCCACAAGAAAT
CTAAGCCACCCTCCATGACCGTCTGCCCTTTGAGCAAGGTGAAGACTTTGAATTCCAGTTC
ACAAGTTGGNNNNNNNNNNAAAGTATACTGTGGTAGAATGAAGACATGCAGTGGATGAT
AATGRAF17AAACCATTCTTCCTTACAG
Proximal part of exon 11 (Total Exon 11 is 753 bp long.)
GGTAATTATGAAAAAGAAGGTCTCGGTGCTTCCAGCCACATAACCACAAAATCAATGGCT
GCTCCTCCAAGCTGTGGTCTGAGCCCACTGCTGGTCCTGGTGGTAACCGCTCTGTCCACCC
TATTATCTTTAACAGAAACATCATAGCTGCATRAR9DCTAAAAAAATACAATATGGACATGA
AAAAAAAAAAAAAAAAAAAAGTCGACGGCGGCC.....................
                                                          
vi Q350H polymorphism reported by Myers et al. in 0.01 control alleles, but no HSCR patients.
vii T366A polymorphism.
viii Insert T polymorphism 15 bp from 5’ end of exon 10.
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Exon 3:
Proximal:
RAF22DC: tct gcc ccg cag act tgc
RAR8: gtt ggt ctc ctt gcc cgc
Fragment length: 139
Distal:
RAF7: cgc acg cta agg cag tgc gt
HRAR2:ggc tct ggt aca tgc tcc agt
Fragment length: 185
PCR: Touchdown program. [Mg2+] = 0.75
Exon 4:
RAF18: c aat ctt tct gtt gtt ttt
RAR20: cc tct tca tta tca tca tcc
Fragment length: 255 (RAF18 -RAR20)
Exon 6:
RAF11: gc aac ctc gac gac att tgc
RAR19: ca tag gag cac aca ggc acg
Fragment length: 225 bp
Exon 9:
IRF1: ag aat ttc tag tgt gcc tct ctg
GRA16R: ggc aaa aca tga gtg gga att tca
Fragment length: 257bp
PCR: Touchdown program. [Mg2+] = 0.75
Exon 10:
RAF10: ca ggc aca gaa gct gaa atc (In exon 8)
RAR13: tc tat aaa tgc acg aag cct (In intron 8)
Fragment length: 96 bp
Exon 11:
RAF17: ac atg cag tgg atg ata atg
RAR9DC: at gca gct atg atg ttt ctg
Fragment length: 192
RET screening.
RET Exon 3
Primers:
RET3 F: A CCG CGG CTT TCC CCT GCT
RET3 R: C CTC CAG GAG CCT GTA GGC(Edery & Lyonnet)
Product: 288 bp.
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RET Exon 10
Primers:
RET10 mul F: GG GGC AGC ATT GTT GGG GGA (Exonic)
RET10 mul R: A ATG TTG GGA CCT CAG ATG TGC(Mulligan) (Intronic)
Product: 199 bp.
RET Exon 11
Primers:
RET11 F: AA GCT TGA AGG CAT CCA CGG (Intronic)
RET11 R:    G CAT ACG CAG CCT GTA CCC(Mulligan)  (Intronic)
Product: 320 bp.
RET Exon 15
Primers:
RET15F: CT GGC CAT GGC CTG ACG ACT
RET15R: CT GGG ATC CCT GGG AGC CCC (Attie, Pelet etal)
Product: 205 bp (calculated from Genbank sequence Accession number AJ243297.)
PCR conditions:
Touchdown program: 4 min at 95O ; 950 20 secs, 650 40 secs, 720 40 secs x 5; 950 20 secs, 650 -10/cycle
40 secs, 720 40 secs x 5 x 15; 950 20 secs, 500 40 secs, 720 40 secs x 30; 40 indefinitely.
[Mg2+] = 1.5mmol
dNTP 2.5mmol
Labelled with α 32P dCTP to 1/10th concentration of dNTP: 0.6µCi/PCR reaction
RET Exon 16
Primers:
RET16 F: AG GGA TAG GGC CTG GGC TTC (to 85 from I/E boundary)
RET16 R: TA ACC TCC ACC CCA AGA GAG (Hofstra)  (to 36 from I/E boundary)
Product: 192 bp. (Intron 71 bp.)
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Fig. 1. Appendix 5. Biorad vertical gel electrophoresis tank, as used for SSCP and microsatellite
work, showing power supply (left), and perspex radiation shield. Samples are loaded between the
teeth of the comb at the top of the gel.
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Appendix 6. (C
hapter 9.)
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m
ary of sequence variants uncovered.
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arked w
ith the asterisks are those reported in our patients by others, attribution is given in the text of the appropriate chapter.)
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Appendix 7. Continence scores. (From chapter 5.)
Frequency of defecation Normal (1 to 2/day) 2
Often    (3 to 5/day) 1
Very often 0
Faecal consistency Normal 2
Loose 1
Liquid 0
Soiling* No 2
Stress/diarrhoea 1
Constant 0
Rectal sensation Normal 2
Defective 1
Missing 0
Ability to hold back stool Minutes 2
Seconds 1
Missing 0
Discrimination between formed, loose,
& gaseous stools. Normal 2
Defective 1
Missing 0
Need for treatment (enemata, drugs,
napkins) No 2
Occasionally 1
Always 0
* In children, nocturnal soiling will be scored with stress/diarrhoea as 1 point.
Scoring (Quoted in Rintala & Lindahl, JPS, vol.27, no.7 1992: 902 - 905 “Faecal continence and
quality of life in adult patients with an operated low ano-rectal malformation.):
14        points Normal
10 - 13 points Good (social continence, few limitations in social life.)
5  -  9  points Fair (marked limitations in social life)
0  -  4  points Poor (total incontinence)
Table 5.2 .  Continence score sheet used for scoring children in this series. (after Holschneider.)
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Name: Date: ID:
Date of surgery:
Age:
Frequency of defecation Normal (1 to 2/day) 2
Often    (3 to 5/day) 1
Very often 0
Faecal consistency Normal 2
Loose 1
Liquid 0
Episodes constipation/obstruction None 2
Rare (<1/month) 1
Ongoing 0
Soiling* No 2
Stress/diarrhoea/night soiling 1
Constant 0
Ability to hold back stool Minutes 2
Seconds 1
Missing 0
Need for treatment (enemata, drugs,
napkins) No 2
Occasionally 1
Always 0
Social disruption None 2
At school/sport 1
Family isolation/disruption/divorce 0
Age at which child could mostly self toilet < 3 years 2
3 - 5 years 1
> 5 years 0
* In children, nocturnal soiling will be scored with stress/diarrhoea as 1 point.
Appendix Table 5.3  Suggested continence score sheet. (modified from Holschneider.)
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Appendix 8: Overo paint horses:
This strain of horse is bred for its piebald coat colour pattern. (See figure below.)
Unfortunately a high percentage (estimated at 12.5%) of the offspring of  two overo paint horses are
completely white, and have total colonic aganglionosis. (The lethal white foal, “lwf”.) The American
Paint Horse registry was set up in 1962, and registers foals conceived by either two registered Paints,
paint and thoroughbred, or paint and quarter horse. It includes foals without obvious spotting, whose
parents fit the above categories. The registry comprised 15,000 horses by 1970, and recognises two
distinct colour pattern genes: tobiano and overo  Two other patterns are also recognised by breeders:
sabino, and splashed white. Work done by the author and others established that a two base pair
mutation in exon 1 of EDNRB was responsible for the overo coat colour when heterozygous, and for
the lwf when homozygous. (Yang et al 1998) Unpublished work by the author suggests that in a small
percentage of cases heterozygote carriers of the mutation show a solid coat colour. These silent
mutation carriers are responsible for the birth of lwf to some breeders who would otherwise avoid the
possibility. The author has noted an analogous pigment pattern in several children, reported in chapter
8.3, which may be a specific marker for homozygous EDNRB mutations.
Fig. Appendix 8a. An extreme form of the heterozygous piebald pattern is the “medicine hat”
overo shown at left. The lethal white foal is shown at right. These two animals have in common
that pigmented hair is only apparent at the top of the head. In the case of the lwf, the head
pigmentation amounts to no more than a few dark hairs between the ears. A few pigmented hairs
may also be seen at the base of the tail. On the next page is a standard overo pattern mare. (See
chapter 8.3 for a discussion of a possible analogous pattern in the human.)
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Fig. Appendix 8b.)   Overo mare. Apparently normal colon.
Reference: Yang G-C, Croaker GDH, Zhang AL, Manglick P, Cass DT, Cartmill T "LWFS Horse as a
model for human Hirschsprung's Disease: A dinucleotide mutation in endothelin-B receptor gene
associated with lethal white foal syndrome.". Hum Mol Genet. 7:1047-52. (1998)
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